diff --git a/404.html b/404.html
index 4043db7..bfbc459 100644
--- a/404.html
+++ b/404.html
@@ -37,7 +37,7 @@
     
     <a class="navbar-brand me-2" href="https://sigven.github.io/pharmOncoX/index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/CODE_OF_CONDUCT.html b/CODE_OF_CONDUCT.html
index 44b1b9c..95556a1 100644
--- a/CODE_OF_CONDUCT.html
+++ b/CODE_OF_CONDUCT.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/LICENSE-text.html b/LICENSE-text.html
index c4589ab..eb8896a 100644
--- a/LICENSE-text.html
+++ b/LICENSE-text.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/articles/index.html b/articles/index.html
index 99b59e5..72b8f05 100644
--- a/articles/index.html
+++ b/articles/index.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/articles/pharmOncoX.html b/articles/pharmOncoX.html
index 00dbe27..89e9c8b 100644
--- a/articles/pharmOncoX.html
+++ b/articles/pharmOncoX.html
@@ -39,7 +39,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
@@ -122,38 +122,18 @@ <h3 id="get-braf-targeted-drugs-list-records-per-indication">Get BRAF-targeted d
 <span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>,</span>
 <span>  drug_targeted_agent <span class="op">=</span> <span class="cn">T</span>,</span>
 <span>    drug_target <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">'BRAF'</span><span class="op">)</span><span class="op">)</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:08] Downloading remote dataset from Google Drive to cache_dir</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:09] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:09] Object 'drug_map_name' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:09] md5 checksum is valid: aafe5e5a43a9eaa3d606db079200865f</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:09] Retrieved 30211 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:09] Downloading remote dataset from Google Drive to cache_dir</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:19] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:19] Object 'drug_map_alias' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:19] md5 checksum is valid: bba52645dbfb432830e4b4ba888ca28f</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:19] Retrieved 655802 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:19] Downloading remote dataset from Google Drive to cache_dir</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:21] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:21] Object 'drug_map_basic' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:21] md5 checksum is valid: db2d666d448ca1e437bb127b9aae7460</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:21] Retrieved 31146 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:21] Downloading remote dataset from Google Drive to cache_dir</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:22] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:22] Object 'drug_map_target' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:22] md5 checksum is valid: 86bab9ec69d7ad2edca64d4ceae1440c</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:22] Retrieved 38127 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:22] Downloading remote dataset from Google Drive to cache_dir</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:28] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:28] Object 'drug_map_indication' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:28] md5 checksum is valid: ae749b0cf93f760651c0e459c3fef232</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:28] Retrieved 58866 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:32] Record set satisfying user-defined criteria: n = 329</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:32] Collapsing record set - providing output on a 'per_drug_target_indication' resolution</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:32] Final record set: n = 240 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:15] Downloading remote dataset from Google Drive to cache_dir</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:17] Downloading remote dataset from Google Drive to cache_dir</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:31] Downloading remote dataset from Google Drive to cache_dir</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:38] Downloading remote dataset from Google Drive to cache_dir</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:40] Downloading remote dataset from Google Drive to cache_dir</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:50] Record set satisfying user-defined criteria: n = 328</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:50] Collapsing record set - providing output on a 'per_drug_target_indication' resolution</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:44:50] Final record set: n = 239 records</span></span>
 <span></span>
 <span><span class="co">## Number of drug records</span></span>
 <span><span class="fu"><a href="https://rdrr.io/r/base/nrow.html" class="external-link">nrow</a></span><span class="op">(</span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span><span class="op">)</span></span>
-<span><span class="co">#&gt; [1] 240</span></span>
+<span><span class="co">#&gt; [1] 239</span></span>
 <span></span>
 <span><span class="co">## Column names of drug records</span></span>
 <span><span class="fu"><a href="https://rdrr.io/r/base/colnames.html" class="external-link">colnames</a></span><span class="op">(</span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span><span class="op">)</span></span>
@@ -212,8 +192,8 @@ <h3 id="get-braf-targeted-drugs-open-targets-platform-only-list-per-drug-only">G
 <span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
 <span><span class="op">)</span></span></code></pre></div>
 <p><br></p>
-<div id="htmlwidget-428d1ff644ad430b7930" style="width:100%;height:auto;" class="datatables html-widget "></div>
-<script type="application/json" data-for="htmlwidget-428d1ff644ad430b7930">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15"],[11993,9654,24606,29259,26194,20190,28256,4557,24053,358,4131,921,21971,17698,23070],["Encorafenib","Dabrafenib","Regorafenib","Vemurafenib","Sorafenib","Naporafenib","Tovorafenib","Belvarafenib","XL-281","Arq-736","RAF-265","Agerafenib","LY-3009120","Lifirafenib","Plixorafenib"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL3301612","CHEMBL2028663","CHEMBL1946170","CHEMBL1229517","CHEMBL1336","CHEMBL4583691","CHEMBL3348923","CHEMBL3977543","CHEMBL3545027","CHEMBL3545296","CHEMBL558752","CHEMBL2029988","CHEMBL3545195","CHEMBL4209157","CHEMBL4303729"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],["An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.","An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.","An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. RAS mutations may result in constitutive activation of the RAS/RAF/MEK/ERK kinase signaling pathway, and have been found to occur frequently in human tumors.","NA","An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.","An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.","An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, plixorafenib selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","TRUE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C98283","C82386","C78204","C64768","C61948","C125003","C106254","C121646","C69135","NA","C61311","C107245","C116861","C124995","C113330"],[1,0.842,0.944,1,0.86,1,1,1,1,1,1,1,0.75,1,1],[false,false,false,false,true,false,false,false,false,false,false,false,false,false,false],[14,19,36,21,100,2,5,3,4,1,2,1,4,1,8],[2018,2013,2012,2011,2005,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,2,2,2,1,1,1,1,1,1,1],["cancer, colon adenocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, cutaneous melanoma, hairy cell leukemia, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, pancreatic carcinoma, rectum cancer, thyroid carcinoma","ameloblastoma, brain neoplasm, cancer, cutaneous melanoma, erdheim-chester disease, follicular thyroid carcinoma, lung cancer, malignant glioma, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, papillary thyroid carcinoma, thyroid cancer, thyroid carcinoma","acute myeloid leukemia, adenoid cystic carcinoma, angiosarcoma, bile duct carcinoma, biliary tract cancer, cancer, cholangiocarcinoma, colon adenocarcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, esophageal cancer, fallopian tube cancer, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, hepatocellular carcinoma, liposarcoma, malignant colon neoplasm, melanoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, thyroid cancer","acute myeloid leukemia, cancer, central nervous system cancer, colorectal adenocarcinoma, colorectal carcinoma, craniopharyngioma, cutaneous melanoma, hairy cell leukemia, histiocytosis, langerhans cell histiocytosis, lymphoma, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, pancreatic carcinoma, skin cancer, skin carcinoma, thyroid cancer, thyroid carcinoma","acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adrenal cortex carcinoma, anaplastic astrocytoma, anaplastic large cell lymphoma, anaplastic oligodendroglioma, biliary tract neoplasm, brain neoplasm, breast cancer, cancer, carcinoma of liver and intrahepatic biliary tract, cervical carcinoma, cholangiocarcinoma, chromophobe renal cell carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, desmoid-type fibromatosis, diffuse large b-cell lymphoma, esophageal cancer, fallopian tube cancer, follicular thyroid carcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, gliosarcoma, hepatoblastoma, hepatocellular carcinoma, hypopharyngeal carcinoma, kaposi's sarcoma, kidney cancer, kidney neoplasm, laryngeal squamous cell carcinoma, leukemia, liver cancer, lung cancer, lymphoma, male breast carcinoma, malignant colon neoplasm, mantle cell lymphoma, medullary thyroid gland carcinoma, melanoma, mesothelioma, metastatic prostate cancer, multiple myeloma, myeloid sarcoma, nasopharyngeal neoplasm, neuroblastoma, non-small cell lung carcinoma, oropharyngeal carcinoma, osteosarcoma, ovarian cancer, ovarian neoplasm, pancreatic carcinoma, pancreatic neoplasm, papillary renal cell carcinoma, papillary thyroid carcinoma, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectal carcinoma, rectum cancer, rhabdomyosarcoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, testicular carcinoma, thyroid cancer, thyroid carcinoma, thyroid neoplasm, tongue neoplasm, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, uterine carcinosarcoma, verrucous carcinoma","melanoma, non-small cell lung carcinoma","cancer, craniopharyngioma, langerhans cell histiocytosis, melanoma, metastatic melanoma","cancer, melanoma","colorectal carcinoma, melanoma, non-small cell lung carcinoma, papillary thyroid carcinoma","cancer","cancer, metastatic melanoma","cancer","colorectal neoplasm, melanoma, non-small cell lung carcinoma","cancer","cancer, cholangiocarcinoma, colorectal carcinoma, hairy cell leukemia, histiocytosis, melanoma, non-small cell lung carcinoma, thyroid cancer"],["4|2","4|3|2|1","4|3|2|1","4|2|1|0.5","4|3|2|1","2|1","2|1","2|1","1","1","1","1","1","1","1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01E","L01E","L01E","L01E","L01E","L01E","L01E|L01X","L01E|L01X","L01E","L01E","L01E","L01E|L01X","L01E|L01X","L01E","L01E"],["PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS"],["L01EC","L01EC","L01EX","L01EC","L01EX","L01EC|L01EX","L01EC|L01EX|L01XX","L01EC|L01EX|L01XX","L01EC|L01EX","L01EC|L01EX","L01EC|L01EK","L01EB|L01EC|L01XX","L01EC|L01EX|L01XX","L01EC","L01EC"],["BRAF inhibitors","BRAF inhibitors","Other protein kinase inhibitors","BRAF inhibitors","Other protein kinase inhibitors","BRAF inhibitors|Other protein kinase inhibitors","BRAF inhibitors|Other antineoplastic agents|Other protein kinase inhibitors","BRAF inhibitors|Other antineoplastic agents|Other protein kinase inhibitors","BRAF inhibitors|Other protein kinase inhibitors","BRAF inhibitors|Other protein kinase inhibitors","BRAF inhibitors|VEGFR inhibitors","BRAF inhibitors|EGFR inhibitors|Other antineoplastic agents","BRAF inhibitors|Other antineoplastic agents|Other protein kinase inhibitors","BRAF inhibitors","BRAF inhibitors"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
+<div id="htmlwidget-fe0b96fd489b30ab0829" style="width:100%;height:auto;" class="datatables html-widget "></div>
+<script type="application/json" data-for="htmlwidget-fe0b96fd489b30ab0829">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15"],[12046,9706,24686,29343,26274,20260,28339,4603,24131,353,4178,922,22044,17766,23145],["Encorafenib","Dabrafenib","Regorafenib","Vemurafenib","Sorafenib","Naporafenib","Tovorafenib","Belvarafenib","XL-281","Arq-736","RAF-265","Agerafenib","LY-3009120","Lifirafenib","Plixorafenib"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL3301612","CHEMBL2028663","CHEMBL1946170","CHEMBL1229517","CHEMBL1336","CHEMBL4583691","CHEMBL3348923","CHEMBL3977543","CHEMBL3545027","CHEMBL3545296","CHEMBL558752","CHEMBL2029988","CHEMBL3545195","CHEMBL4209157","CHEMBL4303729"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],["An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.","An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.","An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. RAS mutations may result in constitutive activation of the RAS/RAF/MEK/ERK kinase signaling pathway, and have been found to occur frequently in human tumors.","NA","An orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms.","An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.","An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.","An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.","An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, plixorafenib selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","TRUE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C98283","C82386","C78204","C64768","C61948","C125003","C106254","C121646","C69135","NA","C61311","C107245","C116861","C124995","C113330"],[1,0.842,0.944,1,0.85,1,1,1,1,1,1,1,0.75,1,1],[false,false,false,false,true,false,false,false,false,false,false,false,false,false,false],[14,19,36,21,100,2,5,3,4,1,2,1,4,1,8],[2018,2013,2012,2011,2005,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,2,2,2,1,1,1,1,1,1,1],["cancer, colon adenocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, cutaneous melanoma, hairy cell leukemia, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, pancreatic carcinoma, rectum cancer, thyroid carcinoma","ameloblastoma, brain neoplasm, cancer, cutaneous melanoma, erdheim-chester disease, follicular thyroid carcinoma, lung cancer, malignant glioma, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, papillary thyroid carcinoma, thyroid cancer, thyroid carcinoma","acute myeloid leukemia, adenoid cystic carcinoma, angiosarcoma, bile duct carcinoma, biliary tract cancer, cancer, cholangiocarcinoma, colon adenocarcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, esophageal cancer, fallopian tube cancer, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, hepatocellular carcinoma, liposarcoma, malignant colon neoplasm, melanoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, thyroid cancer","acute myeloid leukemia, cancer, central nervous system cancer, colorectal adenocarcinoma, colorectal carcinoma, craniopharyngioma, cutaneous melanoma, hairy cell leukemia, histiocytosis, langerhans cell histiocytosis, lymphoma, melanoma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, pancreatic carcinoma, skin cancer, skin carcinoma, thyroid cancer, thyroid carcinoma","acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adrenal cortex carcinoma, anaplastic astrocytoma, anaplastic large cell lymphoma, anaplastic oligodendroglioma, biliary tract neoplasm, brain neoplasm, breast cancer, cancer, carcinoma of liver and intrahepatic biliary tract, cholangiocarcinoma, chromophobe renal cell carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, desmoid-type fibromatosis, diffuse large b-cell lymphoma, esophageal cancer, fallopian tube cancer, follicular thyroid carcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, gliosarcoma, hepatoblastoma, hepatocellular carcinoma, hypopharyngeal carcinoma, kaposi's sarcoma, kidney cancer, kidney neoplasm, laryngeal squamous cell carcinoma, leukemia, liver cancer, lung cancer, lymphoma, male breast carcinoma, malignant colon neoplasm, mantle cell lymphoma, medullary thyroid gland carcinoma, melanoma, mesothelioma, metastatic prostate cancer, multiple myeloma, myeloid sarcoma, nasopharyngeal neoplasm, neuroblastoma, non-small cell lung carcinoma, oropharyngeal carcinoma, osteosarcoma, ovarian cancer, ovarian neoplasm, pancreatic carcinoma, pancreatic neoplasm, papillary renal cell carcinoma, papillary thyroid carcinoma, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectal carcinoma, rectum cancer, rhabdomyosarcoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, testicular carcinoma, thyroid cancer, thyroid carcinoma, thyroid neoplasm, tongue neoplasm, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, uterine carcinosarcoma, verrucous carcinoma","melanoma, non-small cell lung carcinoma","cancer, craniopharyngioma, langerhans cell histiocytosis, melanoma, metastatic melanoma","cancer, melanoma","colorectal carcinoma, melanoma, non-small cell lung carcinoma, papillary thyroid carcinoma","cancer","cancer, metastatic melanoma","cancer","colorectal neoplasm, melanoma, non-small cell lung carcinoma","cancer","cancer, cholangiocarcinoma, colorectal carcinoma, hairy cell leukemia, histiocytosis, melanoma, non-small cell lung carcinoma, thyroid cancer"],["4|2","4|3|2|1","4|3|2|1","4|2|1|0.5","4|3|2|1","2|1","2|1","2|1","1","1","1","1","1","1","1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01E","L01E","L01E","L01E","L01E","L01E","L01E|L01X","L01E|L01X","L01E","L01E","L01E","L01E|L01X","L01E|L01X","L01E","L01E"],["PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","OTHER ANTINEOPLASTIC AGENTS |PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS","PROTEIN KINASE INHIBITORS"],["L01EC","L01EC","L01EX","L01EC","L01EX","L01EC|L01EX","L01EC|L01EX|L01XX","L01EC|L01EX|L01XX","L01EC|L01EX","L01EC|L01EX","L01EC|L01EK","L01EB|L01EC|L01XX","L01EC|L01EX|L01XX","L01EC","L01EC"],["BRAF inhibitors","BRAF inhibitors","Other protein kinase inhibitors","BRAF inhibitors","Other protein kinase inhibitors","BRAF inhibitors|Other protein kinase inhibitors","BRAF inhibitors|Other antineoplastic agents|Other protein kinase inhibitors","BRAF inhibitors|Other antineoplastic agents|Other protein kinase inhibitors","BRAF inhibitors|Other protein kinase inhibitors","BRAF inhibitors|Other protein kinase inhibitors","BRAF inhibitors|VEGFR inhibitors","BRAF inhibitors|EGFR inhibitors|Other antineoplastic agents","BRAF inhibitors|Other antineoplastic agents|Other protein kinase inhibitors","BRAF inhibitors","BRAF inhibitors"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
 </div>
 <div class="section level3">
 <h3 id="get-immune-checkpoint-inhibitors-list-per-drug-target-entry">Get immune checkpoint inhibitors, list per drug-target entry<a class="anchor" aria-label="anchor" href="#get-immune-checkpoint-inhibitors-list-per-drug-target-entry"></a>
@@ -261,8 +241,8 @@ <h3 id="get-immune-checkpoint-inhibitors-list-per-drug-target-entry">Get immune
 <span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
 <span><span class="op">)</span></span></code></pre></div>
 <p><br></p>
-<div id="htmlwidget-569360f1560a9c14b8cd" style="width:100%;height:auto;" class="datatables html-widget "></div>
-<script type="application/json" data-for="htmlwidget-569360f1560a9c14b8cd">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48"],[28422,11138,7207,3977,11415,3406,20686,22266,16656,6173,25255,7330,22320,25499,25875,4384,6266,8692,20919,23926,25707,25973,26553,27989,28201,6385,11077,12322,13424,23804,24736,28004,29337,29865,26252,349,21880,24108,24108,12145,22774,22817,9756,29748,2718,12626,5656,15678],["Tremelimumab","Dostarlimab","Cemiplimab","Avelumab","Durvalumab","Atezolizumab","Nivolumab","Pembrolizumab","Ipilimumab","Cs-1003","Shr-1316","Cetrelimab","Penpulimab","Sasanlimab","Sintilimab","Balstilimab","Cadonilimab","Cosibelimab","Ociperlimab","Quavonlimab","Serplulimab","Socazolimab","Sugemalimab","Tiragolumab","Toripalimab","Camrelizumab","Domvanalimab","Erfonrilimab","Finotonlimab","Pucotenlimab","Retifanlimab","Tislelizumab","Vibostolimab","Zimberelimab","Spartalizumab","Apl-501","Pacmilimab","Ro-7121661","Ro-7121661","Envafolimab","Pidilizumab","Pimivalimab","Danburstotug","Zalifrelimab","ASP-8374","Etigilimab","Budigalimab","Incb-086550"],["Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Unknown","Unknown","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Unknown","Antibody","Unknown","Unknown","Antibody","Antibody","Antibody","Protein","Antibody","Unknown","Antibody","Antibody","Unknown"],["CTLA4","PDCD1","PDCD1","CD274","CD274","CD274","PDCD1","PDCD1","CTLA4","PDCD1","CD274","PDCD1","PDCD1","PDCD1","PDCD1","PDCD1","CTLA4","CD274","TIGIT","CTLA4","PDCD1","CD274","CD274","TIGIT","PDCD1","PDCD1","TIGIT","CTLA4","PDCD1","PDCD1","PDCD1","PDCD1","TIGIT","PDCD1","PDCD1","PDCD1","CD274","HAVCR2","PDCD1","CD274","PDCD1","PDCD1","CD274","CTLA4","TIGIT","TIGIT","PDCD1","CD274"],["cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","CD274 molecule","CD274 molecule","CD274 molecule","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","programmed cell death 1","CD274 molecule","hepatitis A virus cellular receptor 2","programmed cell death 1","CD274 molecule","programmed cell death 1","programmed cell death 1","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","T cell immunoreceptor with Ig and ITIM domains","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","CD274 molecule"],["CHEMBL2108658","CHEMBL4298124","CHEMBL4297723","CHEMBL3833373","CHEMBL3301587","CHEMBL3707227","CHEMBL2108738","CHEMBL3137343","CHEMBL1789844","CHEMBL4594536","CHEMBL4297828","CHEMBL4298001","CHEMBL4297571","CHEMBL4298191","CHEMBL4297829","CHEMBL4297877","CHEMBL4594456","CHEMBL4297729","CHEMBL4650411","CHEMBL4650419","CHEMBL4594550","CHEMBL4802221","CHEMBL4594535","CHEMBL4298050","CHEMBL4297843","CHEMBL4297715","CHEMBL4650392","CHEMBL4650483","CHEMBL4650516","CHEMBL4650472","CHEMBL4298037","CHEMBL4297840","CHEMBL4297785","CHEMBL4297856","CHEMBL4297831","CHEMBL4594355","CHEMBL4297563","CHEMBL4594602","CHEMBL4594602","CHEMBL4298006","CHEMBL2108680","CHEMBL4650482","CHEMBL4650423","CHEMBL4297876","CHEMBL4297894","CHEMBL4298205","CHEMBL4297858","CHEMBL4802209"],["INHIBITOR","ANTAGONIST","INHIBITOR","OTHER","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","BINDING AGENT","INHIBITOR","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","BINDING AGENT","INHIBITOR","INHIBITOR","BINDING AGENT","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR"],["A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","NA","NA","NA","NA","An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","NA","NA","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","NA","A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.","NA","NA","An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","NA","NA","A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","A fully human, immunoglobulin G4 (IgG4) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody ASP8374 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","NA","NA","NA"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C49085","C126799","C121540","C116870","C103194","C106250","C68814","C106432","C2654","NA","NA","NA","NA","C124058","C132992","C136465","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","C142168","C121775","NA","NA","C121625","NA","C132192","NA","NA","C129714","C71014","NA","NA","C126113","C141421","NA","NA","NA"],[1493,5133,5133,29126,29126,29126,5133,5133,1493,5133,29126,5133,5133,5133,5133,5133,1493,29126,201633,1493,5133,29126,29126,201633,5133,5133,201633,1493,5133,5133,5133,5133,201633,5133,5133,5133,29126,84868,5133,29126,5133,5133,29126,1493,201633,201633,5133,29126],["ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000120217","ENSG00000181847","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000135077","ENSG00000188389","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000163599","ENSG00000181847","ENSG00000181847","ENSG00000188389","ENSG00000120217"],["single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein"],[0.881,0.958,0.821,0.905,0.889,0.914,0.863,0.874,0.888,1,1,0.833,0.95,0.8,0.9419999999999999,0.917,1,1,1,0.857,0.909,1,1,0.947,0.957,0.9370000000000001,1,1,1,1,0.857,0.96,0.875,1,0.947,1,1,1,1,0.8,0.778,1,1,1,1,1,0.778,1],[false,false,false,true,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[59,24,28,63,90,81,146,167,98,4,7,6,20,5,52,12,12,2,7,7,11,6,8,19,47,63,5,8,3,7,21,50,8,12,19,6,3,1,1,20,9,2,2,8,2,1,9,1],[2022,2021,2018,2017,2017,2016,2015,2014,2011,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,4,4,4,4,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,2,2,2,2,2,2,2,2,2,1,1,1,1],["biliary tract cancer, biliary tract neoplasm, breast cancer, breast carcinoma, cancer, cholangiocarcinoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, diffuse large b-cell lymphoma, dysgerminoma, esophageal cancer, fallopian tube cancer, fallopian tube carcinoma, follicular thyroid carcinoma, gastric adenocarcinoma, gastric cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lung cancer, lymphoid neoplasm, lymphoma, melanoma, mesothelioma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary thyroid carcinoma, peritoneal neoplasm, prostate adenocarcinoma, prostate cancer, pulmonary neuroendocrine tumor, sarcoma, seminoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell lung carcinoma, thyroid cancer, urinary bladder cancer, urothelial carcinoma","angiosarcoma, breast cancer, cancer, cervical cancer, cervical carcinoma, colorectal carcinoma, endometrial cancer, gestational trophoblastic neoplasm, head and neck malignant neoplasia, liver cancer, malignant colon neoplasm, melanoma, mesothelioma, multiple myeloma, non-small cell lung carcinoma, ovarian cancer, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, rectum cancer, sarcoma, small cell lung carcinoma, triple-negative breast cancer","angiosarcoma, basal cell carcinoma, breast cancer, cancer, cervical cancer, diffuse intrinsic pontine glioma, fallopian tube cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, hodgkins lymphoma, lung cancer, lymphoma, melanoma, multiple myeloma, non-small cell lung carcinoma, oropharyngeal carcinoma, ovarian cancer, pancreatic carcinoma, prostate cancer, skin cancer, squamous cell carcinoma, triple-negative breast cancer","acute myeloid leukemia, adenoid cystic carcinoma, angiosarcoma, breast cancer, breast carcinoma, breast neoplasm, cancer, chordoma, chronic myelogenous leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, diffuse large b-cell lymphoma, endometrial cancer, esophageal squamous cell carcinoma, fallopian tube cancer, follicular lymphoma, gastric adenocarcinoma, gestational trophoblastic neoplasm, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, leiomyosarcoma, lymphoma, malignant colon neoplasm, malignant glioma, melanoma, meningioma, mesothelioma, metastatic prostate cancer, multiple myeloma, nasopharyngeal neoplasm, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, peritoneum cancer, prostate cancer, rectum cancer, renal carcinoma, skin cancer, small cell lung carcinoma, squamous cell carcinoma, thymic carcinoma, thymoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, anal carcinoma, angiosarcoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical cancer, cholangiocarcinoma, chronic lymphocytic leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, dysgerminoma, endometrial cancer, endometrial neoplasm, esophageal cancer, esophageal squamous cell carcinoma, fallopian tube carcinoma, follicular lymphoma, follicular thyroid carcinoma, gastric adenocarcinoma, gastric cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, large cell lung carcinoma, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoid neoplasm, lymphoma, malignant colon neoplasm, malignant pleural mesothelioma, melanoma, mesothelioma, mouth neoplasm, multiple myeloma, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary renal cell carcinoma, papillary thyroid carcinoma, plasmacytoma, polycythemia vera, prostate adenocarcinoma, prostate cancer, pulmonary neuroendocrine tumor, rectum cancer, sarcoma, seminoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, alveolar soft part sarcoma, anus cancer, biliary tract cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical cancer, cervical carcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colonic neoplasm, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, diffuse large b-cell lymphoma, endometrial cancer, endometrial carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder carcinoma, gastric adenocarcinoma, gastrointestinal stromal tumor, glioblastoma multiforme, gliosarcoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, lung cancer, lymphoma, malignant glioma, malignant peritoneal mesothelioma, malignant pleural mesothelioma, melanoma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, mycosis fungoides, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary renal cell carcinoma, peritoneal neoplasm, prostate adenocarcinoma, prostate cancer, rectum cancer, sarcoma, sezary's disease, skin cancer, small cell lung carcinoma, thyroid carcinoma, triple-negative breast cancer, urinary bladder cancer, urothelial carcinoma, uterine carcinosarcoma","acute lymphoblastic leukemia, acute myeloid leukemia, adrenal cortex carcinoma, anaplastic large cell lymphoma, angiosarcoma, basal cell carcinoma, biliary tract cancer, biliary tract neoplasm, bladder tumor, brain cancer, brain neoplasm, breast cancer, breast carcinoma, cancer, carcinosarcoma, central nervous system cancer, cervical adenocarcinoma, cervical cancer, cervical carcinoma, childhood acute lymphoblastic leukemia, cholangiocarcinoma, chordoma, chromophobe renal cell carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, collecting duct carcinoma, colon adenocarcinoma, colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, craniopharyngioma, cutaneous melanoma, dedifferentiated liposarcoma, diffuse intrinsic pontine glioma, diffuse large b-cell lymphoma, digestive system neuroendocrine neoplasm, endometrial cancer, endometrial carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, glioma, gliosarcoma, grade iii meningioma, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, large cell lung carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoid neoplasm, lymphoma, malignant colon neoplasm, malignant glioma, malignant pleural mesothelioma, mantle cell lymphoma, melanoma, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, nerve sheath neoplasm, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oligodendroglioma, oral squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary renal cell carcinoma, peritoneum cancer, pituitary adenocarcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland cancer, sarcoma, sezary's disease, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, t-cell non-hodgkin lymphoma, thyroid cancer, thyroid carcinoma, triple-negative breast cancer, undifferentiated pleomorphic sarcoma, unspecified peripheral t-cell lymphoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma","acute lymphoblastic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adrenal cortex carcinoma, adult lymphoma, alveolar soft part sarcoma, anal carcinoma, anaplastic astrocytoma, angiosarcoma, anus cancer, astrocytoma, asymptomatic myeloma, b-cell acute lymphoblastic leukemia, biliary tract cancer, biliary tract neoplasm, bladder tumor, bone sarcoma, brain cancer, brain neoplasm, breast cancer, breast carcinoma, breast carcinoma in situ, breast ductal carcinoma in situ, breast neoplasm, cancer, carcinoma of liver and intrahepatic biliary tract, carcinosarcoma, cervical adenocarcinoma, cervical cancer, cervical carcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, digestive system neuroendocrine neoplasm, endometrial cancer, endometrial carcinoma, endometrial neoplasm, epithelioid sarcoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder cancer, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, gestational trophoblastic neoplasm, glioblastoma multiforme, glioma, gliosarcoma, grade iii meningioma, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, laryngeal squamous cell carcinoma, leukemia, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoid leukemia, lymphoid neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant glioma, malignant peripheral nerve sheath tumor, malignant pleural mesothelioma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medullary thyroid gland carcinoma, melanoma, meningeal neoplasm, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, mouth neoplasm, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oropharynx cancer, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, papillary renal cell carcinoma, parotid gland cancer, pediatric lymphoma, penile carcinoma, peritoneal neoplasm, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland carcinoma, sarcoma, sezary's disease, skin basal cell carcinoma, skin cancer, skin carcinoma, skin neoplasm, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, stomach neoplasm, thymic carcinoma, thymoma, thyroid cancer, thyroid carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, vulvar carcinoma, waldenstrom macroglobulinemia","acute lymphoblastic leukemia, acute myeloid leukemia, basal cell carcinoma, biliary tract neoplasm, breast cancer, breast carcinoma, cancer, cervical adenocarcinoma, cervical carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, colon carcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, dedifferentiated liposarcoma, diffuse large b-cell lymphoma, digestive system neuroendocrine neoplasm, endometrial cancer, endometrial carcinoma, esophageal cancer, esophageal carcinoma, fallopian tube carcinoma, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, glioma, gliosarcoma, grade iii meningioma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, lung adenocarcinoma, lung cancer, lymphoma, malignant colon neoplasm, malignant glioma, malignant pleural mesothelioma, melanoma, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, myeloproliferative disorder, nasopharyngeal neoplasm, neoplasm of mature b-cells, nerve sheath neoplasm, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, peritoneum cancer, pituitary adenocarcinoma, prostate adenocarcinoma, prostate cancer, prostate carcinoma, rectum cancer, salivary gland cancer, sarcoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, synovial sarcoma, thyroid cancer, undifferentiated pleomorphic sarcoma, urinary bladder cancer, urothelial carcinoma, uterine carcinosarcoma","cancer, hepatocellular carcinoma, lymphoma","breast cancer, cancer, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma, squamous cell carcinoma","bladder tumor, cancer, multiple myeloma, prostate adenocarcinoma, urothelial carcinoma","breast neoplasm, cancer, cervical cancer, colorectal carcinoma, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, gastric carcinoma, glioblastoma multiforme, hepatocellular carcinoma, hodgkins lymphoma, lung cancer, lymphoma, nasopharyngeal neoplasm, non-small cell lung carcinoma, pancreatic carcinoma, pancreatic neoplasm, small cell lung carcinoma, squamous cell lung carcinoma, thyroid cancer","non-small cell lung carcinoma, prostate adenocarcinoma, urinary bladder cancer, urothelial carcinoma","angioimmunoblastic t-cell lymphoma, angiosarcoma, biliary tract cancer, breast cancer, cancer, cervical adenocarcinoma, cervical cancer, cholangiocarcinoma, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, endometrial cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, lung cancer, lung neoplasm, lymphoma, mesothelioma, nasopharyngeal neoplasm, neuroblastoma, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, pancreatic carcinoma, pancreatic neoplasm, rectum cancer, salivary gland cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, undifferentiated pleomorphic sarcoma, unspecified peripheral t-cell lymphoma","angiosarcoma, bladder tumor, cancer, cervical cancer, diffuse intrinsic pontine glioma, endometrial cancer, melanoma, non-small cell lung carcinoma, oropharynx cancer, ovarian cancer, soft tissue sarcoma","cancer, cervical cancer, cervical carcinoma, clear cell renal carcinoma, colorectal carcinoma, hepatocellular carcinoma, lung cancer, melanoma, nasopharyngeal neoplasm, non-small cell lung carcinoma, ovarian cancer","chronic lymphocytic leukemia, non-small cell lung carcinoma","cancer, cervical cancer, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma","cancer, colorectal carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma, small cell lung carcinoma","breast cancer, cancer, cervical cancer, colorectal carcinoma, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma","biliary tract cancer, cervical cancer, metastatic melanoma, osteosarcoma, small cell lung carcinoma, urothelial carcinoma","cancer, gastric adenocarcinoma, hepatocellular carcinoma, hodgkins lymphoma, lymphoma, non-small cell lung carcinoma, small cell lung carcinoma","cancer, cervical cancer, cutaneous melanoma, endometrial cancer, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, follicular lymphoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, rectum cancer, small cell lung carcinoma, triple-negative breast cancer, urinary bladder cancer, urothelial carcinoma","biliary tract cancer, biliary tract neoplasm, breast cancer, cancer, cervical adenocarcinoma, cervical cancer, cholangiocarcinoma, colonic neoplasm, colorectal carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liposarcoma, lung cancer, lymphoma, malignant pleural mesothelioma, melanoma, metastatic melanoma, mouth neoplasm, nasopharyngeal neoplasm, neoplasm of hypopharynx, non-small cell lung carcinoma, oral squamous cell carcinoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, undifferentiated pleomorphic sarcoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, adrenal cortex carcinoma, biliary tract cancer, bladder tumor, breast cancer, cancer, cervical cancer, cervical carcinoma, cholangiocarcinoma, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, diffuse large b-cell lymphoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gestational trophoblastic neoplasm, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, hypopharyngeal carcinoma, intrahepatic cholangiocarcinoma, liver cancer, lung cancer, lung carcinoma, lung neoplasm, lymphoma, malignant colon neoplasm, melanoma, mouth neoplasm, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, paranasal sinus cancer, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, thyroid cancer, triple-negative breast cancer","cancer, glioblastoma multiforme, melanoma, non-small cell lung carcinoma","cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, lymphoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, thymic carcinoma, triple-negative breast cancer","head and neck squamous cell carcinoma, hepatocellular carcinoma, lymphoma","cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma, thyroid cancer, urinary bladder cancer","breast cancer, cancer, endometrial cancer, esophageal cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, prostate cancer, sarcoma, soft tissue sarcoma, squamous cell carcinoma, triple-negative breast cancer, urothelial carcinoma","biliary tract cancer, biliary tract neoplasm, bladder tumor, breast cancer, cancer, cervical cancer, classic hodgkin lymphoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, diffuse large b-cell lymphoma, endometrial cancer, esophageal cancer, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, malignant bone neoplasm, malignant colon neoplasm, melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, prostate cancer, rectum cancer, small cell lung carcinoma, squamous cell carcinoma, squamous cell lung carcinoma, t-cell non-hodgkin lymphoma, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","cancer, colorectal carcinoma, lymphoid neoplasm, melanoma, non-small cell lung carcinoma, prostate cancer, small cell lung carcinoma","cancer, cervical cancer, classic hodgkin lymphoma, glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, pancreatic carcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer","breast cancer, cancer, cutaneous melanoma, esophageal squamous cell carcinoma, gastric cancer, gastrointestinal stromal tumor, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung cancer, lymphoma, melanoma, multiple myeloma, nasopharyngeal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, triple-negative breast cancer","alveolar soft part sarcoma, cancer, cervical cancer, neoplasm of mature b-cells, non-small cell lung carcinoma, unspecified peripheral t-cell lymphoma","breast cancer, lymphoma, metastatic melanoma","esophageal squamous cell carcinoma","esophageal squamous cell carcinoma","biliary tract cancer, biliary tract neoplasm, breast cancer, cancer, colorectal carcinoma, endometrial cancer, gastric adenocarcinoma, hepatocellular carcinoma, lung neoplasm, malignant colon neoplasm, nasopharyngeal neoplasm, non-small cell lung carcinoma, ovarian cancer, pancreatic carcinoma, rectum cancer, soft tissue sarcoma","diffuse large b-cell lymphoma, hepatocellular carcinoma, lymphoma, melanoma, multiple myeloma, pancreatic carcinoma, prostate adenocarcinoma","cancer, non-small cell lung carcinoma","cancer, extranodal nasal nk/t cell lymphoma","angiosarcoma, bladder tumor, cancer, cervical cancer, diffuse intrinsic pontine glioma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, soft tissue sarcoma","cancer, glioblastoma multiforme","cancer","breast cancer, cancer, colorectal carcinoma, head and neck malignant neoplasia, ovarian cancer, small cell lung carcinoma","cancer"],["1|2|3|4","1|2|3|4","1|2|3|4","0.5|1|2|3|4","1|2|3|4","1|2|3|4","0.5|1|2|3|4","0.5|1|2|3|4","1|2|3|4","1|3","1|2|3","1|2|3","1|2|3","1|3","0.5|1|2|3","1|2|3","1|2|3","1|3","1|2|3","1|2","1|2|3","1|3","1|2|3","1|2|3","1|2|3","1|2|3","0.5|2|3","1|2|3","1|2|3","2|3","1|2|3","1|2|3","1|2|3","0.5|1|2|3","1|2|3","1|2","1|2","2","2","1|2","1|2","1|2","2","1|2","1","1","1","1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F"],["MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs"],["L01FX","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF|L01FX","L01FF","L01FX","L01FX","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FX","L01FF|L01FX","L01FF","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FX","L01FX","L01FX","L01FF","L01FF"],["Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs|PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","Other MaBs and ADCs|PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","Other MaBs and ADCs","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>target_symbol<\/th>\n      <th>target_genename<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>target_entrezgene<\/th>\n      <th>target_ensembl_gene_id<\/th>\n      <th>target_type<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,16,19,21,22,23]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
+<div id="htmlwidget-7668e432c528a8445e3c" style="width:100%;height:auto;" class="datatables html-widget "></div>
+<script type="application/json" data-for="htmlwidget-7668e432c528a8445e3c">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48"],[28505,11189,7253,4024,11466,3450,20759,22341,16724,6219,25333,7377,22396,25579,25955,4429,6312,8741,20991,24004,25787,26053,26632,28072,28284,6430,11128,12375,13479,23880,24816,28087,29421,29951,26332,345,21954,24186,24186,12198,22849,22892,9807,29834,2756,12679,5703,15743],["Tremelimumab","Dostarlimab","Cemiplimab","Avelumab","Durvalumab","Atezolizumab","Nivolumab","Pembrolizumab","Ipilimumab","Cs-1003","Shr-1316","Cetrelimab","Penpulimab","Sasanlimab","Sintilimab","Balstilimab","Cadonilimab","Cosibelimab","Ociperlimab","Quavonlimab","Serplulimab","Socazolimab","Sugemalimab","Tiragolumab","Toripalimab","Camrelizumab","Domvanalimab","Erfonrilimab","Finotonlimab","Pucotenlimab","Retifanlimab","Tislelizumab","Vibostolimab","Zimberelimab","Spartalizumab","Apl-501","Pacmilimab","Ro-7121661","Ro-7121661","Envafolimab","Pidilizumab","Pimivalimab","Danburstotug","Zalifrelimab","ASP-8374","Etigilimab","Budigalimab","Incb-086550"],["Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Unknown","Unknown","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Unknown","Antibody","Unknown","Unknown","Antibody","Antibody","Antibody","Protein","Antibody","Unknown","Antibody","Antibody","Unknown"],["CTLA4","PDCD1","PDCD1","CD274","CD274","CD274","PDCD1","PDCD1","CTLA4","PDCD1","CD274","PDCD1","PDCD1","PDCD1","PDCD1","PDCD1","CTLA4","CD274","TIGIT","CTLA4","PDCD1","CD274","CD274","TIGIT","PDCD1","PDCD1","TIGIT","CTLA4","PDCD1","PDCD1","PDCD1","PDCD1","TIGIT","PDCD1","PDCD1","PDCD1","CD274","HAVCR2","PDCD1","CD274","PDCD1","PDCD1","CD274","CTLA4","TIGIT","TIGIT","PDCD1","CD274"],["cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","CD274 molecule","CD274 molecule","CD274 molecule","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","CD274 molecule","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","programmed cell death 1","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","programmed cell death 1","CD274 molecule","hepatitis A virus cellular receptor 2","programmed cell death 1","CD274 molecule","programmed cell death 1","programmed cell death 1","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","T cell immunoreceptor with Ig and ITIM domains","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","CD274 molecule"],["CHEMBL2108658","CHEMBL4298124","CHEMBL4297723","CHEMBL3833373","CHEMBL3301587","CHEMBL3707227","CHEMBL2108738","CHEMBL3137343","CHEMBL1789844","CHEMBL4594536","CHEMBL4297828","CHEMBL4298001","CHEMBL4297571","CHEMBL4298191","CHEMBL4297829","CHEMBL4297877","CHEMBL4594456","CHEMBL4297729","CHEMBL4650411","CHEMBL4650419","CHEMBL4594550","CHEMBL4802221","CHEMBL4594535","CHEMBL4298050","CHEMBL4297843","CHEMBL4297715","CHEMBL4650392","CHEMBL4650483","CHEMBL4650516","CHEMBL4650472","CHEMBL4298037","CHEMBL4297840","CHEMBL4297785","CHEMBL4297856","CHEMBL4297831","CHEMBL4594355","CHEMBL4297563","CHEMBL4594602","CHEMBL4594602","CHEMBL4298006","CHEMBL2108680","CHEMBL4650482","CHEMBL4650423","CHEMBL4297876","CHEMBL4297894","CHEMBL4298205","CHEMBL4297858","CHEMBL4802209"],["INHIBITOR","ANTAGONIST","INHIBITOR","OTHER","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","BINDING AGENT","INHIBITOR","ANTAGONIST","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","BINDING AGENT","INHIBITOR","INHIBITOR","BINDING AGENT","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR"],["A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","NA","NA","NA","NA","An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","NA","NA","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.","NA","A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.","NA","NA","An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","NA","NA","A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","A fully human, immunoglobulin G4 (IgG4) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody ASP8374 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.","NA","NA","NA"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,false,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C49085","C126799","C121540","C116870","C103194","C106250","C68814","C106432","C2654","NA","NA","NA","NA","C124058","C132992","C136465","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","NA","C142168","C121775","NA","NA","C121625","NA","C132192","NA","NA","C129714","C71014","NA","NA","C126113","C141421","NA","NA","NA"],[1493,5133,5133,29126,29126,29126,5133,5133,1493,5133,29126,5133,5133,5133,5133,5133,1493,29126,201633,1493,5133,29126,29126,201633,5133,5133,201633,1493,5133,5133,5133,5133,201633,5133,5133,5133,29126,84868,5133,29126,5133,5133,29126,1493,201633,201633,5133,29126],["ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000120217","ENSG00000181847","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000120217","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000163599","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000135077","ENSG00000188389","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000120217","ENSG00000163599","ENSG00000181847","ENSG00000181847","ENSG00000188389","ENSG00000120217"],["single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein"],[0.881,0.875,0.786,0.905,0.878,0.889,0.849,0.862,0.878,1,1,0.833,0.9,0.8,0.923,0.833,0.833,1,0.857,0.857,0.8179999999999999,0.833,1,0.895,0.9360000000000001,0.905,1,1,1,1,0.857,0.9399999999999999,0.875,0.917,0.947,0.833,1,1,1,0.8,0.778,1,1,0.875,1,1,0.778,1],[false,false,false,true,false,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[59,24,28,63,90,81,146,167,98,4,7,6,20,5,52,12,12,2,7,7,11,6,8,19,47,63,5,8,3,7,21,50,8,12,19,6,3,1,1,20,9,2,2,8,2,1,9,1],[2022,2021,2018,2017,2017,2016,2015,2014,2011,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,4,4,4,4,4,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,2,2,2,2,2,2,2,2,2,1,1,1,1],["biliary tract cancer, biliary tract neoplasm, breast cancer, breast carcinoma, cancer, cholangiocarcinoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, diffuse large b-cell lymphoma, dysgerminoma, esophageal cancer, fallopian tube cancer, fallopian tube carcinoma, follicular thyroid carcinoma, gastric adenocarcinoma, gastric cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lung cancer, lymphoid neoplasm, lymphoma, melanoma, mesothelioma, metastatic melanoma, multiple myeloma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary thyroid carcinoma, peritoneal neoplasm, prostate adenocarcinoma, prostate cancer, pulmonary neuroendocrine tumor, sarcoma, seminoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell lung carcinoma, thyroid cancer, urinary bladder cancer, urothelial carcinoma","angiosarcoma, breast cancer, cancer, colorectal carcinoma, endometrial cancer, gestational trophoblastic neoplasm, head and neck malignant neoplasia, liver cancer, malignant colon neoplasm, melanoma, mesothelioma, multiple myeloma, non-small cell lung carcinoma, ovarian cancer, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, rectum cancer, sarcoma, small cell lung carcinoma, triple-negative breast cancer","angiosarcoma, basal cell carcinoma, breast cancer, cancer, diffuse intrinsic pontine glioma, fallopian tube cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, hodgkins lymphoma, lung cancer, lymphoma, melanoma, multiple myeloma, non-small cell lung carcinoma, oropharyngeal carcinoma, ovarian cancer, pancreatic carcinoma, prostate cancer, skin cancer, squamous cell carcinoma, triple-negative breast cancer","acute myeloid leukemia, adenoid cystic carcinoma, angiosarcoma, breast cancer, breast carcinoma, breast neoplasm, cancer, chordoma, chronic myelogenous leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, diffuse large b-cell lymphoma, endometrial cancer, esophageal squamous cell carcinoma, fallopian tube cancer, follicular lymphoma, gastric adenocarcinoma, gestational trophoblastic neoplasm, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, leiomyosarcoma, lymphoma, malignant colon neoplasm, malignant glioma, melanoma, meningioma, mesothelioma, metastatic prostate cancer, multiple myeloma, nasopharyngeal neoplasm, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, peritoneum cancer, prostate cancer, rectum cancer, renal carcinoma, skin cancer, small cell lung carcinoma, squamous cell carcinoma, thymic carcinoma, thymoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, anal carcinoma, angiosarcoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, breast cancer, breast carcinoma, breast neoplasm, cancer, cholangiocarcinoma, chronic lymphocytic leukemia, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, dysgerminoma, endometrial cancer, endometrial neoplasm, esophageal cancer, esophageal squamous cell carcinoma, fallopian tube carcinoma, follicular lymphoma, follicular thyroid carcinoma, gastric adenocarcinoma, gastric cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, large cell lung carcinoma, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoid neoplasm, lymphoma, malignant colon neoplasm, malignant pleural mesothelioma, melanoma, mesothelioma, mouth neoplasm, multiple myeloma, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary renal cell carcinoma, papillary thyroid carcinoma, plasmacytoma, polycythemia vera, prostate adenocarcinoma, prostate cancer, pulmonary neuroendocrine tumor, rectum cancer, sarcoma, seminoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, alveolar soft part sarcoma, anus cancer, biliary tract cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cholangiocarcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colonic neoplasm, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, diffuse large b-cell lymphoma, endometrial cancer, endometrial carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder carcinoma, gastric adenocarcinoma, gastrointestinal stromal tumor, glioblastoma multiforme, gliosarcoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, lung cancer, lymphoma, malignant glioma, malignant peritoneal mesothelioma, malignant pleural mesothelioma, melanoma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, mycosis fungoides, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary renal cell carcinoma, peritoneal neoplasm, prostate adenocarcinoma, prostate cancer, rectum cancer, sarcoma, sezary's disease, skin cancer, small cell lung carcinoma, thyroid carcinoma, triple-negative breast cancer, urinary bladder cancer, urothelial carcinoma, uterine carcinosarcoma","acute lymphoblastic leukemia, acute myeloid leukemia, adrenal cortex carcinoma, anaplastic large cell lymphoma, angiosarcoma, basal cell carcinoma, biliary tract cancer, biliary tract neoplasm, bladder tumor, brain cancer, brain neoplasm, breast cancer, breast carcinoma, cancer, carcinosarcoma, central nervous system cancer, cervical adenocarcinoma, childhood acute lymphoblastic leukemia, cholangiocarcinoma, chordoma, chromophobe renal cell carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, collecting duct carcinoma, colon adenocarcinoma, colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, craniopharyngioma, cutaneous melanoma, dedifferentiated liposarcoma, diffuse intrinsic pontine glioma, diffuse large b-cell lymphoma, digestive system neuroendocrine neoplasm, endometrial cancer, endometrial carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, glioma, gliosarcoma, grade iii meningioma, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, large cell lung carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoid neoplasm, lymphoma, malignant colon neoplasm, malignant glioma, malignant pleural mesothelioma, mantle cell lymphoma, melanoma, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, nerve sheath neoplasm, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oligodendroglioma, oral squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, papillary renal cell carcinoma, peritoneum cancer, pituitary adenocarcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland cancer, sarcoma, sezary's disease, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, t-cell non-hodgkin lymphoma, thyroid cancer, thyroid carcinoma, triple-negative breast cancer, undifferentiated pleomorphic sarcoma, unspecified peripheral t-cell lymphoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma","acute lymphoblastic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adrenal cortex carcinoma, adult lymphoma, alveolar soft part sarcoma, anal carcinoma, anaplastic astrocytoma, angiosarcoma, anus cancer, astrocytoma, asymptomatic myeloma, b-cell acute lymphoblastic leukemia, biliary tract cancer, biliary tract neoplasm, bladder tumor, bone sarcoma, brain cancer, brain neoplasm, breast cancer, breast carcinoma, breast carcinoma in situ, breast ductal carcinoma in situ, breast neoplasm, cancer, carcinoma of liver and intrahepatic biliary tract, carcinosarcoma, cervical adenocarcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, digestive system neuroendocrine neoplasm, endometrial cancer, endometrial carcinoma, endometrial neoplasm, epithelioid sarcoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder cancer, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, gestational trophoblastic neoplasm, glioblastoma multiforme, glioma, gliosarcoma, grade iii meningioma, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, laryngeal squamous cell carcinoma, leukemia, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoid leukemia, lymphoid neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant glioma, malignant peripheral nerve sheath tumor, malignant pleural mesothelioma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medullary thyroid gland carcinoma, melanoma, meningeal neoplasm, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, mouth neoplasm, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oropharynx cancer, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, papillary renal cell carcinoma, parotid gland cancer, pediatric lymphoma, penile carcinoma, peritoneal neoplasm, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland carcinoma, sarcoma, sezary's disease, skin basal cell carcinoma, skin cancer, skin carcinoma, skin neoplasm, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, stomach neoplasm, thymic carcinoma, thymoma, thyroid cancer, thyroid carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, vulvar carcinoma, waldenstrom macroglobulinemia","acute lymphoblastic leukemia, acute myeloid leukemia, basal cell carcinoma, biliary tract neoplasm, breast cancer, breast carcinoma, cancer, cervical adenocarcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, classic hodgkin lymphoma, clear cell renal carcinoma, colon carcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, dedifferentiated liposarcoma, diffuse large b-cell lymphoma, digestive system neuroendocrine neoplasm, endometrial cancer, endometrial carcinoma, esophageal cancer, esophageal carcinoma, fallopian tube carcinoma, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, glioblastoma multiforme, glioma, gliosarcoma, grade iii meningioma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, inflammatory breast carcinoma, kaposi's sarcoma, kidney cancer, lung adenocarcinoma, lung cancer, lymphoma, malignant colon neoplasm, malignant glioma, malignant pleural mesothelioma, melanoma, meningioma, mesothelioma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, myeloproliferative disorder, nasopharyngeal neoplasm, neoplasm of mature b-cells, nerve sheath neoplasm, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, peritoneum cancer, pituitary adenocarcinoma, prostate adenocarcinoma, prostate cancer, prostate carcinoma, rectum cancer, salivary gland cancer, sarcoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, synovial sarcoma, thyroid cancer, undifferentiated pleomorphic sarcoma, urinary bladder cancer, urothelial carcinoma, uterine carcinosarcoma","cancer, hepatocellular carcinoma, lymphoma","breast cancer, cancer, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma, squamous cell carcinoma","bladder tumor, cancer, multiple myeloma, prostate adenocarcinoma, urothelial carcinoma","breast neoplasm, cancer, colorectal carcinoma, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, gastric carcinoma, glioblastoma multiforme, hepatocellular carcinoma, hodgkins lymphoma, lung cancer, lymphoma, nasopharyngeal neoplasm, non-small cell lung carcinoma, pancreatic carcinoma, pancreatic neoplasm, small cell lung carcinoma, squamous cell lung carcinoma, thyroid cancer","non-small cell lung carcinoma, prostate adenocarcinoma, urinary bladder cancer, urothelial carcinoma","angioimmunoblastic t-cell lymphoma, angiosarcoma, biliary tract cancer, breast cancer, cancer, cervical adenocarcinoma, cholangiocarcinoma, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, endometrial cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, lung cancer, lung neoplasm, lymphoma, mesothelioma, nasopharyngeal neoplasm, neuroblastoma, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, pancreatic carcinoma, pancreatic neoplasm, rectum cancer, salivary gland cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, undifferentiated pleomorphic sarcoma, unspecified peripheral t-cell lymphoma","angiosarcoma, bladder tumor, cancer, diffuse intrinsic pontine glioma, endometrial cancer, melanoma, non-small cell lung carcinoma, oropharynx cancer, ovarian cancer, soft tissue sarcoma","cancer, clear cell renal carcinoma, colorectal carcinoma, hepatocellular carcinoma, lung cancer, melanoma, nasopharyngeal neoplasm, non-small cell lung carcinoma, ovarian cancer","chronic lymphocytic leukemia, non-small cell lung carcinoma","cancer, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma","cancer, colorectal carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma, small cell lung carcinoma","breast cancer, cancer, colorectal carcinoma, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma, small cell lung carcinoma","biliary tract cancer, metastatic melanoma, osteosarcoma, small cell lung carcinoma, urothelial carcinoma","cancer, gastric adenocarcinoma, hepatocellular carcinoma, hodgkins lymphoma, lymphoma, non-small cell lung carcinoma, small cell lung carcinoma","cancer, cutaneous melanoma, endometrial cancer, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, follicular lymphoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, rectum cancer, small cell lung carcinoma, triple-negative breast cancer, urinary bladder cancer, urothelial carcinoma","biliary tract cancer, biliary tract neoplasm, breast cancer, cancer, cervical adenocarcinoma, cholangiocarcinoma, colonic neoplasm, colorectal carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liposarcoma, lung cancer, lymphoma, malignant pleural mesothelioma, melanoma, metastatic melanoma, mouth neoplasm, nasopharyngeal neoplasm, neoplasm of hypopharynx, non-small cell lung carcinoma, oral squamous cell carcinoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, undifferentiated pleomorphic sarcoma, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","acute myeloid leukemia, adrenal cortex carcinoma, biliary tract cancer, bladder tumor, breast cancer, cancer, cholangiocarcinoma, classic hodgkin lymphoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, diffuse large b-cell lymphoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gestational trophoblastic neoplasm, glioblastoma multiforme, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, hypopharyngeal carcinoma, intrahepatic cholangiocarcinoma, liver cancer, lung cancer, lung carcinoma, lung neoplasm, lymphoma, malignant colon neoplasm, melanoma, mouth neoplasm, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, paranasal sinus cancer, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, thyroid cancer, triple-negative breast cancer","cancer, glioblastoma multiforme, melanoma, non-small cell lung carcinoma","cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, lymphoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, thymic carcinoma, triple-negative breast cancer","head and neck squamous cell carcinoma, hepatocellular carcinoma, lymphoma","cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma, thyroid cancer, urinary bladder cancer","breast cancer, cancer, endometrial cancer, esophageal cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, prostate cancer, sarcoma, soft tissue sarcoma, squamous cell carcinoma, triple-negative breast cancer, urothelial carcinoma","biliary tract cancer, biliary tract neoplasm, bladder tumor, breast cancer, cancer, classic hodgkin lymphoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, diffuse large b-cell lymphoma, endometrial cancer, esophageal cancer, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, gastric cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, malignant bone neoplasm, malignant colon neoplasm, melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, prostate cancer, rectum cancer, small cell lung carcinoma, squamous cell carcinoma, squamous cell lung carcinoma, t-cell non-hodgkin lymphoma, triple-negative breast cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma","cancer, colorectal carcinoma, lymphoid neoplasm, melanoma, non-small cell lung carcinoma, prostate cancer, small cell lung carcinoma","cancer, classic hodgkin lymphoma, glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, pancreatic carcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer","breast cancer, cancer, cutaneous melanoma, esophageal squamous cell carcinoma, gastric cancer, gastrointestinal stromal tumor, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung cancer, lymphoma, melanoma, multiple myeloma, nasopharyngeal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, triple-negative breast cancer","alveolar soft part sarcoma, cancer, neoplasm of mature b-cells, non-small cell lung carcinoma, unspecified peripheral t-cell lymphoma","breast cancer, lymphoma, metastatic melanoma","esophageal squamous cell carcinoma","esophageal squamous cell carcinoma","biliary tract cancer, biliary tract neoplasm, breast cancer, cancer, colorectal carcinoma, endometrial cancer, gastric adenocarcinoma, hepatocellular carcinoma, lung neoplasm, malignant colon neoplasm, nasopharyngeal neoplasm, non-small cell lung carcinoma, ovarian cancer, pancreatic carcinoma, rectum cancer, soft tissue sarcoma","diffuse large b-cell lymphoma, hepatocellular carcinoma, lymphoma, melanoma, multiple myeloma, pancreatic carcinoma, prostate adenocarcinoma","cancer, non-small cell lung carcinoma","cancer, extranodal nasal nk/t cell lymphoma","angiosarcoma, bladder tumor, cancer, diffuse intrinsic pontine glioma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, soft tissue sarcoma","cancer, glioblastoma multiforme","cancer","breast cancer, cancer, colorectal carcinoma, head and neck malignant neoplasia, ovarian cancer, small cell lung carcinoma","cancer"],["1|2|3|4","1|2|3|4","1|2|3|4","0.5|1|2|3|4","1|2|3|4","1|2|3|4","0.5|1|2|3|4","0.5|1|2|3|4","1|2|3|4","1|3","1|2|3","1|2|3","1|2|3","1|3","0.5|1|2|3","1|2","1|2|3","1|3","1|2|3","1|2","1|2|3","1|3","1|2|3","1|2|3","1|2|3","1|2|3","0.5|2|3","1|2|3","1|2|3","2|3","1|2|3","1|2|3","1|2|3","0.5|1|2|3","1|2|3","1|2","1|2","2","2","1|2","1|2","1|2","2","1|2","1","1","1","1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F"],["MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs"],["L01FX","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF|L01FX","L01FF","L01FX","L01FX","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FX","L01FF|L01FX","L01FF","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FF","L01FX","L01FX","L01FX","L01FF","L01FF"],["Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs|PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","Other MaBs and ADCs|PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","Other MaBs and ADCs","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>target_symbol<\/th>\n      <th>target_genename<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>target_entrezgene<\/th>\n      <th>target_ensembl_gene_id<\/th>\n      <th>target_type<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,16,19,21,22,23]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
 </div>
 <div class="section level3">
 <h3 id="get-immune-checkpoint-inhibitors-indicated-for-tumor-subtypes-within-colonrectum-list-per-drug-target-entry">Get immune checkpoint inhibitors indicated for tumor subtypes within
@@ -311,8 +291,8 @@ <h3 id="get-immune-checkpoint-inhibitors-indicated-for-tumor-subtypes-within-col
 <span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
 <span><span class="op">)</span></span></code></pre></div>
 <p><br></p>
-<div id="htmlwidget-fcae08ebacf1cf7b956e" style="width:100%;height:auto;" class="datatables html-widget "></div>
-<script type="application/json" data-for="htmlwidget-fcae08ebacf1cf7b956e">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21"],[3977,3406,20686,22266,25875,28422,11138,11415,16656,22320,23926,25707,27989,12145,6385,28004,29337,29865,28201,6266,5656],["Avelumab","Atezolizumab","Nivolumab","Pembrolizumab","Sintilimab","Tremelimumab","Dostarlimab","Durvalumab","Ipilimumab","Penpulimab","Quavonlimab","Serplulimab","Tiragolumab","Envafolimab","Camrelizumab","Tislelizumab","Vibostolimab","Zimberelimab","Toripalimab","Cadonilimab","Budigalimab"],["Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody"],["CD274","CD274","PDCD1","PDCD1","PDCD1","CTLA4","PDCD1","CD274","CTLA4","PDCD1","CTLA4","PDCD1","TIGIT","CD274","PDCD1","PDCD1","TIGIT","PDCD1","PDCD1","CTLA4","PDCD1"],["CD274 molecule","CD274 molecule","programmed cell death 1","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","CD274 molecule","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1"],["CHEMBL3833373","CHEMBL3707227","CHEMBL2108738","CHEMBL3137343","CHEMBL4297829","CHEMBL2108658","CHEMBL4298124","CHEMBL3301587","CHEMBL1789844","CHEMBL4297571","CHEMBL4650419","CHEMBL4594550","CHEMBL4298050","CHEMBL4298006","CHEMBL4297715","CHEMBL4297840","CHEMBL4297785","CHEMBL4297856","CHEMBL4297843","CHEMBL4594456","CHEMBL4297858"],["OTHER","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","BINDING AGENT","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR"],["A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","NA","NA","NA","NA","An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","NA","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","NA","NA","NA","NA","NA"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C116870","C106250","C68814","C106432","C132992","C49085","C126799","C103194","C2654","NA","NA","NA","NA","C129714","NA","C121775","NA","NA","NA","NA","NA"],[29126,29126,5133,5133,5133,1493,5133,29126,1493,5133,1493,5133,201633,29126,5133,5133,201633,5133,5133,1493,5133],["ENSG00000120217","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000163599","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000181847","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389"],["single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein"],[0.905,0.914,0.863,0.874,0.9419999999999999,0.881,0.958,0.889,0.888,0.95,0.857,0.909,0.947,0.8,0.9370000000000001,0.96,0.875,1,0.957,1,0.778],[true,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[63,81,146,167,52,59,24,90,98,20,7,11,19,20,63,50,8,12,47,12,9],[2017,2016,2015,2014,null,2022,2021,2017,2011,null,null,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,3,4,4,4,4,3,3,3,3,2,3,3,3,3,3,3,1],["colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","anus cancer, colonic neoplasm, colorectal carcinoma, colorectal neoplasm, rectum cancer","colon adenocarcinoma, colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","anal carcinoma, anus cancer, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, rectum cancer","colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm","colorectal carcinoma, malignant colon neoplasm, rectum cancer","anal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, malignant colon neoplasm, rectum cancer","colon carcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal carcinoma","colorectal carcinoma","colorectal carcinoma","rectum cancer","colorectal carcinoma, malignant colon neoplasm, rectum cancer","colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal cancer, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal carcinoma","rectum cancer","colonic neoplasm, colorectal carcinoma","colorectal carcinoma","colorectal carcinoma"],["2|3","2|3","2|3","2|3","2|3","2","2","2","2","2","2","2","2","2","2","2","2","2","1|2","1","1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F"],["MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs"],["L01FF","L01FF","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FX","L01FF","L01FX","L01FF","L01FX","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FF|L01FX","L01FF"],["PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs|PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>target_symbol<\/th>\n      <th>target_genename<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>target_entrezgene<\/th>\n      <th>target_ensembl_gene_id<\/th>\n      <th>target_type<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,16,19,21,22,23]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
+<div id="htmlwidget-76f56892189ad2b001b0" style="width:100%;height:auto;" class="datatables html-widget "></div>
+<script type="application/json" data-for="htmlwidget-76f56892189ad2b001b0">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21"],[4024,3450,20759,22341,25955,28505,11189,11466,16724,22396,24004,25787,28072,12198,6430,28087,29421,29951,28284,6312,5703],["Avelumab","Atezolizumab","Nivolumab","Pembrolizumab","Sintilimab","Tremelimumab","Dostarlimab","Durvalumab","Ipilimumab","Penpulimab","Quavonlimab","Serplulimab","Tiragolumab","Envafolimab","Camrelizumab","Tislelizumab","Vibostolimab","Zimberelimab","Toripalimab","Cadonilimab","Budigalimab"],["Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody","Antibody"],["CD274","CD274","PDCD1","PDCD1","PDCD1","CTLA4","PDCD1","CD274","CTLA4","PDCD1","CTLA4","PDCD1","TIGIT","CD274","PDCD1","PDCD1","TIGIT","PDCD1","PDCD1","CTLA4","PDCD1"],["CD274 molecule","CD274 molecule","programmed cell death 1","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","CD274 molecule","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","CD274 molecule","programmed cell death 1","programmed cell death 1","T cell immunoreceptor with Ig and ITIM domains","programmed cell death 1","programmed cell death 1","cytotoxic T-lymphocyte associated protein 4","programmed cell death 1"],["CHEMBL3833373","CHEMBL3707227","CHEMBL2108738","CHEMBL3137343","CHEMBL4297829","CHEMBL2108658","CHEMBL4298124","CHEMBL3301587","CHEMBL1789844","CHEMBL4297571","CHEMBL4650419","CHEMBL4594550","CHEMBL4298050","CHEMBL4298006","CHEMBL4297715","CHEMBL4297840","CHEMBL4297785","CHEMBL4297856","CHEMBL4297843","CHEMBL4594456","CHEMBL4297858"],["OTHER","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","ANTAGONIST","INHIBITOR","BINDING AGENT","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR"],["A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","NA","NA","NA","NA","An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.","NA","A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","NA","NA","NA","NA","NA"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C116870","C106250","C68814","C106432","C132992","C49085","C126799","C103194","C2654","NA","NA","NA","NA","C129714","NA","C121775","NA","NA","NA","NA","NA"],[29126,29126,5133,5133,5133,1493,5133,29126,1493,5133,1493,5133,201633,29126,5133,5133,201633,5133,5133,1493,5133],["ENSG00000120217","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000120217","ENSG00000163599","ENSG00000188389","ENSG00000163599","ENSG00000188389","ENSG00000181847","ENSG00000120217","ENSG00000188389","ENSG00000188389","ENSG00000181847","ENSG00000188389","ENSG00000188389","ENSG00000163599","ENSG00000188389"],["single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein","single_protein"],[0.905,0.889,0.849,0.862,0.923,0.881,0.875,0.878,0.878,0.9,0.857,0.8179999999999999,0.895,0.8,0.905,0.9399999999999999,0.875,0.917,0.9360000000000001,0.833,0.778],[true,false,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[63,81,146,167,52,59,24,90,98,20,7,11,19,20,63,50,8,12,47,12,9],[2017,2016,2015,2014,null,2022,2021,2017,2011,null,null,null,null,null,null,null,null,null,null,null,null],[4,4,4,4,3,4,4,4,4,3,3,3,3,2,3,3,3,3,3,3,1],["colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","anus cancer, colonic neoplasm, colorectal carcinoma, colorectal neoplasm, rectum cancer","colon adenocarcinoma, colon carcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","anal carcinoma, anus cancer, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, rectum cancer","colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm","colorectal carcinoma, malignant colon neoplasm, rectum cancer","anal carcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, malignant colon neoplasm, rectum cancer","colon carcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal carcinoma","colorectal carcinoma","colorectal carcinoma","rectum cancer","colorectal carcinoma, malignant colon neoplasm, rectum cancer","colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal cancer, colorectal carcinoma, colorectal neoplasm, malignant colon neoplasm, rectum cancer","colorectal carcinoma","rectum cancer","colonic neoplasm, colorectal carcinoma","colorectal carcinoma","colorectal carcinoma"],["2|3","2|3","2|3","2|3","2|3","2","2","2","2","2","2","2","2","2","2","2","2","2","1|2","1","1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F","L01F"],["MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs","MONOCLONAL ANTIBODIES AND ADCs"],["L01FF","L01FF","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FX","L01FF","L01FX","L01FF","L01FX","L01FF","L01FF","L01FF","L01FX","L01FF","L01FF","L01FF|L01FX","L01FF"],["PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs","PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors","Other MaBs and ADCs|PD-1/PDL-1 inhibitors","PD-1/PDL-1 inhibitors"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>target_symbol<\/th>\n      <th>target_genename<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>target_entrezgene<\/th>\n      <th>target_ensembl_gene_id<\/th>\n      <th>target_type<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,16,19,21,22,23]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
 </div>
 <div class="section level3">
 <h3 id="get-antimetabolite-drugs">Get antimetabolite drugs<a class="anchor" aria-label="anchor" href="#get-antimetabolite-drugs"></a>
@@ -322,24 +302,24 @@ <h3 id="get-antimetabolite-drugs">Get antimetabolite drugs<a class="anchor" aria
 <span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
 <span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>, </span>
 <span>  output_resolution <span class="op">=</span> <span class="st">"drug"</span><span class="op">)</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:48] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:48] Object 'drug_map_name' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:48] Retrieved n = 30211 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Object 'drug_map_alias' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Retrieved n = 655802 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Object 'drug_map_basic' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Retrieved n = 31146 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Object 'drug_map_target' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Retrieved n = 38127 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Object 'drug_map_indication' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:49] Retrieved n = 58866 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:52] Record set satisfying user-defined criteria: n = 74633</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:52] Collapsing record set - providing output on a 'per_drug' resolution</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:53] Final record set: n = 1162 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Object 'drug_map_name' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Retrieved n = 30298 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Object 'drug_map_alias' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Retrieved n = 655065 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Object 'drug_map_basic' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Retrieved n = 31232 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Object 'drug_map_target' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:06] Retrieved n = 38215 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:07] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:07] Object 'drug_map_indication' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:07] Retrieved n = 56512 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:10] Record set satisfying user-defined criteria: n = 72161</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:10] Collapsing record set - providing output on a 'per_drug' resolution</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:10] Final record set: n = 1079 records</span></span>
 <span></span>
 <span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">&lt;-</span> <span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">|&gt;</span></span>
 <span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/filter.html" class="external-link">filter</a></span><span class="op">(</span></span>
@@ -366,8 +346,8 @@ <h3 id="get-antimetabolite-drugs">Get antimetabolite drugs<a class="anchor" aria
 <span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
 <span><span class="op">)</span></span></code></pre></div>
 <p><br></p>
-<div id="htmlwidget-45f8c2dd6a148175e2a4" style="width:100%;height:auto;" class="datatables html-widget "></div>
-<script type="application/json" data-for="htmlwidget-45f8c2dd6a148175e2a4">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19"],[23366,9925,20330,22273,4023,8266,6431,14432,8152,13517,9317,13654,19027,18843,27270,24232,12072,25447,27547],["Pralatrexate","Decitabine","Nelarabine","Pemetrexed","Azacitidine","Clofarabine","Capecitabine","Gemcitabine","Cladribine","Floxuridine","Cytarabine","Fluorouracil","Methotrexate","Mercaptopurine","Tegafur","Raltitrexed","Eniluracil","Sapacitabine","Tezacitabine"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL1201746","CHEMBL1201129","CHEMBL1201112","CHEMBL225072","CHEMBL1489","CHEMBL1750","CHEMBL1773","CHEMBL888","CHEMBL1619","CHEMBL917","CHEMBL803","CHEMBL185","CHEMBL34259","CHEMBL1425","CHEMBL20883","CHEMBL225071","CHEMBL355200","CHEMBL2105681","CHEMBL2105467"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],["A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","A congener of the antimetabolite fluorouracil with antineoplastic activity. Tegafur is a prodrug that is gradually converted to fluorouracil in the liver by the cytochrome P-450 enzyme. Subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by inhibiting thymidylate synthase and reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","An orally-active fluoropyrimidine analogue. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU.","An orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine is hydrolyzed by amidases to the deoxycytosine analogue CNDAC (2'-Cyano-2'-deoxyarabinofuranosylcytosine), which is then phosphorylated into the active triphosphate form. As an analogue of deoxycytidine triphosphate, CNDAC triphosphate incorporates into DNA strands during replication, resulting in single-stranded DNA breaks during polymerization due to beta-elimination during the fidelity checkpoint process; cell cycle arrest in the G2 phase and apoptosis ensue. The unmetabolized prodrug may exhibit antineoplastic activity as well.","A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication. This agent is relatively resistant to metabolic deactivation by cytidine deaminase. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates necessary for DNA synthesis and is overexpressed in many tumor types."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","TRUE","FALSE","FALSE","FALSE","TRUE","FALSE","TRUE","TRUE","TRUE","FALSE","TRUE","FALSE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C2250","C981","C1704","C61614","C288","C26638","C1794","C66876","C1336","C504","C408","C505","C642","C195","C513","C1804","C1773","C64541","C1539"],[1,0.793,0.923,0.9,0.806,0.8100000000000001,0.89,0.913,0.714,0.947,0.74,0.806,0.54,0.87,0.927,1,1,1,1],[false,true,false,false,true,false,false,false,true,false,true,true,true,false,false,false,false,false,false],[19,58,13,70,62,21,82,115,28,19,77,103,163,23,41,15,8,6,5],[2009,2006,2005,2004,2004,2004,1998,1996,1993,1970,1969,1962,1953,1953,null,null,null,null,null],[4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,4,3,3,2],["adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, breast carcinoma, cancer, cutaneous t-cell lymphoma, fallopian tube cancer, head and neck malignant neoplasia, lung cancer, lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, multiple myeloma, mycosis fungoides, non-small cell lung carcinoma, ovarian cancer, peritoneum cancer, sezary's disease, t-cell non-hodgkin lymphoma, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adult lymphoma, blast phase chronic myelogenous leukemia, bcr-abl1 positive, breast cancer, breast neoplasm, burkitts lymphoma, cancer, central nervous system cancer, childhood acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, cutaneous melanoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, follicular thyroid carcinoma, head and neck malignant neoplasia, hodgkins lymphoma, leukemia, lymphoid neoplasm, lymphoma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medulloblastoma, melanoma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, myeloproliferative disorder, neoplasm of mature b-cells, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, papillary thyroid carcinoma, pediatric lymphoma, peritoneum cancer, prostate carcinoma, refractory anemia with excess blasts, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, cancer, chronic myeloproliferative disorder, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, multiple myeloma, mycosis fungoides, sezary's disease, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma","biliary tract cancer, breast cancer, breast carcinoma, breast neoplasm, bronchoalveolar adenocarcinoma, cancer, cervical cancer, chordoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, diffuse large b-cell lymphoma, endometrial cancer, esophageal cancer, esophageal carcinoma, fallopian tube cancer, fallopian tube carcinoma, gastric cancer, gastric carcinoma, gestational trophoblastic neoplasm, head and neck malignant neoplasia, head and neck squamous cell carcinoma, large cell lung carcinoma, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant glioma, malignant peritoneal mesothelioma, malignant pleural mesothelioma, medulloblastoma, mesothelioma, metastatic melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic neoplasm, peritoneum cancer, prostate cancer, rectum cancer, salivary gland carcinoma, sarcoma, small cell lung carcinoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, thymic carcinoma, thymoma, thymus cancer, thyroid cancer, urethra cancer, urinary bladder cancer, urothelial carcinoma","acute lymphoblastic leukemia, acute myeloid leukemia, angioimmunoblastic t-cell lymphoma, brain neoplasm, breast cancer, breast neoplasm, cancer, central nervous system cancer, childhood ependymoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, classic hodgkin lymphoma, colorectal carcinoma, cutaneous melanoma, diffuse large b-cell lymphoma, ependymoma, esophageal cancer, follicular lymphoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, leukemia, liposarcoma, lymphoid leukemia, lymphoid neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, mature t-cell and nk-cell non-hodgkin lymphoma, metastatic melanoma, multiple myeloma, myeloproliferative disorder, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer, refractory anemia with excess blasts, squamous cell carcinoma, t-cell acute lymphoblastic leukemia, t-cell large granular lymphocyte leukemia, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, hodgkins lymphoma, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoma, multiple myeloma, neoplasm of mature b-cells, non-hodgkins lymphoma, t-cell non-hodgkin lymphoma","anus cancer, biliary tract cancer, biliary tract neoplasm, brain cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical cancer, cholangiocarcinoma, colon adenocarcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, gallbladder cancer, gallbladder carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, glioblastoma multiforme, glioma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, kidney neoplasm, laryngeal squamous cell carcinoma, liver cancer, lung cancer, male breast carcinoma, malignant colon neoplasm, malignant glioma, melanoma, mesothelioma, metastatic melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, oropharyngeal carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, pancreatic neuroendocrine tumor, peritoneum cancer, prostate cancer, rectal carcinoma, rectal neoplasm, rectum cancer, skin cancer, skin carcinoma, squamous cell carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, urothelial carcinoma","acute lymphoblastic leukemia, acute myeloid leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, bone sarcoma, brain cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical adenocarcinoma, cervical cancer, cervical carcinoma, cholangiocarcinoma, classic hodgkin lymphoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, cutaneous t-cell lymphoma, diffuse intrinsic pontine glioma, diffuse large b-cell lymphoma, endometrial cancer, endometrioid carcinoma, esophageal cancer, ewing sarcoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder cancer, gallbladder carcinoma, gallbladder neoplasm, gastric cancer, gastrointestinal stromal tumor, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hilar cholangiocarcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, large cell lung carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant epithelial tumor of ovary, malignant pleural mesothelioma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medulloblastoma, melanoma, mesothelioma, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, peritoneal neoplasm, peritoneum cancer, plasma cell leukemia, plasmacytoma, prostate cancer, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, synovial sarcoma, t-cell non-hodgkin lymphoma, testicular carcinoma, thyroid cancer, triple-negative breast cancer, unspecified peripheral t-cell lymphoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm","acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, cancer, chronic lymphocytic leukemia, chronic myeloproliferative disorder, diffuse large b-cell lymphoma, hairy cell leukemia, histiocytosis, langerhans cell histiocytosis, leukemia, lymphoma, malt lymphoma, mantle cell lymphoma, multiple myeloma, myeloid leukemia, systemic mastocytosis, unspecified peripheral t-cell lymphoma","cancer, cholangiocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, esophageal cancer, fallopian tube cancer, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liver cancer, malignant colon neoplasm, ovarian cancer, peritoneum cancer, rectum cancer","acute basophilic leukemia, acute erythroleukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute megakaryoblastic leukaemia, acute monocytic leukemia, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, b-cell acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, brain neoplasm, breast cancer, burkitts lymphoma, cancer, childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, classic hodgkin lymphoma, diffuse large b-cell lymphoma, essential thrombocythemia, follicular lymphoma, glioblastoma multiforme, granulocytic sarcoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, juvenile myelomonocytic leukemia, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, mantle cell lymphoma, medulloblastoma, melanoma, multiple myeloma, myeloid sarcoma, myeloproliferative disorder, neoplasm of mature b-cells, non-hodgkins lymphoma, ovarian cancer, plasma cell leukemia, polycythemia vera, prostate cancer, refractory anemia, refractory anemia with excess blasts, sarcoma, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma, unspecified peripheral t-cell lymphoma","actinic keratosis, anal carcinoma, anal neoplasm, anus cancer, basal cell carcinoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, breast cancer, breast carcinoma, breast neoplasm, cancer, central nervous system cancer, cervical cancer, cholangiocarcinoma, chronic myeloproliferative disorder, colon adenocarcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, ependymoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, laryngeal carcinoma, laryngeal neoplasm, liver cancer, lymphoma, malignant colon neoplasm, melanoma, metastatic melanoma, mucinous carcinoma, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-hodgkins lymphoma, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paranasal sinus neoplasm, peritoneal neoplasm, peritoneum cancer, pharynx cancer, rectal carcinoma, rectum cancer, skin carcinoma, squamous cell carcinoma, stomach neoplasm, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine neoplasm","acute erythroleukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute megakaryoblastic leukaemia, acute monocytic leukemia, acute myeloblastic leukemia without maturation, acute myeloid leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, b-cell acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, bone sarcoma, brain cancer, brain neoplasm, breast cancer, breast carcinoma, breast neoplasm, burkitts lymphoma, cancer, cervical cancer, childhood acute lymphoblastic leukemia, childhood ependymoma, choriocarcinoma, choroid plexus neoplasm, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, colorectal cancer, colorectal carcinoma, cutaneous melanoma, desmoid-type fibromatosis, diffuse large b-cell lymphoma, extranodal nasal nk/t cell lymphoma, follicular lymphoma, gestational trophoblastic neoplasm, hairy cell leukemia, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, hydatidiform mole, juvenile myelomonocytic leukemia, kidney cancer, langerhans cell histiocytosis, leukemia, lung cancer, lymphoblastic lymphoma, lymphoid leukemia, lymphoid neoplasm, lymphoma, malignant pleural mesothelioma, malt lymphoma, mantle cell lymphoma, medulloblastoma, mesothelioma, multiple myeloma, mycosis fungoides, myeloproliferative disorder, neoplasm of mature b-cells, neuroblastoma, neurofibromatosis type 1, non-hodgkins lymphoma, osteosarcoma, ovarian cancer, ovarian carcinoma, plasma cell leukemia, polycythemia vera, primitive neuroectodermal tumor, refractory anemia, refractory anemia with excess blasts, sarcoma, sezary's disease, squamous cell carcinoma, t-cell acute lymphoblastic leukemia, t-cell large granular lymphocyte leukemia, t-lymphoblastic lymphoma, unspecified peripheral t-cell lymphoma, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, waldenstrom macroglobulinemia","acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, anaplastic astrocytoma, anaplastic oligodendroglioma, b-cell acute lymphoblastic leukemia, brain neoplasm, burkitts lymphoma, cancer, childhood acute lymphoblastic leukemia, glioblastoma multiforme, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, mixed glioma, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma","biliary tract cancer, biliary tract neoplasm, breast cancer, breast neoplasm, cancer, cervical cancer, cholangiocarcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, gallbladder carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, nasopharyngeal neoplasm, neoplasm of esophagus, non-small cell lung carcinoma, oral squamous cell carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, pancreatic neuroendocrine tumor, rectal carcinoma, rectum cancer, small cell lung carcinoma, stomach neoplasm, urinary bladder cancer","bile duct adenoma, cancer, childhood acute lymphoblastic leukemia, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, esophageal cancer, esophageal squamous cell carcinoma, gastric cancer, mesothelioma, nasopharyngeal neoplasm, pancreatic carcinoma, rectum cancer, squamous cell carcinoma","breast cancer, cancer, colorectal adenocarcinoma, colorectal carcinoma, head and neck malignant neoplasia, lymphoma, malignant colon neoplasm, rectum cancer","acute myeloid leukemia, breast cancer, cancer, cutaneous t-cell lymphoma, leukemia, non-small cell lung carcinoma","cancer, colorectal neoplasm, esophageal carcinoma, stomach neoplasm"],["4|3|2|1","4|3|2|1|0.5","4|3|2|1","4|3|2|1|0.5","4|3|2|1|0.5","4|3|2|1","4|3|2|1","4|3|2|1|0.5","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2|1","3|2|1","3|2|1","2|1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01|L04","L01","L01","L01","L01|L04","L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS|IMMUNOSUPPRESSANTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS|IMMUNOSUPPRESSANTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01B","L01B","L01B","L01B","L01B","L01B","L01B","L01B","L01B|L04A","L01B","L01B","L01B","L01B|L04A","L01B","L01B","L01B","L01B","L01B","L01B"],["ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES|IMMUNOSUPPRESSANTS","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES|IMMUNOSUPPRESSANTS","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES"],["L01BA","L01BC","L01BB","L01BA","L01BC","L01BB","L01BC","L01BC","L01BB|L04AA","L01BC","L01BC","L01BC","L01BA|L04AX","L01BB","L01BC","L01BA","L01BC","L01BC","L01BC"],["Folic acid analogues","Pyrimidine analogues","Purine analogues","Folic acid analogues","Pyrimidine analogues","Purine analogues","Pyrimidine analogues","Pyrimidine analogues","Purine analogues|Selective immunosuppressants","Pyrimidine analogues","Pyrimidine analogues","Pyrimidine analogues","Folic acid analogues|Other immunosuppressants","Purine analogues","Pyrimidine analogues","Folic acid analogues","Pyrimidine analogues","Pyrimidine analogues","Pyrimidine analogues"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
+<div id="htmlwidget-ec62c50c9bd46048ccbc" style="width:100%;height:auto;" class="datatables html-widget "></div>
+<script type="application/json" data-for="htmlwidget-ec62c50c9bd46048ccbc">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16"],[23441,9976,22348,4070,8314,6476,14495,13572,9369,13709,19096,18912,27348,24311,12125,27625],["Pralatrexate","Decitabine","Pemetrexed","Azacitidine","Clofarabine","Capecitabine","Gemcitabine","Floxuridine","Cytarabine","Fluorouracil","Methotrexate","Mercaptopurine","Tegafur","Raltitrexed","Eniluracil","Tezacitabine"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL1201746","CHEMBL1201129","CHEMBL225072","CHEMBL1489","CHEMBL1750","CHEMBL1773","CHEMBL888","CHEMBL917","CHEMBL803","CHEMBL185","CHEMBL34259","CHEMBL1425","CHEMBL20883","CHEMBL225071","CHEMBL355200","CHEMBL2105467"],["INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR","INHIBITOR"],["A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","A congener of the antimetabolite fluorouracil with antineoplastic activity. Tegafur is a prodrug that is gradually converted to fluorouracil in the liver by the cytochrome P-450 enzyme. Subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by inhibiting thymidylate synthase and reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","An orally-active fluoropyrimidine analogue. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU.","A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication. This agent is relatively resistant to metabolic deactivation by cytidine deaminase. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates necessary for DNA synthesis and is overexpressed in many tumor types."],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true,true,true,true,true,true,true,true,true,true,true,true,true],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],["FALSE","FALSE","FALSE","FALSE","FALSE","TRUE","FALSE","TRUE","TRUE","FALSE","TRUE","FALSE","FALSE","FALSE","FALSE","FALSE"],["C2250","C981","C61614","C288","C26638","C1794","C66876","C504","C408","C505","C642","C195","C513","C1804","C1773","C1539"],[1,0.793,0.886,0.806,0.8100000000000001,0.878,0.896,0.947,0.74,0.796,0.537,0.87,0.902,1,1,1],[false,true,false,true,false,false,false,false,true,true,true,false,false,false,false,false],[19,58,70,62,21,82,115,19,77,103,162,23,41,15,8,5],[2009,2006,2004,2004,2004,1998,1996,1970,1969,1962,1953,1953,null,null,null,null],[4,4,4,4,4,4,4,4,4,4,4,4,4,4,3,2],["adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, breast carcinoma, cancer, cutaneous t-cell lymphoma, fallopian tube cancer, head and neck malignant neoplasia, lung cancer, lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, multiple myeloma, mycosis fungoides, non-small cell lung carcinoma, ovarian cancer, peritoneum cancer, sezary's disease, t-cell non-hodgkin lymphoma, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adult lymphoma, blast phase chronic myelogenous leukemia, bcr-abl1 positive, breast cancer, breast neoplasm, burkitts lymphoma, cancer, central nervous system cancer, childhood acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, cutaneous melanoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, follicular thyroid carcinoma, head and neck malignant neoplasia, hodgkins lymphoma, leukemia, lymphoid neoplasm, lymphoma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medulloblastoma, melanoma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, myeloproliferative disorder, neoplasm of mature b-cells, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, papillary thyroid carcinoma, pediatric lymphoma, peritoneum cancer, prostate carcinoma, refractory anemia with excess blasts, unspecified peripheral t-cell lymphoma","biliary tract cancer, breast cancer, breast carcinoma, breast neoplasm, bronchoalveolar adenocarcinoma, cancer, chordoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, diffuse large b-cell lymphoma, endometrial cancer, esophageal cancer, esophageal carcinoma, fallopian tube cancer, fallopian tube carcinoma, gastric cancer, gastric carcinoma, gestational trophoblastic neoplasm, head and neck malignant neoplasia, head and neck squamous cell carcinoma, large cell lung carcinoma, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant glioma, malignant peritoneal mesothelioma, malignant pleural mesothelioma, medulloblastoma, mesothelioma, metastatic melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic neoplasm, peritoneum cancer, prostate cancer, rectum cancer, salivary gland carcinoma, sarcoma, small cell lung carcinoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, thymic carcinoma, thymoma, thymus cancer, thyroid cancer, urethra cancer, urinary bladder cancer, urothelial carcinoma","acute lymphoblastic leukemia, acute myeloid leukemia, angioimmunoblastic t-cell lymphoma, brain neoplasm, breast cancer, breast neoplasm, cancer, central nervous system cancer, childhood ependymoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, classic hodgkin lymphoma, colorectal carcinoma, cutaneous melanoma, diffuse large b-cell lymphoma, ependymoma, esophageal cancer, follicular lymphoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, leukemia, liposarcoma, lymphoid leukemia, lymphoid neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, mature t-cell and nk-cell non-hodgkin lymphoma, metastatic melanoma, multiple myeloma, myeloproliferative disorder, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic carcinoma, pancreatic ductal adenocarcinoma, prostate adenocarcinoma, prostate cancer, rectum cancer, refractory anemia with excess blasts, squamous cell carcinoma, t-cell acute lymphoblastic leukemia, t-cell large granular lymphocyte leukemia, unspecified peripheral t-cell lymphoma","acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, hodgkins lymphoma, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoma, multiple myeloma, neoplasm of mature b-cells, non-hodgkins lymphoma, t-cell non-hodgkin lymphoma","anus cancer, biliary tract cancer, biliary tract neoplasm, brain cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cholangiocarcinoma, colon adenocarcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, gallbladder cancer, gallbladder carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, glioblastoma multiforme, glioma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, kidney neoplasm, laryngeal squamous cell carcinoma, liver cancer, lung cancer, male breast carcinoma, malignant colon neoplasm, malignant glioma, melanoma, mesothelioma, metastatic melanoma, nasopharyngeal neoplasm, non-hodgkins lymphoma, non-small cell lung carcinoma, oropharyngeal carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, pancreatic neuroendocrine tumor, peritoneum cancer, prostate cancer, rectal carcinoma, rectal neoplasm, rectum cancer, skin cancer, skin carcinoma, squamous cell carcinoma, stomach neoplasm, thyroid cancer, triple-negative breast cancer, urothelial carcinoma","acute lymphoblastic leukemia, acute myeloid leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, bone sarcoma, brain cancer, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical adenocarcinoma, cholangiocarcinoma, classic hodgkin lymphoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, cutaneous t-cell lymphoma, diffuse intrinsic pontine glioma, diffuse large b-cell lymphoma, endometrial cancer, endometrioid carcinoma, esophageal cancer, ewing sarcoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder cancer, gallbladder carcinoma, gallbladder neoplasm, gastric cancer, gastrointestinal stromal tumor, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hilar cholangiocarcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, kidney cancer, large cell lung carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant epithelial tumor of ovary, malignant pleural mesothelioma, mantle cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, medulloblastoma, melanoma, mesothelioma, multiple myeloma, mycosis fungoides, nasopharyngeal neoplasm, neoplasm of mature b-cells, non-hodgkins lymphoma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, peritoneal neoplasm, peritoneum cancer, plasma cell leukemia, plasmacytoma, prostate cancer, rectum cancer, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, synovial sarcoma, t-cell non-hodgkin lymphoma, testicular carcinoma, thyroid cancer, triple-negative breast cancer, unspecified peripheral t-cell lymphoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm","cancer, cholangiocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, esophageal cancer, fallopian tube cancer, gastric adenocarcinoma, gastric cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, liver cancer, malignant colon neoplasm, ovarian cancer, peritoneum cancer, rectum cancer","acute basophilic leukemia, acute erythroleukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute megakaryoblastic leukaemia, acute monocytic leukemia, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, b-cell acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, brain neoplasm, breast cancer, burkitts lymphoma, cancer, childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, classic hodgkin lymphoma, diffuse large b-cell lymphoma, essential thrombocythemia, follicular lymphoma, glioblastoma multiforme, granulocytic sarcoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, juvenile myelomonocytic leukemia, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, mantle cell lymphoma, medulloblastoma, melanoma, multiple myeloma, myeloid sarcoma, myeloproliferative disorder, neoplasm of mature b-cells, non-hodgkins lymphoma, ovarian cancer, plasma cell leukemia, polycythemia vera, prostate cancer, refractory anemia, refractory anemia with excess blasts, sarcoma, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma, unspecified peripheral t-cell lymphoma","actinic keratosis, anal carcinoma, anal neoplasm, anus cancer, basal cell carcinoma, bile duct cancer, biliary tract cancer, biliary tract neoplasm, bladder tumor, breast cancer, breast carcinoma, breast neoplasm, cancer, central nervous system cancer, cholangiocarcinoma, chronic myeloproliferative disorder, colon adenocarcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, ependymoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, laryngeal carcinoma, laryngeal neoplasm, liver cancer, lymphoma, malignant colon neoplasm, melanoma, metastatic melanoma, mucinous carcinoma, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-hodgkins lymphoma, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paranasal sinus neoplasm, peritoneal neoplasm, peritoneum cancer, pharynx cancer, rectal carcinoma, rectum cancer, skin carcinoma, squamous cell carcinoma, stomach neoplasm, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine neoplasm","acute erythroleukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute megakaryoblastic leukaemia, acute monocytic leukemia, acute myeloblastic leukemia without maturation, acute myeloid leukemia, acute myelomonocytic leukemia, acute promyelocytic leukemia, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, b-cell acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, bone sarcoma, brain cancer, brain neoplasm, breast cancer, breast carcinoma, breast neoplasm, burkitts lymphoma, cancer, childhood acute lymphoblastic leukemia, childhood ependymoma, choriocarcinoma, choroid plexus neoplasm, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic myeloproliferative disorder, colorectal cancer, colorectal carcinoma, cutaneous melanoma, desmoid-type fibromatosis, diffuse large b-cell lymphoma, extranodal nasal nk/t cell lymphoma, follicular lymphoma, gestational trophoblastic neoplasm, hairy cell leukemia, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm, hodgkins lymphoma, hydatidiform mole, juvenile myelomonocytic leukemia, kidney cancer, langerhans cell histiocytosis, leukemia, lung cancer, lymphoblastic lymphoma, lymphoid leukemia, lymphoid neoplasm, lymphoma, malignant pleural mesothelioma, malt lymphoma, mantle cell lymphoma, medulloblastoma, mesothelioma, multiple myeloma, mycosis fungoides, myeloproliferative disorder, neoplasm of mature b-cells, neuroblastoma, neurofibromatosis type 1, non-hodgkins lymphoma, osteosarcoma, ovarian cancer, ovarian carcinoma, plasma cell leukemia, polycythemia vera, primitive neuroectodermal tumor, refractory anemia, refractory anemia with excess blasts, sarcoma, sezary's disease, squamous cell carcinoma, t-cell acute lymphoblastic leukemia, t-cell large granular lymphocyte leukemia, t-lymphoblastic lymphoma, unspecified peripheral t-cell lymphoma, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, waldenstrom macroglobulinemia","acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, anaplastic astrocytoma, anaplastic oligodendroglioma, b-cell acute lymphoblastic leukemia, brain neoplasm, burkitts lymphoma, cancer, childhood acute lymphoblastic leukemia, glioblastoma multiforme, langerhans cell histiocytosis, leukemia, lymphoblastic lymphoma, lymphoid leukemia, lymphoma, mixed glioma, t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma","biliary tract cancer, biliary tract neoplasm, breast cancer, breast neoplasm, cancer, cholangiocarcinoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, gallbladder carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, nasopharyngeal neoplasm, neoplasm of esophagus, non-small cell lung carcinoma, oral squamous cell carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, pancreatic neuroendocrine tumor, rectal carcinoma, rectum cancer, small cell lung carcinoma, stomach neoplasm, urinary bladder cancer","bile duct adenoma, cancer, childhood acute lymphoblastic leukemia, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, esophageal cancer, esophageal squamous cell carcinoma, gastric cancer, mesothelioma, nasopharyngeal neoplasm, pancreatic carcinoma, rectum cancer, squamous cell carcinoma","breast cancer, cancer, colorectal adenocarcinoma, colorectal carcinoma, head and neck malignant neoplasia, lymphoma, malignant colon neoplasm, rectum cancer","cancer, colorectal neoplasm, esophageal carcinoma, stomach neoplasm"],["4|3|2|1","4|3|2|1|0.5","4|3|2|1|0.5","4|3|2|1|0.5","4|3|2|1","4|3|2|1","4|3|2|1|0.5","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2|1","4|3|2","4|3|2|1","3|2|1","2|1"],["L01","L01","L01","L01","L01","L01","L01","L01","L01","L01","L01|L04","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS|IMMUNOSUPPRESSANTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01B","L01B","L01B","L01B","L01B","L01B","L01B","L01B","L01B","L01B","L01B|L04A","L01B","L01B","L01B","L01B","L01B"],["ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES|IMMUNOSUPPRESSANTS","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES","ANTIMETABOLITES"],["L01BA","L01BC","L01BA","L01BC","L01BB","L01BC","L01BC","L01BC","L01BC","L01BC","L01BA|L04AX","L01BB","L01BC","L01BA","L01BC","L01BC"],["Folic acid analogues","Pyrimidine analogues","Folic acid analogues","Pyrimidine analogues","Purine analogues","Pyrimidine analogues","Pyrimidine analogues","Pyrimidine analogues","Pyrimidine analogues","Pyrimidine analogues","Folic acid analogues|Other immunosuppressants","Purine analogues","Pyrimidine analogues","Folic acid analogues","Pyrimidine analogues","Pyrimidine analogues"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
 </div>
 <div class="section level3">
 <h3 id="get-taxanes">Get taxanes<a class="anchor" aria-label="anchor" href="#get-taxanes"></a>
@@ -377,24 +357,24 @@ <h3 id="get-taxanes">Get taxanes<a class="anchor" aria-label="anchor" href="#get
 <span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
 <span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>, </span>
 <span>  output_resolution <span class="op">=</span> <span class="st">"drug"</span><span class="op">)</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:53] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:53] Object 'drug_map_name' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:53] Retrieved n = 30211 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:53] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:53] Object 'drug_map_alias' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:53] Retrieved n = 655802 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Object 'drug_map_basic' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Retrieved n = 31146 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Object 'drug_map_target' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Retrieved n = 38127 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Object 'drug_map_indication' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:54] Retrieved n = 58866 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:57] Record set satisfying user-defined criteria: n = 74633</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:57] Collapsing record set - providing output on a 'per_drug' resolution</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:57] Final record set: n = 1162 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:10] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:10] Object 'drug_map_name' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:10] Retrieved n = 30298 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Object 'drug_map_alias' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Retrieved n = 655065 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Object 'drug_map_basic' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Retrieved n = 31232 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Object 'drug_map_target' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Retrieved n = 38215 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Object 'drug_map_indication' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:11] Retrieved n = 56512 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:14] Record set satisfying user-defined criteria: n = 72161</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:14] Collapsing record set - providing output on a 'per_drug' resolution</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:15] Final record set: n = 1079 records</span></span>
 <span></span>
 <span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">&lt;-</span> <span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">|&gt;</span></span>
 <span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/filter.html" class="external-link">filter</a></span><span class="op">(</span></span>
@@ -421,8 +401,8 @@ <h3 id="get-taxanes">Get taxanes<a class="anchor" aria-label="anchor" href="#get
 <span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
 <span><span class="op">)</span></span></code></pre></div>
 <p><br></p>
-<div id="htmlwidget-b0d3d01adf70d4f53b15" style="width:100%;height:auto;" class="datatables html-widget "></div>
-<script type="application/json" data-for="htmlwidget-b0d3d01adf70d4f53b15">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6"],[6245,10942,21842,17317,21855,9573],["Cabazitaxel","Docetaxel","Paclitaxel","Larotaxel","Paclitaxel Poliglumex","Paclitaxel Docosahexaenoic Acid"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL1201748","CHEMBL92","CHEMBL428647","CHEMBL4279455","CHEMBL2108628","CHEMBL4297441"],["INHIBITOR","INHIBITOR","INHIBITOR","STABILISER","STABILISER","STABILISER"],["A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.","NA","A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel.  Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).  DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. (NCI04)"],[true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,false,false,false],[false,false,false,false,false,false],[false,false,false,false,false,false],["TRUE","TRUE","TRUE","FALSE","FALSE","FALSE"],["C66937","C1526","C1411","C48427","NA","C2649"],[0.917,0.86,0.769,1,0.929,1],[false,false,true,false,false,false],[24,114,156,4,14,3],[2010,1996,1992,null,null,null],[4,4,4,3,3,3],["adrenal cortex carcinoma, brain cancer, breast cancer, cancer, central nervous system cancer, colorectal carcinoma, dedifferentiated liposarcoma, gastric cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, metastatic prostate cancer, non-small cell lung carcinoma, ovarian cancer, prostate adenocarcinoma, prostate cancer, prostate carcinoma, small cell lung carcinoma, testicular carcinoma, urinary bladder carcinoma, urothelial carcinoma","anal carcinoma, biliary tract cancer, biliary tract neoplasm, breast cancer, breast carcinoma, breast ductal carcinoma in situ, breast neoplasm, cancer, cervical adenocarcinoma, cervical cancer, chronic myeloproliferative disorder, colorectal cancer, colorectal carcinoma, endometrial cancer, endometrial neoplasm, endometrioid carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, ewing sarcoma, fallopian tube cancer, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, kidney cancer, kidney neoplasm, laryngeal carcinoma, laryngeal neoplasm, laryngeal squamous cell carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant epithelial tumor of ovary, malignant tumor of neck, mediastinal cancer, melanoma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx cancer, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, pancreatic carcinoma, pancreatic neoplasm, paranasal sinus neoplasm, penile cancer, peritoneal neoplasm, peritoneum cancer, pharynx cancer, prostate adenocarcinoma, prostate cancer, prostate carcinoma, salivary gland cancer, salivary gland carcinoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, synovial sarcoma, testicular carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, tonsil cancer, triple-negative breast cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm, vaginal cancer, vulva cancer","actinic keratosis, adrenal cortex carcinoma, angiosarcoma, anus cancer, biliary tract cancer, bladder tumor, brain neoplasm, breast cancer, breast carcinoma, breast carcinoma in situ, breast ductal adenocarcinoma, breast ductal carcinoma in situ, breast neoplasm, bronchoalveolar adenocarcinoma, cancer, cervical adenocarcinoma, cervical cancer, cervical carcinoma, cervical intraepithelial neoplasia, cholangiocarcinoma, chronic lymphocytic leukemia, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, endometrial cancer, endometrial carcinoma, endometrial neoplasm, endometrioid carcinoma, endometrium neoplasm, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, gallbladder cancer, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, gestational trophoblastic neoplasm, glioblastoma multiforme, gliosarcoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kaposi's sarcoma, kidney cancer, large cell lung carcinoma, laryngeal squamous cell carcinoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant bone neoplasm, malignant epithelial tumor of ovary, malignant glioma, malignant peritoneal mesothelioma, melanoma, mesothelioma, metastatic melanoma, mouth neoplasm, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharyngeal carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, ovarian sex cord-stromal tumor, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, penile cancer, peritoneal neoplasm, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland cancer, sarcoma, sex cord-stromal tumor, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, testicular carcinoma, thymic carcinoma, thymoma, thyroid cancer, thyroid carcinoma, triple-negative breast cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm, vaginal cancer, verrucous carcinoma, vulva cancer","bladder tumor, breast cancer, breast neoplasm, pancreatic neoplasm","brain neoplasm, breast cancer, cancer, colorectal cancer, endometrioid carcinoma, fallopian tube cancer, lung cancer, non-small cell lung carcinoma, ovarian cancer, peritoneum cancer, prostate adenocarcinoma, prostate cancer, squamous cell carcinoma","hepatocellular carcinoma, metastatic melanoma, non-small cell lung carcinoma"],["4|2|1","4|3|2|1","4|3|2|1","3","3|2|1","3|2"],["L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01C","L01C","L01C","L01C","L01C","L01C"],["PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS"],["L01CD","L01CD","L01CD","L01CD","L01CD","L01CD"],["Taxanes","Taxanes","Taxanes","Taxanes","Taxanes","Taxanes"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
+<div id="htmlwidget-4515517cbe57e6bb5ece" style="width:100%;height:auto;" class="datatables html-widget "></div>
+<script type="application/json" data-for="htmlwidget-4515517cbe57e6bb5ece">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6"],[6291,10993,21916,17384,21929,9624],["Cabazitaxel","Docetaxel","Paclitaxel","Larotaxel","Paclitaxel Poliglumex","Paclitaxel Docosahexaenoic Acid"],["Small molecule","Small molecule","Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL1201748","CHEMBL92","CHEMBL428647","CHEMBL4279455","CHEMBL2108628","CHEMBL4297441"],["INHIBITOR","INHIBITOR","INHIBITOR","STABILISER","STABILISER","STABILISER"],["A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.","NA","A prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel.  Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).  DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. (NCI04)"],[true,true,true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,false,false,false],[false,false,false,false,false,false],[false,false,false,false,false,false],["TRUE","TRUE","TRUE","FALSE","FALSE","FALSE"],["C66937","C1526","C1411","C48427","NA","C2649"],[0.917,0.851,0.756,1,0.929,1],[false,false,true,false,false,false],[24,114,156,4,14,3],[2010,1996,1992,null,null,null],[4,4,4,3,3,3],["adrenal cortex carcinoma, brain cancer, breast cancer, cancer, central nervous system cancer, colorectal carcinoma, dedifferentiated liposarcoma, gastric cancer, glioblastoma multiforme, head and neck malignant neoplasia, head and neck squamous cell carcinoma, metastatic prostate cancer, non-small cell lung carcinoma, ovarian cancer, prostate adenocarcinoma, prostate cancer, prostate carcinoma, small cell lung carcinoma, testicular carcinoma, urinary bladder carcinoma, urothelial carcinoma","anal carcinoma, biliary tract cancer, biliary tract neoplasm, breast cancer, breast carcinoma, breast ductal carcinoma in situ, breast neoplasm, cancer, cervical adenocarcinoma, chronic myeloproliferative disorder, colorectal cancer, colorectal carcinoma, endometrial cancer, endometrial neoplasm, endometrioid carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, ewing sarcoma, fallopian tube cancer, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, head and neck carcinoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, kidney cancer, kidney neoplasm, laryngeal carcinoma, laryngeal neoplasm, laryngeal squamous cell carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant colon neoplasm, malignant epithelial tumor of ovary, malignant tumor of neck, mediastinal cancer, melanoma, metastatic melanoma, metastatic prostate cancer, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharynx cancer, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, pancreatic carcinoma, pancreatic neoplasm, paranasal sinus neoplasm, penile cancer, peritoneal neoplasm, peritoneum cancer, pharynx cancer, prostate adenocarcinoma, prostate cancer, prostate carcinoma, salivary gland cancer, salivary gland carcinoma, sarcoma, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, synovial sarcoma, testicular carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, tonsil cancer, triple-negative breast cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm, vaginal cancer, vulva cancer","actinic keratosis, adrenal cortex carcinoma, angiosarcoma, anus cancer, biliary tract cancer, bladder tumor, brain neoplasm, breast cancer, breast carcinoma, breast carcinoma in situ, breast ductal adenocarcinoma, breast ductal carcinoma in situ, breast neoplasm, bronchoalveolar adenocarcinoma, cancer, cervical adenocarcinoma, cervical intraepithelial neoplasia, cholangiocarcinoma, chronic lymphocytic leukemia, colorectal adenocarcinoma, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, endometrial cancer, endometrial carcinoma, endometrial neoplasm, endometrioid carcinoma, endometrium neoplasm, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, gallbladder cancer, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, gestational trophoblastic neoplasm, glioblastoma multiforme, gliosarcoma, head and neck malignant neoplasia, head and neck squamous cell carcinoma, hepatocellular carcinoma, hodgkins lymphoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kaposi's sarcoma, kidney cancer, large cell lung carcinoma, laryngeal squamous cell carcinoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoma, male breast carcinoma, malignant bone neoplasm, malignant epithelial tumor of ovary, malignant glioma, malignant peritoneal mesothelioma, melanoma, mesothelioma, metastatic melanoma, mouth neoplasm, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, non-hodgkins lymphoma, non-small cell lung carcinoma, oral squamous cell carcinoma, oropharyngeal carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, ovarian sex cord-stromal tumor, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, penile cancer, peritoneal neoplasm, peritoneum cancer, prostate adenocarcinoma, prostate cancer, rectum cancer, salivary gland cancer, sarcoma, sex cord-stromal tumor, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, testicular carcinoma, thymic carcinoma, thymoma, thyroid cancer, thyroid carcinoma, triple-negative breast cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm, vaginal cancer, verrucous carcinoma, vulva cancer","bladder tumor, breast cancer, breast neoplasm, pancreatic neoplasm","brain neoplasm, breast cancer, cancer, colorectal cancer, endometrioid carcinoma, fallopian tube cancer, lung cancer, non-small cell lung carcinoma, ovarian cancer, peritoneum cancer, prostate adenocarcinoma, prostate cancer, squamous cell carcinoma","hepatocellular carcinoma, metastatic melanoma, non-small cell lung carcinoma"],["4|2|1","4|3|2|1","4|3|2|1","3","3|2|1","3|2"],["L01","L01","L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01C","L01C","L01C","L01C","L01C","L01C"],["PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS","PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS"],["L01CD","L01CD","L01CD","L01CD","L01CD","L01CD"],["Taxanes","Taxanes","Taxanes","Taxanes","Taxanes","Taxanes"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
 </div>
 <div class="section level3">
 <h3 id="get-platinum-compounds">Get platinum compounds<a class="anchor" aria-label="anchor" href="#get-platinum-compounds"></a>
@@ -432,24 +412,24 @@ <h3 id="get-platinum-compounds">Get platinum compounds<a class="anchor" aria-lab
 <span><span class="va">drugs</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_drugs.html">get_drugs</a></span><span class="op">(</span></span>
 <span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span>, </span>
 <span>  output_resolution <span class="op">=</span> <span class="st">"drug"</span><span class="op">)</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:57] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:57] Object 'drug_map_name' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:57] Retrieved n = 30211 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Object 'drug_map_alias' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Retrieved n = 655802 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Object 'drug_map_basic' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Retrieved n = 31146 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Object 'drug_map_target' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Retrieved n = 38127 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Object 'drug_map_indication' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:25:58] Retrieved n = 58866 records</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:26:01] Record set satisfying user-defined criteria: n = 74633</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:26:01] Collapsing record set - providing output on a 'per_drug' resolution</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:26:02] Final record set: n = 1162 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:15] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:15] Object 'drug_map_name' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:15] Retrieved n = 30298 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Object 'drug_map_alias' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Retrieved n = 655065 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Object 'drug_map_basic' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Retrieved n = 31232 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Object 'drug_map_target' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Retrieved n = 38215 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Object 'drug_map_indication' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:16] Retrieved n = 56512 records</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:19] Record set satisfying user-defined criteria: n = 72161</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:19] Collapsing record set - providing output on a 'per_drug' resolution</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:20] Final record set: n = 1079 records</span></span>
 <span></span>
 <span><span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">&lt;-</span> <span class="va">drugs</span><span class="op">$</span><span class="va">records</span> <span class="op">|&gt;</span></span>
 <span>  <span class="fu">dplyr</span><span class="fu">::</span><span class="fu"><a href="https://dplyr.tidyverse.org/reference/filter.html" class="external-link">filter</a></span><span class="op">(</span></span>
@@ -476,8 +456,8 @@ <h3 id="get-platinum-compounds">Get platinum compounds<a class="anchor" aria-lab
 <span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
 <span><span class="op">)</span></span></code></pre></div>
 <p><br></p>
-<div id="htmlwidget-83ca93e0d95550db2015" style="width:100%;height:auto;" class="datatables html-widget "></div>
-<script type="application/json" data-for="htmlwidget-83ca93e0d95550db2015">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4"],[21406,6569,7789,22759],["Oxaliplatin","Carboplatin","Cisplatin","Picoplatin"],["Small molecule","Small molecule","Small molecule","Small molecule"],["CHEMBL414804","CHEMBL1351","CHEMBL11359","CHEMBL3544907"],["INHIBITOR","INHIBITOR","INHIBITOR","CROSS-LINKING AGENT"],["An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis."],[true,true,true,true],["by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp","by_cancer_condition_otp"],[true,true,true,true],[false,false,false,false],[false,false,false,false],["TRUE","TRUE","TRUE","FALSE"],["C1181","C1282","C376","C48416"],[0.821,0.851,0.822,1],[false,false,false,false],[95,181,180,10],[2002,1989,1978,null],[4,4,4,3],["acute myeloid leukemia, adult t-cell leukemia/lymphoma, anus cancer, bile duct cancer, biliary tract cancer, biliary tract neoplasm, breast cancer, breast carcinoma, breast neoplasm, cancer, cervical cancer, cholangiocarcinoma, colon adenocarcinoma, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, cutaneous t-cell lymphoma, diffuse large b-cell lymphoma, endometrial cancer, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, follicular lymphoma, gallbladder cancer, gallbladder carcinoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, gliosarcoma, head and neck carcinoma, head and neck malignant neoplasia, hematopoietic and lymphoid cell neoplasm, hepatoblastoma, hepatocellular carcinoma, hodgkins lymphoma, intrahepatic cholangiocarcinoma, leukemia, liver cancer, lung cancer, lymphoma, malignant colon neoplasm, malignant epithelial tumor of ovary, mesothelioma, metastatic melanoma, mucinous carcinoma, nasopharyngeal neoplasm, neoplasm of mature b-cells, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, ovarian cancer, ovarian carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, peritoneal neoplasm, peritoneum cancer, prostate cancer, rectal carcinoma, rectum cancer, small cell lung carcinoma, squamous cell carcinoma, stomach neoplasm, urinary bladder cancer, urothelial carcinoma, uterine neoplasm","acute myeloid leukemia, adrenal cortex carcinoma, adult t-cell leukemia/lymphoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic large cell lymphoma, anaplastic oligodendroglioma, anus cancer, appendix carcinoma, astrocytoma, brain cancer, brain neoplasm, brain stem neoplasm, breast cancer, breast carcinoma, breast ductal carcinoma in situ, breast neoplasm, bronchoalveolar adenocarcinoma, burkitts lymphoma, cancer, carcinosarcoma, central nervous system cancer, cervical adenocarcinoma, cervical cancer, cervical carcinoma, childhood ependymoma, cholangiocarcinoma, choroid plexus neoplasm, chronic myeloproliferative disorder, classic hodgkin lymphoma, colorectal carcinoma, cutaneous melanoma, diffuse large b-cell lymphoma, digestive system neuroendocrine neoplasm, endometrial cancer, endometrial carcinoma, endometrial neoplasm, endometrioid carcinoma, ependymoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, fallopian tube cancer, fallopian tube carcinoma, fallopian tube neoplasm, follicular lymphoma, follicular thyroid carcinoma, gallbladder cancer, gallbladder carcinoma, ganglioneuroblastoma, gastric cancer, gastrointestinal stromal tumor, gestational trophoblastic neoplasm, glioblastoma multiforme, glioma, gliosarcoma, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hodgkins lymphoma, hypopharyngeal carcinoma, inflammatory breast carcinoma, insulinoma, intrahepatic cholangiocarcinoma, kidney cancer, kidney wilms tumor, large cell lung carcinoma, laryngeal carcinoma, laryngeal neoplasm, laryngeal squamous cell carcinoma, leiomyosarcoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung neoplasm, lymphoblastic lymphoma, lymphoma, male breast carcinoma, malignant epithelial tumor of ovary, malignant glioma, malignant peritoneal mesothelioma, malignant pleural mesothelioma, malignant testicular germ cell tumor, malignant tumor of parathyroid gland, mantle cell lymphoma, medulloblastoma, melanoma, mesothelioma, metastatic melanoma, metastatic prostate cancer, mouth neoplasm, multiple myeloma, nasopharyngeal neoplasm, neoplasm of mature b-cells, neoplasm of oropharynx, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oligoastrocytoma, optic nerve glioblastoma, oral squamous cell carcinoma, oropharyngeal carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, ovarian sex cord-stromal tumor, pancreatic carcinoma, pancreatic endocrine carcinoma, papillary thyroid carcinoma, peritoneal neoplasm, peritoneum cancer, primitive neuroectodermal tumor, prostate adenocarcinoma, prostate cancer, prostate carcinoma, retinoblastoma, salivary gland cancer, sarcoma, seminoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, somatostatinoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, testicular carcinoma, thymic carcinoma, thymoma, thyroid cancer, triple-negative breast cancer, ureter cancer, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine carcinosarcoma, uterine neoplasm, vaginal cancer, verrucous carcinoma, vulva cancer","adrenal cortex carcinoma, adult t-cell leukemia/lymphoma, anal carcinoma, anaplastic ependymoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, anus cancer, basal cell carcinoma, biliary tract cancer, biliary tract neoplasm, bladder tumor, brain cancer, brain neoplasm, breast cancer, breast carcinoma, breast neoplasm, cancer, central nervous system cancer, cervical adenocarcinoma, cervical cancer, cervical carcinoma, childhood ependymoma, cholangiocarcinoma, choroid plexus neoplasm, classic hodgkin lymphoma, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, cutaneous melanoma, differentiated thyroid carcinoma, diffuse large b-cell lymphoma, endometrial cancer, endometrial neoplasm, endometrioid carcinoma, esophageal cancer, esophageal carcinoma, esophageal squamous cell carcinoma, extranodal nasal nk/t cell lymphoma, fallopian tube cancer, fallopian tube carcinoma, gallbladder cancer, gallbladder carcinoma, gallbladder neoplasm, ganglioneuroblastoma, gastric adenocarcinoma, gastric cancer, gastric carcinoma, gastrointestinal stromal tumor, gestational trophoblastic neoplasm, glioma, head and neck carcinoma, head and neck malignant neoplasia, head and neck neoplasia, head and neck squamous cell carcinoma, hepatoblastoma, hepatocellular carcinoma, hilar cholangiocarcinoma, hodgkins lymphoma, hypopharyngeal carcinoma, hypopharyngeal squamous cell carcinoma, inflammatory breast carcinoma, intrahepatic cholangiocarcinoma, kidney cancer, large cell lung carcinoma, laryngeal carcinoma, laryngeal neoplasm, laryngeal squamous cell carcinoma, leukemia, liver cancer, lung adenocarcinoma, lung cancer, lung carcinoma, lung neoplasm, lymphoma, malignant glioma, malignant pleural mesothelioma, malignant tumor of neck, mantle cell lymphoma, mediastinal cancer, medulloblastoma, melanoma, mesothelioma, metastatic melanoma, mouth neoplasm, multiple myeloma, nasopharyngeal neoplasm, neoplasm of esophagus, neoplasm of mature b-cells, neoplasm of oropharynx, neuroblastoma, non-hodgkins lymphoma, non-small cell lung carcinoma, oral cavity cancer, oral squamous cell carcinoma, oropharyngeal carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma, osteosarcoma, ovarian cancer, ovarian carcinoma, ovarian embryonal carcinoma, ovarian neoplasm, ovarian serous cystadenocarcinoma, ovarian sex cord-stromal tumor, ovarian yolk sac tumor, pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paranasal sinus neoplasm, penile cancer, peritoneal neoplasm, peritoneum cancer, pharynx cancer, primitive neuroectodermal tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, seminoma, skin cancer, small cell lung carcinoma, soft tissue sarcoma, squamous cell carcinoma, squamous cell lung carcinoma, stomach neoplasm, testicular carcinoma, testicular choriocarcinoma, testicular yolk sac tumor, thymic carcinoma, thymoma, thyroid cancer, tongue neoplasm, triple-negative breast cancer, unspecified peripheral t-cell lymphoma, urethra cancer, urinary bladder cancer, urinary bladder carcinoma, urothelial carcinoma, uterine neoplasm, vulva cancer","breast cancer, cancer, colorectal carcinoma, head and neck malignant neoplasia, lung cancer, ovarian cancer, pancreatic carcinoma, prostate cancer, small cell lung carcinoma, urinary bladder cancer"],["4|3|2|1","4|3|2|1","4|3|2|1|0.5","3|2|1"],["L01","L01","L01","L01"],["ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS","ANTINEOPLASTIC AGENTS"],["L01X","L01X","L01X","L01X"],["OTHER ANTINEOPLASTIC AGENTS ","OTHER ANTINEOPLASTIC AGENTS ","OTHER ANTINEOPLASTIC AGENTS ","OTHER ANTINEOPLASTIC AGENTS "],["L01XA","L01XA","L01XA","L01XA"],["Platinum compounds","Platinum compounds","Platinum compounds","Platinum compounds"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
+<div id="htmlwidget-b98f56f24ad8dd96c4f6" style="width:100%;height:auto;" class="datatables html-widget "></div>
+<script type="application/json" data-for="htmlwidget-b98f56f24ad8dd96c4f6">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug_id<\/th>\n      <th>drug_name<\/th>\n      <th>drug_type<\/th>\n      <th>molecule_chembl_id<\/th>\n      <th>drug_action_type<\/th>\n      <th>nci_concept_definition<\/th>\n      <th>opentargets<\/th>\n      <th>drug_cancer_relevance<\/th>\n      <th>inhibition_moa<\/th>\n      <th>is_salt<\/th>\n      <th>is_adc<\/th>\n      <th>drug_blackbox_warning<\/th>\n      <th>nci_t<\/th>\n      <th>drug_frac_cancer_indications<\/th>\n      <th>drug_approved_noncancer<\/th>\n      <th>drug_n_indications<\/th>\n      <th>drug_year_first_approval<\/th>\n      <th>drug_max_ct_phase<\/th>\n      <th>disease_indication<\/th>\n      <th>disease_indication_max_phase<\/th>\n      <th>atc_code_level1<\/th>\n      <th>atc_level1<\/th>\n      <th>atc_code_level2<\/th>\n      <th>atc_level2<\/th>\n      <th>atc_code_level3<\/th>\n      <th>atc_level3<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":[1,14,16,17,18]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
 </div>
 </div>
 <div class="section level2">
@@ -494,10 +474,10 @@ <h3 id="reported-associations-between-brca12-alterations-and-drug-sensitivity">R
 <code class="sourceCode R"><span></span>
 <span><span class="va">biomarkers</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/get_biomarkers.html">get_biomarkers</a></span><span class="op">(</span></span>
 <span>  cache_dir <span class="op">=</span> <span class="va">cache_dir</span><span class="op">)</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:26:02] Downloading remote dataset from Google Drive to cache_dir</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:26:05] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:26:05] Object 'biomarkers' sucessfully loaded</span></span>
-<span><span class="co">#&gt; INFO  [2023-09-01 14:26:05] md5 checksum is valid: f4523f47b77d68beda72d1f9c46d96c7</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:20] Downloading remote dataset from Google Drive to cache_dir</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:24] Reading from cache_dir = ' (/tmp/RtmpT04Il1'), argument force_download = F</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:24] Object 'biomarkers' sucessfully loaded</span></span>
+<span><span class="co">#&gt; INFO  [2023-10-06 13:45:24] md5 checksum is valid: fe0159f12bb564506cdf1087cfca4b99</span></span>
 <span></span>
 <span><span class="va">brca1_biomarkers</span> <span class="op">&lt;-</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="op">)</span></span>
 <span><span class="kw">for</span><span class="op">(</span><span class="va">source</span> <span class="kw">in</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">'civic'</span>,<span class="st">'cgi'</span><span class="op">)</span><span class="op">)</span><span class="op">{</span></span>
@@ -547,8 +527,8 @@ <h3 id="reported-associations-between-brca12-alterations-and-drug-sensitivity">R
 <span>    dom <span class="op">=</span> <span class="st">"Bfrtip"</span><span class="op">)</span></span>
 <span><span class="op">)</span></span></code></pre></div>
 <p><br></p>
-<div id="htmlwidget-ed9c6a0d2973144172d3" style="width:100%;height:auto;" class="datatables html-widget "></div>
-<script type="application/json" data-for="htmlwidget-ed9c6a0d2973144172d3">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94"],["BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA1","BRCA2","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA2","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA2","BRCA2","BRCA1","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA2"],["Breast","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Prostate","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Prostate","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Pancreas","Breast","Breast","Pancreas","Breast","Breast","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Ovary/Fallopian Tube","Prostate","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Breast","Breast","Ovary/Fallopian Tube","Breast","Breast","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Prostate","Breast","Ovary/Fallopian Tube","Breast",null,"Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Pancreas","Pancreas","Pancreas","Pancreas","Ovary/Fallopian Tube",null,"Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Pancreas","Pancreas","Pancreas","Pancreas","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Pancreas","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","CNS/Brain","Pancreas",null,"Skin","Pancreas","Breast","Pancreas","Breast","Pleura","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube"],["Talazoparib","Niraparib","Olaparib","Rucaparib","Olaparib","Olaparib","Rucaparib","Talazoparib","Niraparib","Olaparib","Rucaparib","Olaparib","Olaparib","Rucaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Platinum Agent (Chemotherapy)","Platinum Agent (Chemotherapy)","PARP inhibitor + Chemotherapys","PARP inhibitors (Olaparib,etc)","Platinum Agent (Chemotherapy)","Veliparib + Cisplatin","PARP inhibitor + Chemotherapys","PARP inhibitors (Olaparib,etc)","Platinum Agent (Chemotherapy)","Veliparib + Cisplatin","Olaparib","Talazoparib","Talazoparib","Olaparib","Olaparib","Olaparib","Talazoparib","Talazoparib","Olaparib","Olaparib","Platinum Compound","Platinum Compound","Cediranib,Olaparib","Cisplatin,Carboplatin","Olaparib","Olaparib","Rucaparib","Olaparib","Olaparib","Oxaliplatin,Cisplatin","Cisplatin,Veliparib,Gemcitabine","Veliparib","Rucaparib","Olaparib","Platinum Compound","Platinum Compound","Cediranib,Olaparib","Cisplatin,Carboplatin","Olaparib","Olaparib","Rucaparib","Olaparib","Olaparib","Platinum Compound","Cisplatin,Gemcitabine,Veliparib","Veliparib","Rucaparib","Platinum Compound,Taxane Compound","Olaparib","Iniparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Olaparib,Temozolomide","PARP inhibitors","WEE1 inhibitors","PD1 Ab inhibitors","Platinum Agent (Chemotherapy)","Pidnarulex,Quarfloxin","Mitomycin","Quarfloxin,Pidnarulex","Vinorelbine","Olaparib","PARP inhibitors","PARP inhibitors (Olaparib,etc)"],["BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA1 Underexpression","BRCA1 Loss-of-function","BRCA2 Mutation","BRCA1 Q1467*","BRCA2 M1R","BRCA2 M1I","BRCA2 V159M","BRCA2 V211L","BRCA2 V211I","BRCA2 R2336P","BRCA2 K3326*","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA1 Expression","BRCA1 W1815X","BRCA1 deletion","BRCA2 deletion"],["A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","B1: Clinical evidence: late trials","B1: Clinical evidence: late trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence"],[161,161,161,161,161,161,161,163,163,163,163,163,163,163,131,131,131,132,132,132,185,185,185,186,186,161,163,161,161,161,161,163,163,163,163,131,131,131,131,132,132,132,132,132,185,185,185,185,185,185,185,185,185,185,185,185,185,185,186,186,186,186,186,186,186,186,186,186,186,186,186,186,403,131,186,1246,1247,1248,1249,1250,1251,1252,2871,161,161,163,163,131,132,132,397,1555,160,162],["protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","transcript_ablation","loss_of_heterozygosity,loss_of_function_variant","gene_variant,loss_of_function_variant","stop_gained","missense_variant","missense_variant","missense_variant","missense_variant","missense_variant","missense_variant","missense_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","transcript_amplification","stop_gained","transcript_ablation","transcript_ablation"],["MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","UNDEREXPRESSION","MUTATION","MUTATION","Q1467X, p.Q1467X, Gln1467Ter, p.Gln1467Ter, rs397509171, c.4399C>T, 17_41228590_G_A, 17_43076573_G_A","M1R, p.M1R, Met1Arg, p.Met1Arg, rs80358547, c.2T>G, 13_32890599_T_G, 13_32316462_T_G","M1I, p.M1I, Met1Ile, p.Met1Ile, rs80358650, c.3G>T, 13_32890600_G_T, 13_32316463_G_T","V159M, p.V159M, Val159Met, p.Val159Met, rs80358702, c.475G>A, 13_32900287_G_A, 13_32326150_G_A","V211L, p.V211L, Val211Leu, p.Val211Leu, 13_32900751_G_C, 13_32326614_G_C","V211I, p.V211I, Val211Ile, p.Val211Ile, 13_32900751_G_A, 13_32326614_G_A","R2336P, p.R2336P, Arg2336Pro, p.Arg2336Pro, rs28897743, c.7007G>C, 13_32921033_G_C, 13_32346896_G_C","K3326X, p.K3326X, Lys3326Ter, p.Lys3326Ter","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","EXPRESSION","W1815X, p.W1815X, Trp1815Ter, p.Trp1815Ter, W125X, p.W125X, Trp125Ter, p.Trp125Ter, W1519X, p.W1519X, Trp1519Ter, p.Trp1519Ter, W1550X, p.W1550X, Trp1550Ter, p.Trp1550Ter, W1576X, p.W1576X, Trp1576Ter, p.Trp1576Ter, W1768X, p.W1768X, Trp1768Ter, p.Trp1768Ter, W1836X, p.W1836X, Trp1836Ter, p.Trp1836Ter, W306X, p.W306X, Trp306Ter, p.Trp306Ter, W48X, p.W48X, Trp48Ter, p.Trp48Ter, W632X, p.W632X, Trp632Ter, p.Trp632Ter, W664X, p.W664X, Trp664Ter, p.Trp664Ter, W673X, p.W673X, Trp673Ter, p.Trp673Ter, W711X, p.W711X, Trp711Ter, p.Trp711Ter, 17_41199682_C_T, 17_43047665_C_T","DELETION","DELETION"],["cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","cgi","cgi","cgi","cgi","civic","civic","civic","civic","civic","cgi","cgi"],["20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20230901","20221027","20221027","20221027","20221027","20230901","20230901","20230901","20230901","20230901","20221027","20221027"],["CGI10","CGI34","CGI36","CGI49","CGI264","CGI265","CGI268","CGI11","CGI35","CGI37","CGI50","CGI274","CGI275","CGI279","EID7384","EID11201","EID11216","EID7385","EID11202","EID11217","EID7274","EID7275","EID11203","EID7276","EID8842","CGI267","CGI277","CGI259","CGI263","CGI266","CGI269","CGI270","CGI272","CGI276","CGI280","EID211","EID4838","EID4876","EID5815","EID212","EID650","EID4839","EID4875","EID5816","EID1370","EID1529","EID1531","EID1677","EID1684","EID1772","EID1775","EID1897","EID5830","EID5914","EID5915","EID5932","EID5934","EID6341","EID1371","EID1530","EID1532","EID1678","EID1685","EID1773","EID1776","EID2868","EID5831","EID5913","EID5916","EID5933","EID5935","EID6343","EID942","EID845","EID5936","EID2878","EID2879","EID2880","EID2881","EID2882","EID2883","EID2884","EID7724","CGI260","CGI262","CGI271","CGI278","EID1924","EID1308","EID1925","EID933","EID4623","CGI261","CGI273"],["Germline","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Germline","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Germline","Germline","Germline","Germline","Germline","Germline","Germline","Somatic",null,"Germline",null,"Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Germline","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Germline","Germline",null,"Somatic","Germline","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic",null,"Somatic","Somatic","Somatic","Somatic",null,"Germline",null,null,"Somatic","Somatic","Somatic"],["30110579;NCCN","30948273;FDA","FDA","32795228;FDA","26510020;32343890","FDA","FDA","30110579;NCCN","30948273;FDA","FDA","32795228;FDA","26510020;32343890;NCT01682772","FDA","FDA","31157963","34081848","34081848","31157963","34081848","34081848","30345884","30345884","32343890","30345884","32343890","22406760;22711857","22406760;22711857","22307137","20609467;25366685","25847936","26801247","22307137","20609467","25847936","26801247","23346317","28242752","28242752","28578601","23346317","26510020","28242752","28242752","28578601","19553641","24240112","24240112","25218906","25847936","21862407","21862407","27908594","28792849","25366685","25072261","29338080","29223478","27908594","19553641","24240112","24240112","25218906","25847936","21862407","21862407","27908594","28792849","25366685","25072261","29338080","29223478","27908594","21920589","26510020","21508395","27908594","27908594","27908594","27908594","27908594","27908594","27908594","32043779","19553641;25366685;25719666","25964244","26997480","25719666","28211448","16243825","28211448","22190288","23415752","22392482","22392482"],["https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://civicdb.org/links/evidence_items/7384","https://civicdb.org/links/evidence_items/11201","https://civicdb.org/links/evidence_items/11216","https://civicdb.org/links/evidence_items/7385","https://civicdb.org/links/evidence_items/11202","https://civicdb.org/links/evidence_items/11217","https://civicdb.org/links/evidence_items/7274","https://civicdb.org/links/evidence_items/7275","https://civicdb.org/links/evidence_items/11203","https://civicdb.org/links/evidence_items/7276","https://civicdb.org/links/evidence_items/8842","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://civicdb.org/links/evidence_items/211","https://civicdb.org/links/evidence_items/4838","https://civicdb.org/links/evidence_items/4876","https://civicdb.org/links/evidence_items/5815","https://civicdb.org/links/evidence_items/212","https://civicdb.org/links/evidence_items/650","https://civicdb.org/links/evidence_items/4839","https://civicdb.org/links/evidence_items/4875","https://civicdb.org/links/evidence_items/5816","https://civicdb.org/links/evidence_items/1370","https://civicdb.org/links/evidence_items/1529","https://civicdb.org/links/evidence_items/1531","https://civicdb.org/links/evidence_items/1677","https://civicdb.org/links/evidence_items/1684","https://civicdb.org/links/evidence_items/1772","https://civicdb.org/links/evidence_items/1775","https://civicdb.org/links/evidence_items/1897","https://civicdb.org/links/evidence_items/5830","https://civicdb.org/links/evidence_items/5914","https://civicdb.org/links/evidence_items/5915","https://civicdb.org/links/evidence_items/5932","https://civicdb.org/links/evidence_items/5934","https://civicdb.org/links/evidence_items/6341","https://civicdb.org/links/evidence_items/1371","https://civicdb.org/links/evidence_items/1530","https://civicdb.org/links/evidence_items/1532","https://civicdb.org/links/evidence_items/1678","https://civicdb.org/links/evidence_items/1685","https://civicdb.org/links/evidence_items/1773","https://civicdb.org/links/evidence_items/1776","https://civicdb.org/links/evidence_items/2868","https://civicdb.org/links/evidence_items/5831","https://civicdb.org/links/evidence_items/5913","https://civicdb.org/links/evidence_items/5916","https://civicdb.org/links/evidence_items/5933","https://civicdb.org/links/evidence_items/5935","https://civicdb.org/links/evidence_items/6343","https://civicdb.org/links/evidence_items/942","https://civicdb.org/links/evidence_items/845","https://civicdb.org/links/evidence_items/5936","https://civicdb.org/links/evidence_items/2878","https://civicdb.org/links/evidence_items/2879","https://civicdb.org/links/evidence_items/2880","https://civicdb.org/links/evidence_items/2881","https://civicdb.org/links/evidence_items/2882","https://civicdb.org/links/evidence_items/2883","https://civicdb.org/links/evidence_items/2884","https://civicdb.org/links/evidence_items/7724","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://civicdb.org/links/evidence_items/1924","https://civicdb.org/links/evidence_items/1308","https://civicdb.org/links/evidence_items/1925","https://civicdb.org/links/evidence_items/933","https://civicdb.org/links/evidence_items/4623","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA1 mutations were present in 29/92 patients in the olaparib group and 16/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations.","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA2 mutations were present in 62/92 patients in the olaparib group and 46/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations.","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).","In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. Two patients were found to have somatic BRCA1/2 mutations. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).","This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 15 patients with BRCA1 mutations specifically, PFS HR 0.41 [0.13-1.39]. . Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.","In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).","In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombinant repair-related gene mutation detected from a tumor sample, olaparib showed significant PFS benefit in an ITT population (HR [95%CI] 0.49 [0.38, 0.63]). But in subgroup analysis, the treatment effect differed in each mutated genes. Among them, patients with BRCA2 mutations (olaparib: n=92, control: n=53) showed a prominent benefit of olaparib (PFS HR [95%CI] 0.21 [0.13, 0.32]).",null,null,null,null,null,null,null,null,null,null,"The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).","The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.","In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07.","In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.","In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.","In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.","46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).","In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.","In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.","In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant (BRCA1 or BRCA2) patients, 14 had homozygous somatic BRCA1 mutation or deletion. Confirmed objective response was seen in 71% (10/14) of the somatic BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.","Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.","Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)","In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.","Veliparib 400mg BID was administered to patients with germline BRCA1/2-mutated pancreatic cancer. Sixteen patients were enrolled. All except two (12.5%) had previously been treated with platinum therapy. No confirmed partial response was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 14 had germline BRCA1 mutation, 13 of which were homozygous mutation and one with unknown zygosity. Confirmed objective response was seen in 86% (12/14) of the germline BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.","In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.","In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.","46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).","In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.","In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.","In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 5 had somatic BRCA2 mutation, 4 of which were homozygous mutations and one had unknown zygosity. Confirmed objective response was seen in 80% (4/5) of the somatic BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.","Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation.  In total of patients with BRCA1/2 mutation , all but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.","Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)","In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.","Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 6 had germline homozygous BRCA2 mutation. Confirmed objective response was seen in 83% (5/6) of the germline BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029).","1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.","Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine plus iniparib in clinical trial. Excellent response to therapy was observed and surgery was performed but no residual tumor tissue was detected","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a case report, a 3‐year‐old girl with glioblastoma harboring a probable germline heterozygous BRCA2 Lys3326Ter (K3326*) nonsense variant. After debulking surgery, the patient received standard‐of‐care treatment with radiation and temozolomide. Nine months later the PARP inhibitor olaparib was administered in combination with temozolomide for 16 cycles. This regimen was well tolerated by the patient and serial imaging showed a reduction in tumor size.",null,null,null,null,"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.","In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2). Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line.","The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. The BRCA and NHE J pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.","Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.","In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines expressing BRCA1 wild-type. Sensitivity was determined by assessing cytotoxicity and doubling time. The authors note that the slow doubling time of SNU-251 cells was compensated for with a 2 week cytotoxicity assay as compared to the 1 week assay used for all other cell lines.",null,null],["Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive"],["Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Resistance","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity","Sensitivity"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>symbol<\/th>\n      <th>primary_site<\/th>\n      <th>therapeutic_context<\/th>\n      <th>molecular_profile_name<\/th>\n      <th>evidence_level<\/th>\n      <th>variant_id<\/th>\n      <th>variant_consequence<\/th>\n      <th>variant_alias<\/th>\n      <th>biomarker_source<\/th>\n      <th>biomarker_source_datestamp<\/th>\n      <th>evidence_id<\/th>\n      <th>variant_origin<\/th>\n      <th>literature_id<\/th>\n      <th>evidence_url<\/th>\n      <th>evidence_description<\/th>\n      <th>evidence_type<\/th>\n      <th>clinical_significance<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
+<div id="htmlwidget-e333ebf0cd4c5c4b13cf" style="width:100%;height:auto;" class="datatables html-widget "></div>
+<script type="application/json" data-for="htmlwidget-e333ebf0cd4c5c4b13cf">{"x":{"filter":"none","vertical":false,"extensions":["Buttons","Responsive"],"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98"],["BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA2","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA2","BRCA1","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA2","BRCA1","BRCA1","BRCA2","BRCA2","BRCA1","BRCA2","BRCA2","BRCA1","BRCA1","BRCA1","BRCA2"],["Breast","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Prostate","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Prostate","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Pancreas","Breast","Breast","Pancreas","Breast","Breast","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Ovary/Fallopian Tube","Prostate","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Breast","Breast","Ovary/Fallopian Tube","Breast","Breast","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Prostate","Breast","Ovary/Fallopian Tube","Breast",null,"Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Pancreas","Pancreas","Pancreas","Pancreas","Ovary/Fallopian Tube",null,"Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Ovary/Fallopian Tube","Breast","Pancreas","Pancreas","Pancreas","Pancreas","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Prostate","Pancreas","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube","CNS/Brain","Pancreas",null,"Skin","Pancreas","Breast","Pancreas","Breast","Pleura","Ovary/Fallopian Tube","Ovary/Fallopian Tube","Ovary/Fallopian Tube"],["Talazoparib","Niraparib","Olaparib","Rucaparib","Olaparib","Olaparib","Rucaparib","Talazoparib","Niraparib","Olaparib","Rucaparib","Olaparib","Olaparib","Rucaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Olaparib","Rucaparib","Rucaparib","Olaparib","Olaparib","Olaparib","Rucaparib","Rucaparib","Platinum Agent (Chemotherapy)","Platinum Agent (Chemotherapy)","PARP inhibitor + Chemotherapys","PARP inhibitors (Olaparib,etc)","Platinum Agent (Chemotherapy)","Veliparib + Cisplatin","PARP inhibitor + Chemotherapys","PARP inhibitors (Olaparib,etc)","Platinum Agent (Chemotherapy)","Veliparib + Cisplatin","Olaparib","Talazoparib","Talazoparib","Olaparib","Olaparib","Olaparib","Talazoparib","Talazoparib","Olaparib","Olaparib","Platinum Compound","Platinum Compound","Olaparib,Cediranib","Cisplatin,Carboplatin","Olaparib","Olaparib","Rucaparib","Olaparib","Olaparib","Oxaliplatin,Cisplatin","Cisplatin,Gemcitabine,Veliparib","Veliparib","Rucaparib","Olaparib","Platinum Compound","Platinum Compound","Cediranib,Olaparib","Cisplatin,Carboplatin","Olaparib","Olaparib","Rucaparib","Olaparib","Olaparib","Platinum Compound","Gemcitabine,Cisplatin,Veliparib","Veliparib","Rucaparib","Taxane Compound,Platinum Compound","Olaparib","Iniparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Rucaparib","Temozolomide,Olaparib","PARP inhibitors","WEE1 inhibitors","PD1 Ab inhibitors","Platinum Agent (Chemotherapy)","Pidnarulex,Quarfloxin","Mitomycin","Quarfloxin,Pidnarulex","Vinorelbine","Olaparib","PARP inhibitors","PARP inhibitors (Olaparib,etc)"],["BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA1 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA1 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA2 Mutation","BRCA1 Underexpression","BRCA1 Loss-of-function","BRCA2 Mutation","BRCA1 Q1467*","BRCA2 M1R","BRCA2 M1I","BRCA2 V159M","BRCA2 V211L","BRCA2 V211I","BRCA2 R2336P","BRCA2 K3326*","BRCA1 oncogenic mutation","BRCA1 oncogenic mutation","BRCA2 oncogenic mutation","BRCA2 oncogenic mutation","BRCA1 Loss-of-function","BRCA2 Loss-of-function","BRCA2 Loss-of-function","BRCA1 Expression","BRCA1 W1815X","BRCA1 deletion","BRCA2 deletion"],["A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: FDA/NCCN/ELN guidelines","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","A: Validated","B1: Clinical evidence: late trials","B1: Clinical evidence: late trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B2: Clinical evidence: early trials","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","B: Clinical evidence","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","C: Case study","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence","D: Preclinical evidence"],[161,161,161,161,161,161,161,163,163,163,163,163,163,163,131,131,131,132,132,132,185,185,185,185,185,186,186,186,186,161,163,161,161,161,161,163,163,163,163,131,131,131,131,132,132,132,132,132,185,185,185,185,185,185,185,185,185,185,185,185,185,185,186,186,186,186,186,186,186,186,186,186,186,186,186,186,403,131,186,1246,1247,1248,1249,1250,1251,1252,2871,161,161,163,163,131,132,132,397,1555,160,162],["protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","gene_variant,loss_of_function_variant","transcript_ablation","loss_of_heterozygosity,loss_of_function_variant","gene_variant,loss_of_function_variant","stop_gained","missense_variant","missense_variant","missense_variant","missense_variant","missense_variant","missense_variant","missense_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","protein_altering_variant","loss_of_heterozygosity,loss_of_function_variant","loss_of_function_variant","loss_of_function_variant","transcript_amplification","stop_gained","transcript_ablation","transcript_ablation"],["MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","UNDEREXPRESSION","MUTATION","MUTATION","Q1467X, p.Q1467X, Gln1467Ter, p.Gln1467Ter, rs397509171, c.4399C>T, 17_41228590_G_A, 17_43076573_G_A","M1R, p.M1R, Met1Arg, p.Met1Arg, rs80358547, c.2T>G, 13_32890599_T_G, 13_32316462_T_G","M1I, p.M1I, Met1Ile, p.Met1Ile, rs80358650, c.3G>T, 13_32890600_G_T, 13_32316463_G_T","V159M, p.V159M, Val159Met, p.Val159Met, rs80358702, c.475G>A, 13_32900287_G_A, 13_32326150_G_A","V211L, p.V211L, Val211Leu, p.Val211Leu, 13_32900751_G_C, 13_32326614_G_C","V211I, p.V211I, Val211Ile, p.Val211Ile, 13_32900751_G_A, 13_32326614_G_A","R2336P, p.R2336P, Arg2336Pro, p.Arg2336Pro, rs28897743, c.7007G>C, 13_32921033_G_C, 13_32346896_G_C","K3326X, p.K3326X, Lys3326Ter, p.Lys3326Ter","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","MUTATION","EXPRESSION","W1815X, p.W1815X, Trp1815Ter, p.Trp1815Ter, W125X, p.W125X, Trp125Ter, p.Trp125Ter, W1519X, p.W1519X, Trp1519Ter, p.Trp1519Ter, W1550X, p.W1550X, Trp1550Ter, p.Trp1550Ter, W1576X, p.W1576X, Trp1576Ter, p.Trp1576Ter, W1768X, p.W1768X, Trp1768Ter, p.Trp1768Ter, W1836X, p.W1836X, Trp1836Ter, p.Trp1836Ter, W306X, p.W306X, Trp306Ter, p.Trp306Ter, W48X, p.W48X, Trp48Ter, p.Trp48Ter, W632X, p.W632X, Trp632Ter, p.Trp632Ter, W664X, p.W664X, Trp664Ter, p.Trp664Ter, W673X, p.W673X, Trp673Ter, p.Trp673Ter, W711X, p.W711X, Trp711Ter, p.Trp711Ter, 17_41199682_C_T, 17_43047665_C_T","DELETION","DELETION"],["cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","cgi","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","civic","cgi","cgi","cgi","cgi","civic","civic","civic","civic","civic","cgi","cgi"],["20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20221027","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20231006","20221027","20221027","20221027","20221027","20231006","20231006","20231006","20231006","20231006","20221027","20221027"],["CGI10","CGI34","CGI36","CGI49","CGI264","CGI265","CGI268","CGI11","CGI35","CGI37","CGI50","CGI274","CGI275","CGI279","EID7384","EID11201","EID11216","EID7385","EID11202","EID11217","EID7274","EID7275","EID11136","EID11138","EID11203","EID7276","EID8842","EID11137","EID11139","CGI267","CGI277","CGI259","CGI263","CGI266","CGI269","CGI270","CGI272","CGI276","CGI280","EID211","EID4838","EID4876","EID5815","EID212","EID650","EID4839","EID4875","EID5816","EID1370","EID1529","EID1531","EID1677","EID1684","EID1772","EID1775","EID1897","EID5830","EID5914","EID5915","EID5932","EID5934","EID6341","EID1371","EID1530","EID1532","EID1678","EID1685","EID1773","EID1776","EID2868","EID5831","EID5913","EID5916","EID5933","EID5935","EID6343","EID942","EID845","EID5936","EID2878","EID2879","EID2880","EID2881","EID2882","EID2883","EID2884","EID7724","CGI260","CGI262","CGI271","CGI278","EID1924","EID1308","EID1925","EID933","EID4623","CGI261","CGI273"],["Germline","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Germline","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Germline","Germline","Germline","Germline","Germline","Germline","Germline","Somatic","Somatic","Germline",null,"Germline",null,"Somatic","Germline","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Germline","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Somatic","Germline","Germline","Germline","Germline","Germline","Germline",null,"Somatic","Germline","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic","Somatic",null,"Somatic","Somatic","Somatic","Somatic",null,"Germline",null,null,"Somatic","Somatic","Somatic"],["30110579;NCCN","30948273;FDA","FDA","32795228;FDA","26510020;32343890","FDA","FDA","30110579;NCCN","30948273;FDA","FDA","32795228;FDA","26510020;32343890;NCT01682772","FDA","FDA","31157963","34081848","34081848","31157963","34081848","34081848","30345884","30345884","28882436","28882436","32343890","30345884","32343890","28882436","28882436","22406760;22711857","22406760;22711857","22307137","20609467;25366685","25847936","26801247","22307137","20609467","25847936","26801247","23346317","28242752","28242752","28578601","23346317","26510020","28242752","28242752","28578601","19553641","24240112","24240112","25218906","25847936","21862407","21862407","27908594","28792849","25366685","25072261","29338080","29223478","27908594","19553641","24240112","24240112","25218906","25847936","21862407","21862407","27908594","28792849","25366685","25072261","29338080","29223478","27908594","21920589","26510020","21508395","27908594","27908594","27908594","27908594","27908594","27908594","27908594","32043779","19553641;25366685;25719666","25964244","26997480","25719666","28211448","16243825","28211448","22190288","23415752","22392482","22392482"],["https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://civicdb.org/links/evidence_items/7384","https://civicdb.org/links/evidence_items/11201","https://civicdb.org/links/evidence_items/11216","https://civicdb.org/links/evidence_items/7385","https://civicdb.org/links/evidence_items/11202","https://civicdb.org/links/evidence_items/11217","https://civicdb.org/links/evidence_items/7274","https://civicdb.org/links/evidence_items/7275","https://civicdb.org/links/evidence_items/11136","https://civicdb.org/links/evidence_items/11138","https://civicdb.org/links/evidence_items/11203","https://civicdb.org/links/evidence_items/7276","https://civicdb.org/links/evidence_items/8842","https://civicdb.org/links/evidence_items/11137","https://civicdb.org/links/evidence_items/11139","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://civicdb.org/links/evidence_items/211","https://civicdb.org/links/evidence_items/4838","https://civicdb.org/links/evidence_items/4876","https://civicdb.org/links/evidence_items/5815","https://civicdb.org/links/evidence_items/212","https://civicdb.org/links/evidence_items/650","https://civicdb.org/links/evidence_items/4839","https://civicdb.org/links/evidence_items/4875","https://civicdb.org/links/evidence_items/5816","https://civicdb.org/links/evidence_items/1370","https://civicdb.org/links/evidence_items/1529","https://civicdb.org/links/evidence_items/1531","https://civicdb.org/links/evidence_items/1677","https://civicdb.org/links/evidence_items/1684","https://civicdb.org/links/evidence_items/1772","https://civicdb.org/links/evidence_items/1775","https://civicdb.org/links/evidence_items/1897","https://civicdb.org/links/evidence_items/5830","https://civicdb.org/links/evidence_items/5914","https://civicdb.org/links/evidence_items/5915","https://civicdb.org/links/evidence_items/5932","https://civicdb.org/links/evidence_items/5934","https://civicdb.org/links/evidence_items/6341","https://civicdb.org/links/evidence_items/1371","https://civicdb.org/links/evidence_items/1530","https://civicdb.org/links/evidence_items/1532","https://civicdb.org/links/evidence_items/1678","https://civicdb.org/links/evidence_items/1685","https://civicdb.org/links/evidence_items/1773","https://civicdb.org/links/evidence_items/1776","https://civicdb.org/links/evidence_items/2868","https://civicdb.org/links/evidence_items/5831","https://civicdb.org/links/evidence_items/5913","https://civicdb.org/links/evidence_items/5916","https://civicdb.org/links/evidence_items/5933","https://civicdb.org/links/evidence_items/5935","https://civicdb.org/links/evidence_items/6343","https://civicdb.org/links/evidence_items/942","https://civicdb.org/links/evidence_items/845","https://civicdb.org/links/evidence_items/5936","https://civicdb.org/links/evidence_items/2878","https://civicdb.org/links/evidence_items/2879","https://civicdb.org/links/evidence_items/2880","https://civicdb.org/links/evidence_items/2881","https://civicdb.org/links/evidence_items/2882","https://civicdb.org/links/evidence_items/2883","https://civicdb.org/links/evidence_items/2884","https://civicdb.org/links/evidence_items/7724","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers","https://civicdb.org/links/evidence_items/1924","https://civicdb.org/links/evidence_items/1308","https://civicdb.org/links/evidence_items/1925","https://civicdb.org/links/evidence_items/933","https://civicdb.org/links/evidence_items/4623","https://www.cancergenomeinterpreter.org/biomarkers","https://www.cancergenomeinterpreter.org/biomarkers"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA1 mutations were present in 29/92 patients in the olaparib group and 16/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations.","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA2 mutations were present in 62/92 patients in the olaparib group and 46/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations.","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).","In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).","In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. Two patients were found to have somatic BRCA1/2 mutations. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).","Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or BRCA2 deleterious germline or somatic mutations. Mutation status was determined by local testing or by central Foundation Medicine sequencing. Of 106 patients, OR was 53.8% (95% CI, 43.8-63.5); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. Median duration of response was 9.2 months (95% CI, 6.6-11.6). Response rates by gene/mutation: BRCA1/2 germline (n=88, OR 53.4); BRCA1/2 somatic (n=18, OR 55.6); BRCA1 (n=67, OR 53.7); BRCA2 (n=39, OR 53.8).","Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or BRCA2 deleterious germline or somatic mutations. Mutation status was determined by local testing or by central Foundation Medicine sequencing. Of 106 patients, OR was 53.8% (95% CI, 43.8-63.5); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. Median duration of response was 9.2 months (95% CI, 6.6-11.6). Response rates by gene/mutation: BRCA1/2 germline (n=88, OR 53.4); BRCA1/2 somatic (n=18, OR 55.6); BRCA1 (n=67, OR 53.7); BRCA2 (n=39, OR 53.8).","This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 15 patients with BRCA1 mutations specifically, PFS HR 0.41 [0.13-1.39]. . Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone.","In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001).","In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombinant repair-related gene mutation detected from a tumor sample, olaparib showed significant PFS benefit in an ITT population (HR [95%CI] 0.49 [0.38, 0.63]). But in subgroup analysis, the treatment effect differed in each mutated genes. Among them, patients with BRCA2 mutations (olaparib: n=92, control: n=53) showed a prominent benefit of olaparib (PFS HR [95%CI] 0.21 [0.13, 0.32]).","Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or BRCA2 deleterious germline or somatic mutations. Mutation status was determined by local testing or by central Foundation Medicine sequencing. Of 106 patients, OR was 53.8% (95% CI, 43.8-63.5); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. Median duration of response was 9.2 months (95% CI, 6.6-11.6). Response rates by gene/mutation: BRCA1/2 germline (n=88, OR 53.4); BRCA1/2 somatic (n=18, OR 55.6); BRCA1 (n=67, OR 53.7); BRCA2 (n=39, OR 53.8).","Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or BRCA2 deleterious germline or somatic mutations. Mutation status was determined by local testing or by central Foundation Medicine sequencing. Of 106 patients, OR was 53.8% (95% CI, 43.8-63.5); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. Median duration of response was 9.2 months (95% CI, 6.6-11.6). Response rates by gene/mutation: BRCA1/2 germline (n=88, OR 53.4); BRCA1/2 somatic (n=18, OR 55.6); BRCA1 (n=67, OR 53.7); BRCA2 (n=39, OR 53.8).",null,null,null,null,null,null,null,null,null,null,"The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).","The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.","In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.","302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07.","In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.","In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.","In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.","46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).","In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.","In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.","In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant (BRCA1 or BRCA2) patients, 14 had homozygous somatic BRCA1 mutation or deletion. Confirmed objective response was seen in 71% (10/14) of the somatic BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.","Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.","Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)","In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.","Veliparib 400mg BID was administered to patients with germline BRCA1/2-mutated pancreatic cancer. Sixteen patients were enrolled. All except two (12.5%) had previously been treated with platinum therapy. No confirmed partial response was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 14 had germline BRCA1 mutation, 13 of which were homozygous mutation and one with unknown zygosity. Confirmed objective response was seen in 86% (12/14) of the germline BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.","In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.","In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.","46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).","In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.","In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.","In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 5 had somatic BRCA2 mutation, 4 of which were homozygous mutations and one had unknown zygosity. Confirmed objective response was seen in 80% (4/5) of the somatic BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.","Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation.  In total of patients with BRCA1/2 mutation , all but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.","Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)","In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.","Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.","A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 6 had germline homozygous BRCA2 mutation. Confirmed objective response was seen in 83% (5/6) of the germline BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001).","Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029).","1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.","Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine plus iniparib in clinical trial. Excellent response to therapy was observed and surgery was performed but no residual tumor tissue was detected","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5).","In a case report, a 3‐year‐old girl with glioblastoma harboring a probable germline heterozygous BRCA2 Lys3326Ter (K3326*) nonsense variant. After debulking surgery, the patient received standard‐of‐care treatment with radiation and temozolomide. Nine months later the PARP inhibitor olaparib was administered in combination with temozolomide for 16 cycles. This regimen was well tolerated by the patient and serial imaging showed a reduction in tumor size.",null,null,null,null,"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.","In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2). Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line.","The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. The BRCA and NHE J pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.","Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.","In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines expressing BRCA1 wild-type. Sensitivity was determined by assessing cytotoxicity and doubling time. The authors note that the slow doubling time of SNU-251 cells was compensated for with a 2 week cytotoxicity assay as compared to the 1 week assay used for all other cell lines.",null,null],["Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive","Predictive"],["Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Resistance","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity","Sensitivity","Sensitivity","Sensitivity","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity/Response","Sensitivity","Sensitivity"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>symbol<\/th>\n      <th>primary_site<\/th>\n      <th>therapeutic_context<\/th>\n      <th>molecular_profile_name<\/th>\n      <th>evidence_level<\/th>\n      <th>variant_id<\/th>\n      <th>variant_consequence<\/th>\n      <th>variant_alias<\/th>\n      <th>biomarker_source<\/th>\n      <th>biomarker_source_datestamp<\/th>\n      <th>evidence_id<\/th>\n      <th>variant_origin<\/th>\n      <th>literature_id<\/th>\n      <th>evidence_url<\/th>\n      <th>evidence_description<\/th>\n      <th>evidence_type<\/th>\n      <th>clinical_significance<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"buttons":["csv","excel"],"dom":"Bfrtip","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"responsive":true}},"evals":[],"jsHooks":[]}</script><p><br><br></p>
 </div>
 </div>
 <div class="section level2">
@@ -579,21 +559,21 @@ <h2 id="session-info">Session Info<a class="anchor" aria-label="anchor" href="#s
 <span><span class="co">#&gt; [1] stats     graphics  grDevices utils     datasets  methods   base     </span></span>
 <span><span class="co">#&gt; </span></span>
 <span><span class="co">#&gt; other attached packages:</span></span>
-<span><span class="co">#&gt; [1] pharmOncoX_1.4.4</span></span>
+<span><span class="co">#&gt; [1] pharmOncoX_1.4.5</span></span>
 <span><span class="co">#&gt; </span></span>
 <span><span class="co">#&gt; loaded via a namespace (and not attached):</span></span>
-<span><span class="co">#&gt;  [1] jsonlite_1.8.7    dplyr_1.1.2       compiler_4.3.1    crayon_1.5.2     </span></span>
+<span><span class="co">#&gt;  [1] jsonlite_1.8.7    dplyr_1.1.3       compiler_4.3.1    crayon_1.5.2     </span></span>
 <span><span class="co">#&gt;  [5] tidyselect_1.2.0  stringr_1.5.0     assertthat_0.2.1  jquerylib_0.1.4  </span></span>
 <span><span class="co">#&gt;  [9] systemfonts_1.0.4 textshaping_0.3.6 yaml_2.3.7        fastmap_1.1.1    </span></span>
-<span><span class="co">#&gt; [13] R6_2.5.1          generics_0.1.3    curl_5.0.2        knitr_1.43       </span></span>
+<span><span class="co">#&gt; [13] R6_2.5.1          generics_0.1.3    curl_5.1.0        knitr_1.44       </span></span>
 <span><span class="co">#&gt; [17] htmlwidgets_1.6.2 tibble_3.2.1      desc_1.4.2        rprojroot_2.0.3  </span></span>
 <span><span class="co">#&gt; [21] bslib_0.5.1       pillar_1.9.0      rlang_1.1.1       DT_0.29          </span></span>
 <span><span class="co">#&gt; [25] utf8_1.2.3        cachem_1.0.8      stringi_1.7.12    lgr_0.4.4        </span></span>
 <span><span class="co">#&gt; [29] xfun_0.40         fs_1.6.3          sass_0.4.7        memoise_2.0.1    </span></span>
-<span><span class="co">#&gt; [33] cli_3.6.1         withr_2.5.0       pkgdown_2.0.7     magrittr_2.0.3   </span></span>
+<span><span class="co">#&gt; [33] cli_3.6.1         withr_2.5.1       pkgdown_2.0.7     magrittr_2.0.3   </span></span>
 <span><span class="co">#&gt; [37] crosstalk_1.2.0   digest_0.6.33     lifecycle_1.0.3   vctrs_0.6.3      </span></span>
-<span><span class="co">#&gt; [41] evaluate_0.21     gargle_1.5.2      glue_1.6.2        ragg_1.2.5       </span></span>
-<span><span class="co">#&gt; [45] googledrive_2.1.1 fansi_1.0.4       httr_1.4.7        rmarkdown_2.24   </span></span>
+<span><span class="co">#&gt; [41] evaluate_0.22     gargle_1.5.2      glue_1.6.2        ragg_1.2.5       </span></span>
+<span><span class="co">#&gt; [45] googledrive_2.1.1 fansi_1.0.4       httr_1.4.7        rmarkdown_2.25   </span></span>
 <span><span class="co">#&gt; [49] purrr_1.0.2       ellipsis_0.3.2    pkgconfig_2.0.3   tools_4.3.1      </span></span>
 <span><span class="co">#&gt; [53] htmltools_0.5.6</span></span></code></pre></div>
 <p><br><br></p>
diff --git a/authors.html b/authors.html
index 5271edd..8e59b42 100644
--- a/authors.html
+++ b/authors.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
@@ -65,12 +65,12 @@ <h2>Authors</h2>
       <h2 id="citation">Citation</h2>
       <p><small class="dont-index">Source: <a href="https://github.com/sigven/pharmOncoX/blob/HEAD/inst/CITATION" class="external-link"><code>inst/CITATION</code></a></small></p>
 
-      <p>Nakken S.  (2023)  pharmOncoX: Targeted and non-targeted anti-cancer drugs and drug regimens.  R package version 1.4.4.  (https://github.com/sigven/pharmOncoX)</p>
+      <p>Nakken S.  (2023)  pharmOncoX: Targeted and non-targeted anti-cancer drugs and drug regimens.  R package version 1.4.5.  (https://github.com/sigven/pharmOncoX)</p>
       <pre>@Manual{,
   title = {pharmOncoX: Targeted and non-targeted anti-cancer drugs and drug regimens},
   author = {Sigve Nakken},
   year = {2023},
-  note = {R package version 1.4.4},
+  note = {R package version 1.4.5},
   url = {https://github.com/sigven/pharmOncoX},
 }</pre>
     </div>
diff --git a/index.html b/index.html
index 1c2d6b4..9fd6e50 100644
--- a/index.html
+++ b/index.html
@@ -55,7 +55,7 @@
     
     <a class="navbar-brand me-2" href="index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/news/index.html b/news/index.html
index c4601d0..be88778 100644
--- a/news/index.html
+++ b/news/index.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
@@ -53,6 +53,13 @@
       <small>Source: <a href="https://github.com/sigven/pharmOncoX/blob/HEAD/NEWS.md" class="external-link"><code>NEWS.md</code></a></small>
     </div>
 
+    <div class="section level2">
+<h2 class="pkg-version" data-toc-text="1.4.5" id="version-145-october-6th-2023">Version 1.4.5 (October 6th 2023)<a class="anchor" aria-label="anchor" href="#version-145-october-6th-2023"></a></h2>
+<ul><li>Updated NCI Thesaurus - 23.09d</li>
+<li>Updated CIViC data</li>
+<li>Added drug class (ATC) to <code><a href="../reference/get_on_off_label_drugs.html">get_on_off_label_drugs()</a></code>
+</li>
+</ul></div>
     <div class="section level2">
 <h2 class="pkg-version" data-toc-text="1.4.4" id="version-144-september-1st-2023">Version 1.4.4 (September 1st 2023)<a class="anchor" aria-label="anchor" href="#version-144-september-1st-2023"></a></h2>
 <ul><li>Updated NCI Thesaurus - 23.08d</li>
diff --git a/pkgdown.yml b/pkgdown.yml
index 7d84e49..e5e8384 100644
--- a/pkgdown.yml
+++ b/pkgdown.yml
@@ -3,7 +3,7 @@ pkgdown: 2.0.7
 pkgdown_sha: ~
 articles:
   pharmOncoX: pharmOncoX.html
-last_built: 2023-09-01T14:25Z
+last_built: 2023-10-06T13:44Z
 urls:
   reference: https://sigven.github.io/pharmOncoX/reference
   article: https://sigven.github.io/pharmOncoX/articles
diff --git a/reference/get_biomarkers.html b/reference/get_biomarkers.html
index 4dc62e1..81b9384 100644
--- a/reference/get_biomarkers.html
+++ b/reference/get_biomarkers.html
@@ -32,7 +32,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/reference/get_drug_records.html b/reference/get_drug_records.html
index cdfb1a6..2e89c69 100644
--- a/reference/get_drug_records.html
+++ b/reference/get_drug_records.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/reference/get_drugs.html b/reference/get_drugs.html
index 6a50021..3122ec8 100644
--- a/reference/get_drugs.html
+++ b/reference/get_drugs.html
@@ -28,7 +28,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/reference/get_on_off_label_drugs.html b/reference/get_on_off_label_drugs.html
index 7f52cc7..f8f937b 100644
--- a/reference/get_on_off_label_drugs.html
+++ b/reference/get_on_off_label_drugs.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/reference/index.html b/reference/index.html
index dbae656..2298270 100644
--- a/reference/index.html
+++ b/reference/index.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/reference/tidyeval.html b/reference/tidyeval.html
index 8a7897e..e7e9553 100644
--- a/reference/tidyeval.html
+++ b/reference/tidyeval.html
@@ -16,7 +16,7 @@
     
     <a class="navbar-brand me-2" href="../index.html">pharmOncoX</a>
 
-    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.4</small>
+    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.4.5</small>
 
     
     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
diff --git a/search.json b/search.json
index 664713a..f2b2af7 100644
--- a/search.json
+++ b/search.json
@@ -1 +1 @@
-[{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"our-pledge","dir":"","previous_headings":"","what":"Our Pledge","title":"Contributor Covenant Code of Conduct","text":"members, contributors, leaders pledge make participation community harassment-free experience everyone, regardless age, body size, visible invisible disability, ethnicity, sex characteristics, gender identity expression, level experience, education, socio-economic status, nationality, personal appearance, race, religion, sexual identity orientation. pledge act interact ways contribute open, welcoming, diverse, inclusive, healthy community.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"our-standards","dir":"","previous_headings":"","what":"Our Standards","title":"Contributor Covenant Code of Conduct","text":"Examples behavior contributes positive environment community include: Demonstrating empathy kindness toward people respectful differing opinions, viewpoints, experiences Giving gracefully accepting constructive feedback Accepting responsibility apologizing affected mistakes, learning experience Focusing best just us individuals, overall community Examples unacceptable behavior include: use sexualized language imagery, sexual attention advances kind Trolling, insulting derogatory comments, personal political attacks Public private harassment Publishing others’ private information, physical email address, without explicit permission conduct reasonably considered inappropriate professional setting","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"enforcement-responsibilities","dir":"","previous_headings":"","what":"Enforcement Responsibilities","title":"Contributor Covenant Code of Conduct","text":"Community leaders responsible clarifying enforcing standards acceptable behavior take appropriate fair corrective action response behavior deem inappropriate, threatening, offensive, harmful. Community leaders right responsibility remove, edit, reject comments, commits, code, wiki edits, issues, contributions aligned Code Conduct, communicate reasons moderation decisions appropriate.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"scope","dir":"","previous_headings":"","what":"Scope","title":"Contributor Covenant Code of Conduct","text":"Code Conduct applies within community spaces, also applies individual officially representing community public spaces. Examples representing community include using official e-mail address, posting via official social media account, acting appointed representative online offline event.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"enforcement","dir":"","previous_headings":"","what":"Enforcement","title":"Contributor Covenant Code of Conduct","text":"Instances abusive, harassing, otherwise unacceptable behavior may reported community leaders responsible enforcement [INSERT CONTACT METHOD]. complaints reviewed investigated promptly fairly. community leaders obligated respect privacy security reporter incident.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"enforcement-guidelines","dir":"","previous_headings":"","what":"Enforcement Guidelines","title":"Contributor Covenant Code of Conduct","text":"Community leaders follow Community Impact Guidelines determining consequences action deem violation Code Conduct:","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_1-correction","dir":"","previous_headings":"Enforcement Guidelines","what":"1. Correction","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Use inappropriate language behavior deemed unprofessional unwelcome community. Consequence: private, written warning community leaders, providing clarity around nature violation explanation behavior inappropriate. public apology may requested.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_2-warning","dir":"","previous_headings":"Enforcement Guidelines","what":"2. Warning","title":"Contributor Covenant Code of Conduct","text":"Community Impact: violation single incident series actions. Consequence: warning consequences continued behavior. interaction people involved, including unsolicited interaction enforcing Code Conduct, specified period time. includes avoiding interactions community spaces well external channels like social media. Violating terms may lead temporary permanent ban.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_3-temporary-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"3. Temporary Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: serious violation community standards, including sustained inappropriate behavior. Consequence: temporary ban sort interaction public communication community specified period time. public private interaction people involved, including unsolicited interaction enforcing Code Conduct, allowed period. Violating terms may lead permanent ban.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_4-permanent-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"4. Permanent Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Demonstrating pattern violation community standards, including sustained inappropriate behavior, harassment individual, aggression toward disparagement classes individuals. Consequence: permanent ban sort public interaction within community.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"attribution","dir":"","previous_headings":"","what":"Attribution","title":"Contributor Covenant Code of Conduct","text":"Code Conduct adapted Contributor Covenant, version 2.0, available https://www.contributor-covenant.org/version/2/0/ code_of_conduct.html. Community Impact Guidelines inspired Mozilla’s code conduct enforcement ladder. answers common questions code conduct, see FAQ https://www.contributor-covenant.org/faq. Translations available https:// www.contributor-covenant.org/translations.","code":""},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"installation","dir":"Articles","previous_headings":"","what":"Installation","title":"Getting started","text":"","code":"if (!(\"remotes\" %in% installed.packages()) {   install.packages(\"remotes\") } remotes::install_github('sigven/pharmOncoX')"},{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-braf-targeted-drugs-list-records-per-indication","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get BRAF-targeted drugs, list records per indication","title":"Getting started","text":"","code":"library(pharmOncoX)  ## load the data cache_dir <- tempdir()  drugs <- get_drugs(   cache_dir = cache_dir,   drug_targeted_agent = T,     drug_target = c('BRAF')) #> INFO  [2023-09-01 14:25:08] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-09-01 14:25:09] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F #> INFO  [2023-09-01 14:25:09] Object 'drug_map_name' sucessfully loaded #> INFO  [2023-09-01 14:25:09] md5 checksum is valid: aafe5e5a43a9eaa3d606db079200865f #> INFO  [2023-09-01 14:25:09] Retrieved 30211 records #> INFO  [2023-09-01 14:25:09] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-09-01 14:25:19] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F #> INFO  [2023-09-01 14:25:19] Object 'drug_map_alias' sucessfully loaded #> INFO  [2023-09-01 14:25:19] md5 checksum is valid: bba52645dbfb432830e4b4ba888ca28f #> INFO  [2023-09-01 14:25:19] Retrieved 655802 records #> INFO  [2023-09-01 14:25:19] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-09-01 14:25:21] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F #> INFO  [2023-09-01 14:25:21] Object 'drug_map_basic' sucessfully loaded #> INFO  [2023-09-01 14:25:21] md5 checksum is valid: db2d666d448ca1e437bb127b9aae7460 #> INFO  [2023-09-01 14:25:21] Retrieved 31146 records #> INFO  [2023-09-01 14:25:21] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-09-01 14:25:22] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F #> INFO  [2023-09-01 14:25:22] Object 'drug_map_target' sucessfully loaded #> INFO  [2023-09-01 14:25:22] md5 checksum is valid: 86bab9ec69d7ad2edca64d4ceae1440c #> INFO  [2023-09-01 14:25:22] Retrieved 38127 records #> INFO  [2023-09-01 14:25:22] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-09-01 14:25:28] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F #> INFO  [2023-09-01 14:25:28] Object 'drug_map_indication' sucessfully loaded #> INFO  [2023-09-01 14:25:28] md5 checksum is valid: ae749b0cf93f760651c0e459c3fef232 #> INFO  [2023-09-01 14:25:28] Retrieved 58866 records #> INFO  [2023-09-01 14:25:32] Record set satisfying user-defined criteria: n = 329 #> INFO  [2023-09-01 14:25:32] Collapsing record set - providing output on a 'per_drug_target_indication' resolution #> INFO  [2023-09-01 14:25:32] Final record set: n = 240 records  ## Number of drug records nrow(drugs$records) #> [1] 240  ## Column names of drug records colnames(drugs$records) #>  [1] \"drug_id\"                      \"drug_name\"                    #>  [3] \"drug_type\"                    \"molecule_chembl_id\"           #>  [5] \"drug_action_type\"             \"drug_alias\"                   #>  [7] \"nci_concept_definition\"       \"opentargets\"                  #>  [9] \"drug_cancer_relevance\"        \"inhibition_moa\"               #> [11] \"is_salt\"                      \"is_adc\"                       #> [13] \"drug_blackbox_warning\"        \"nci_t\"                        #> [15] \"target_symbol\"                \"target_entrezgene\"            #> [17] \"target_genename\"              \"target_ensembl_gene_id\"       #> [19] \"target_type\"                  \"drug_max_phase_indication\"    #> [21] \"drug_approved_indication\"     \"drug_frac_cancer_indications\" #> [23] \"drug_approved_noncancer\"      \"drug_n_indications\"           #> [25] \"drug_year_first_approval\"     \"drug_max_ct_phase\"            #> [27] \"disease_efo_id\"               \"disease_efo_label\"            #> [29] \"primary_site\"                 \"drug_clinical_id\"             #> [31] \"drug_clinical_source\"         \"atc_code_level1\"              #> [33] \"atc_level1\"                   \"atc_code_level2\"              #> [35] \"atc_level2\"                   \"atc_code_level3\"              #> [37] \"atc_level3\""},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-braf-targeted-drugs-open-targets-platform-only-list-per-drug-only","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get BRAF-targeted drugs, Open Targets Platform only, list per drug only","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    drug_targeted_agent = T,   drug_action_inhibition = T,     drug_target = c('BRAF'),    drug_source_opentargets = T,    output_resolution = \"drug\" )  drugs$records <- drugs$records |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_braf_inhibitors <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-immune-checkpoint-inhibitors-list-per-drug-target-entry","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get immune checkpoint inhibitors, list per drug-target entry","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    drug_source_opentargets = F,   drug_classified_cancer = T,    output_resolution = \"drug2target\")  drugs$records <- drugs$records |>   dplyr::filter(     ((!is.na(atc_level3) &        atc_level3 == \"PD-1/PDL-1 inhibitors\") |      (!is.na(target_symbol) &       target_symbol == \"CTLA4\" |       target_symbol == \"TIGIT\"))   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     ) |>   dplyr::select(     drug_id,     drug_name,     drug_type,     target_symbol,     target_genename,     dplyr::everything()   )  dt_drugtable_ici <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-immune-checkpoint-inhibitors-indicated-for-tumor-subtypes-within-colonrectum-list-per-drug-target-entry","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get immune checkpoint inhibitors indicated for tumor subtypes within “Colon/Rectum”, list per drug-target entry","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug2target\",    drug_source_opentargets = T,   drug_indication_main = \"Colon/Rectum\")  drugs$records <- drugs$records |>   dplyr::filter(      ((!is.na(atc_level3) &        atc_level3 == \"PD-1/PDL-1 inhibitors\") |      (!is.na(target_symbol) &       target_symbol == \"CTLA4\" |       target_symbol == \"TIGIT\"))   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     ) |>   dplyr::select(     drug_id,     drug_name,     drug_type,     target_symbol,     target_genename,     dplyr::everything()   )  dt_drugtable_ici_colon <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-antimetabolite-drugs","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get antimetabolite drugs","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug\") #> INFO  [2023-09-01 14:25:48] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:48] Object 'drug_map_name' sucessfully loaded #> INFO  [2023-09-01 14:25:48] Retrieved n = 30211 records #> INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:49] Object 'drug_map_alias' sucessfully loaded #> INFO  [2023-09-01 14:25:49] Retrieved n = 655802 records #> INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:49] Object 'drug_map_basic' sucessfully loaded #> INFO  [2023-09-01 14:25:49] Retrieved n = 31146 records #> INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:49] Object 'drug_map_target' sucessfully loaded #> INFO  [2023-09-01 14:25:49] Retrieved n = 38127 records #> INFO  [2023-09-01 14:25:49] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:49] Object 'drug_map_indication' sucessfully loaded #> INFO  [2023-09-01 14:25:49] Retrieved n = 58866 records #> INFO  [2023-09-01 14:25:52] Record set satisfying user-defined criteria: n = 74633 #> INFO  [2023-09-01 14:25:52] Collapsing record set - providing output on a 'per_drug' resolution #> INFO  [2023-09-01 14:25:53] Final record set: n = 1162 records  drugs$records <- drugs$records |>   dplyr::filter(     stringr::str_detect(       atc_level2, \"ANTIMETABOLITES\"     )   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_metabolites <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-taxanes","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get taxanes","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug\") #> INFO  [2023-09-01 14:25:53] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:53] Object 'drug_map_name' sucessfully loaded #> INFO  [2023-09-01 14:25:53] Retrieved n = 30211 records #> INFO  [2023-09-01 14:25:53] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:53] Object 'drug_map_alias' sucessfully loaded #> INFO  [2023-09-01 14:25:53] Retrieved n = 655802 records #> INFO  [2023-09-01 14:25:54] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:54] Object 'drug_map_basic' sucessfully loaded #> INFO  [2023-09-01 14:25:54] Retrieved n = 31146 records #> INFO  [2023-09-01 14:25:54] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:54] Object 'drug_map_target' sucessfully loaded #> INFO  [2023-09-01 14:25:54] Retrieved n = 38127 records #> INFO  [2023-09-01 14:25:54] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:54] Object 'drug_map_indication' sucessfully loaded #> INFO  [2023-09-01 14:25:54] Retrieved n = 58866 records #> INFO  [2023-09-01 14:25:57] Record set satisfying user-defined criteria: n = 74633 #> INFO  [2023-09-01 14:25:57] Collapsing record set - providing output on a 'per_drug' resolution #> INFO  [2023-09-01 14:25:57] Final record set: n = 1162 records  drugs$records <- drugs$records |>   dplyr::filter(     stringr::str_detect(       atc_level3, \"Taxanes\"     )   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_taxanes <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-platinum-compounds","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get platinum compounds","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug\") #> INFO  [2023-09-01 14:25:57] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:57] Object 'drug_map_name' sucessfully loaded #> INFO  [2023-09-01 14:25:57] Retrieved n = 30211 records #> INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:58] Object 'drug_map_alias' sucessfully loaded #> INFO  [2023-09-01 14:25:58] Retrieved n = 655802 records #> INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:58] Object 'drug_map_basic' sucessfully loaded #> INFO  [2023-09-01 14:25:58] Retrieved n = 31146 records #> INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:58] Object 'drug_map_target' sucessfully loaded #> INFO  [2023-09-01 14:25:58] Retrieved n = 38127 records #> INFO  [2023-09-01 14:25:58] Reading from cache_dir = '/tmp/RtmpBhEKao', argument force_download = F #> INFO  [2023-09-01 14:25:58] Object 'drug_map_indication' sucessfully loaded #> INFO  [2023-09-01 14:25:58] Retrieved n = 58866 records #> INFO  [2023-09-01 14:26:01] Record set satisfying user-defined criteria: n = 74633 #> INFO  [2023-09-01 14:26:01] Collapsing record set - providing output on a 'per_drug' resolution #> INFO  [2023-09-01 14:26:02] Final record set: n = 1162 records  drugs$records <- drugs$records |>   dplyr::filter(     stringr::str_detect(       atc_level3, \"Platinum compounds\"     )   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_platins <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"reported-associations-between-brca12-alterations-and-drug-sensitivity","dir":"Articles","previous_headings":"Retrieval of biomarkers","what":"Reported associations between BRCA1/2 alterations and drug sensitivity","title":"Getting started","text":"Get evidence CIViC CGI cancer drug sensitivity BRCA1/2 alterations (somatically (tumor) inherited/germline)","code":"biomarkers <- get_biomarkers(   cache_dir = cache_dir) #> INFO  [2023-09-01 14:26:02] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-09-01 14:26:05] Reading from cache_dir = ' (/tmp/RtmpBhEKao'), argument force_download = F #> INFO  [2023-09-01 14:26:05] Object 'biomarkers' sucessfully loaded #> INFO  [2023-09-01 14:26:05] md5 checksum is valid: f4523f47b77d68beda72d1f9c46d96c7  brca1_biomarkers <- list() for(source in c('civic','cgi')){   brca1_biomarkers[[source]] <-      biomarkers$data[[source]]$variant |>      dplyr::filter(       !is.na(symbol) & (symbol == \"BRCA1\" | symbol == \"BRCA2\")) |>     dplyr::group_by(variant_id, symbol, variant_consequence) |>     dplyr::summarise(       variant_alias = paste(variant_alias, collapse=\", \"),        .groups = \"drop\") |>      dplyr::inner_join(       biomarkers$data[[source]]$clinical, by = \"variant_id\") |>     dplyr::select(       variant_id, symbol, variant_consequence, variant_alias,       biomarker_source, biomarker_source_datestamp,       molecular_profile_name, evidence_id, variant_origin,       primary_site, evidence_id, source_id,       evidence_url, therapeutic_context,       evidence_description, evidence_type, evidence_level,       clinical_significance) |>      dplyr::distinct() |>      dplyr::rename(literature_id = source_id) |>     dplyr::filter(evidence_type == \"Predictive\") |>     dplyr::select(       symbol, primary_site,       therapeutic_context,       molecular_profile_name,        evidence_level,       dplyr::everything()     ) }  brca1_biomarkers_all <-    dplyr::bind_rows(brca1_biomarkers[['civic']],                    brca1_biomarkers[['cgi']]) |>     dplyr::arrange(evidence_level)     dt_brca1_biomarkers <- DT::datatable(   brca1_biomarkers_all,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"session-info","dir":"Articles","previous_headings":"","what":"Session Info","title":"Getting started","text":"","code":"# set eval = FALSE if you don't want this info (useful for reproducibility)  # to appear sessionInfo() #> R version 4.3.1 (2023-06-16) #> Platform: x86_64-pc-linux-gnu (64-bit) #> Running under: Ubuntu 22.04.3 LTS #>  #> Matrix products: default #> BLAS:   /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3  #> LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so;  LAPACK version 3.10.0 #>  #> locale: #>  [1] LC_CTYPE=C.UTF-8       LC_NUMERIC=C           LC_TIME=C.UTF-8        #>  [4] LC_COLLATE=C.UTF-8     LC_MONETARY=C.UTF-8    LC_MESSAGES=C.UTF-8    #>  [7] LC_PAPER=C.UTF-8       LC_NAME=C              LC_ADDRESS=C           #> [10] LC_TELEPHONE=C         LC_MEASUREMENT=C.UTF-8 LC_IDENTIFICATION=C    #>  #> time zone: UTC #> tzcode source: system (glibc) #>  #> attached base packages: #> [1] stats     graphics  grDevices utils     datasets  methods   base      #>  #> other attached packages: #> [1] pharmOncoX_1.4.4 #>  #> loaded via a namespace (and not attached): #>  [1] jsonlite_1.8.7    dplyr_1.1.2       compiler_4.3.1    crayon_1.5.2      #>  [5] tidyselect_1.2.0  stringr_1.5.0     assertthat_0.2.1  jquerylib_0.1.4   #>  [9] systemfonts_1.0.4 textshaping_0.3.6 yaml_2.3.7        fastmap_1.1.1     #> [13] R6_2.5.1          generics_0.1.3    curl_5.0.2        knitr_1.43        #> [17] htmlwidgets_1.6.2 tibble_3.2.1      desc_1.4.2        rprojroot_2.0.3   #> [21] bslib_0.5.1       pillar_1.9.0      rlang_1.1.1       DT_0.29           #> [25] utf8_1.2.3        cachem_1.0.8      stringi_1.7.12    lgr_0.4.4         #> [29] xfun_0.40         fs_1.6.3          sass_0.4.7        memoise_2.0.1     #> [33] cli_3.6.1         withr_2.5.0       pkgdown_2.0.7     magrittr_2.0.3    #> [37] crosstalk_1.2.0   digest_0.6.33     lifecycle_1.0.3   vctrs_0.6.3       #> [41] evaluate_0.21     gargle_1.5.2      glue_1.6.2        ragg_1.2.5        #> [45] googledrive_2.1.1 fansi_1.0.4       httr_1.4.7        rmarkdown_2.24    #> [49] purrr_1.0.2       ellipsis_0.3.2    pkgconfig_2.0.3   tools_4.3.1       #> [53] htmltools_0.5.6"},{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Sigve Nakken. Author, maintainer.","code":""},{"path":"https://sigven.github.io/pharmOncoX/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Nakken S.  (2023)  pharmOncoX: Targeted non-targeted anti-cancer drugs drug regimens.  R package version 1.4.4.  (https://github.com/sigven/pharmOncoX)","code":"@Manual{,   title = {pharmOncoX: Targeted and non-targeted anti-cancer drugs and drug regimens},   author = {Sigve Nakken},   year = {2023},   note = {R package version 1.4.4},   url = {https://github.com/sigven/pharmOncoX}, }"},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"pharmoncox-","dir":"","previous_headings":"","what":"Molecularly targeted cancer drugs and biomarkers","title":"Molecularly targeted cancer drugs and biomarkers","text":"pharmOncoX provides access targeted non-targeted cancer drugs, including comprehensive annotations per target, drug mechanism--action, approval dates, clinical trial phases various indications etc. data largely based drug-target-indication associations provided Open Targets Platform (Ochoa et al., Nucleic Acids Res., 2021). Associations retrieved Open Targets Platform integrated cancer-relevant indications/conditions (provided sigven/phenOncoX), allowing user retrieve drugs indicated main tumor types (e.g. Lung, Colon/Rectum etc.) Drug-target associations Open Targets Platform furthermore integrated appended drug information NCI Thesaurus, showing also non-targeted cancer drugs (chemotherapeutic agents etc.), various drug regimens. provide anti-cancer drugs pharmOncoX drug class labeling Anatomical Therapeutic Chemical (ATC) Classification System, enabling filtering drugs according main mechanisms action. Currently (late April 2023), pharmOncoX built upon following releases external databases: Open Targets Platform (2023.02) ChEMBL (v31) NCI Thesaurus (23.04d)","code":""},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"getting-started","dir":"","previous_headings":"","what":"Getting started","title":"Molecularly targeted cancer drugs and biomarkers","text":"Installation instructions Usage examples","code":""},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"contact","dir":"","previous_headings":"","what":"Contact","title":"Molecularly targeted cancer drugs and biomarkers","text":"sigven ifi.uio.","code":""},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"code-of-conduct","dir":"","previous_headings":"","what":"Code of Conduct","title":"Molecularly targeted cancer drugs and biomarkers","text":"Please note project released Contributor Code Conduct. participating project agree abide terms.","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":null,"dir":"Reference","previous_headings":"","what":"Get curated cancer biomarker datasets — get_biomarkers","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"Downloads preprocessed datasets local cache directory returns curated set genomic biomarkers multiple sources (CIViC, CGI, MitelmanDB) dataset comes list object, three elements: metadata - data frame metadata regarding drug resources used data - list four elements ('civic','cgi','mitelmandb','custom_fusions') fpath - path cache file","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"","code":"get_biomarkers(cache_dir = NA, force_download = F)"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"cache_dir Local directory data download force_download Logical indicating local cache force downloaded (.e. set TRUE re-download even data exists cache)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"entry source-spefic (CGI, CIViC etc.) entry data list contains list three data frames: variant - list biomarker variants, extensively populated according variant aliases (identifer - column variant_id) clinical - cross-references variants recorded variant data frame clinical evidence items (identifier - column evidence_id) underlying literature evidence (identifier - column source_id) literature - lists literature source_id's listed clinical data frame","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drug_records.html","id":null,"dir":"Reference","previous_headings":"","what":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","title":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","text":"Function retrieves pharmOncoX data Google Drive","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drug_records.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","text":"","code":"get_drug_records(cache_dir = NA, force_download = F)"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drug_records.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","text":"cache_dir Local directory data download force_download Logical indicating local cache force downloaded (.e. set TRUE re-download even data exists cache)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":null,"dir":"Reference","previous_headings":"","what":"Get antineoplastic drugs and drug regimens — get_drugs","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"Downloads preprocessed datasets local cache directory returns selected set drugs based various criteria set user. dataset comes list object, two elements: metadata - data frame metadata regarding drug resources used records - data frame drug records","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"","code":"get_drugs(   cache_dir = NA,   force_download = FALSE,   exclude_salt_forms = TRUE,   exclude_adc = TRUE,   drug_targeted_agent = FALSE,   drug_is_approved = FALSE,   drug_target = NULL,   drug_action_type = NULL,   drug_indication_main = NULL,   drug_source_opentargets = FALSE,   drug_cancer_indication = TRUE,   drug_classified_cancer = TRUE,   drug_has_blackbox_warning = FALSE,   drug_approval_year = 1939,   drug_minimum_phase_any_indication = 0,   output_resolution = \"drug2target2indication\",   drug_action_inhibition = F )"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"cache_dir local cache directory data retrieval force_download force download data remote repository even data exists cache exclude_salt_forms exclude salt forms drugs exclude_adc exclude antibody-drug conjugates (ADCs) drug_targeted_agent logical indicating resulting drug records contain drugs considered targeted agents (.e. chemotherapeutic drugs/immunosuppressants) drug_is_approved logical indicating resulting drug records contain approved drugs drug_target character vector drug targets (gene symbols) drug records included results drug_action_type character vector drug action types include drug record list - possible values \"INHIBITOR\",\"AGONIST\",\"MODULATOR\",\"ANTAGONIST\", \"BLOCKER\",\"ACTIVATOR\",\"BINDING AGENT\",\"OPENER\", \"STABILISER\",\"CROSS-LINKING AGENT\",DISRUPTING AGENT\",\"\" drug_indication_main character vector main tumor types drug(s) indicated. Possible values: \"Adrenal Gland\",\"Biliary Tract\", \"Bladder/Urinary Tract\",\"Bone\",\"Breast\",\"Cervix\",\"CNS/Brain\", \"Colon/Rectum\",\"Esophagus/Stomach\",\"Eye\",\"Head Neck\",\"Kidney\", \"Liver\",\"Lung\",\"Lymphoid\",\"Myeloid\",\"Ovary/Fallopian Tube\", \"Pancreas\",\"Penis\",\"Peripheral Nervous System\",\"Peritoneum\", \"Pleura\",\"Prostate\",\"Skin\",\"Soft Tissue\",\"Testis\",\"Thymus\", \"Thyroid\",\"Uterus\",\"Vulva/Vagina\" drug_source_opentargets logical indicating resulting drug records contain drug records Open Targets Platform/ChEMBL drug_cancer_indication logical indicating resulting drug records indicated cancer conditions (approved conditions, found clinical trials etc.) drug_classified_cancer logical indicating resulting drug records classified \"L\" class ATC ( \"ANTINEOPLASTIC IMMUNOMODULATING AGENTS\") drug_has_blackbox_warning logical indicating resulting drug records contain drugs black box warnings drug_approval_year include records drugs approved later date (year) drug_minimum_phase_any_indication include drug records clinical phase (indication) greater equal phase output_resolution dictate output record resolution ('drug','drug2target','drug2target2indication') drug_action_inhibition logical indicating return drug records inhibitory mechanism--action","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"records data frame contains following columns (selected columns shown based value output_resolution) drug_id - drug identifier (pharmaOncoX) drug_name - primary drug name (upper case, NCI Thesaurus) drug_type - type drug molecule (Antibody, small molecule etc) molecule_chembl_id - ChEMBL compound identifier drug_action_type - main action elicited drug (antagonist, inhibitor, stabiliser etc) drug_alias - collection unambiguous drug aliases (separated '|') nci_concept_definition - detailed description drug mechanism--action (NCI Thesaurus) opentargets - logical - drug found Open Targets Platform resource is_salt - logical - drug record represents salt form (excluded default) is_adc - logical - drug record represents antibody-drug conjugate (ADC - excluded default) drug_blacbox_warning - logical indicating drug blackbox warning nci_t - NCI thesaurus identifier target_symbol - gene symbol drug target target_entrezgene - Entrez gene identifier drug target target_genename - gene name/description drug target target_ensembl_gene_id - Ensembl gene identifier drug target target_type - type drug target (single protein, protein family etc.) drug_max_phase_indication - maximum clinical phase drug (given indication) drug_approved_indication - logical indicating drug approved indication drug_frac_cancer_indications - fraction drug indications cancers drug_approved_noncancer - logical indicating drug approved non-cancer disease drug_n_indications - number indications given drug (approved indications, clinical trials etc) drug_year_first_approval - year drug first approved drug_max_ct_phase - maximum clinical phase drug (indication) disease_efo_id - EFO (Experimental Factor Ontology) identifier drug indication disease_efo_label - EFO (Experimental Factor Ontology) label drug indication primary_site - primary tumor site/type (obtained https://github.com/sigven/oncoPhenoMap) drug_clinical_id - drug clinical identifier (clinicaltrials.gov, DailyMed, FDA etc.) drug_clinical_source - underlying source drug entry (DailyMed, clinicaltrials.gov, FDA etc.) atc_code_level1 - drug identifier ATC (level 1) atc_level1 - drug label ATC (level 1) atc_code_level1 - drug identifier ATC (level 2) atc_level2 - drug label ATC (level 2) atc_code_level3 - drug identifier ATC (level 3) atc_level3 - drug label ATC (level 3)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_on_off_label_drugs.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"Utility function get -label/-label drugs (complete)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_on_off_label_drugs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"","code":"get_on_off_label_drugs(cache_dir = NA)"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_on_off_label_drugs.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"cache_dir Local cache directory","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/tidyeval.html","id":null,"dir":"Reference","previous_headings":"","what":"Tidy eval helpers — tidyeval","title":"Tidy eval helpers — tidyeval","text":"https://cran.r-project.org/web/packages/dplyr/vignettes/programming.html","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-144-september-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.4 (September 1st 2023)","title":"Version 1.4.4 (September 1st 2023)","text":"Updated NCI Thesaurus - 23.08d Updated CIViC data Updated Mitelman database (20230803) get_biomarkers() now exported main function","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-143-august-7th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.3 (August 7th 2023)","title":"Version 1.4.3 (August 7th 2023)","text":"NCI Thesaurus 23.07e","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-142-august-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.2 (August 1st 2023)","title":"Version 1.4.2 (August 1st 2023)","text":"Added biomarker aliases Updated CIViC data","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-141-july-23rd-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.1 (July 23rd 2023)","title":"Version 1.4.1 (July 23rd 2023)","text":"Added missing biomarker aliases synonymous variants","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-140-july-11th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.0 (July 11th 2023)","title":"Version 1.4.0 (July 11th 2023)","text":"Updated metadata Updated CIViC","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-138-july-5th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.8 (July 5th 2023)","title":"Version 1.3.8 (July 5th 2023)","text":"Cleaned biomarker data (CIViC)","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-137-june-28th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.7 (June 28th 2023)","title":"Version 1.3.7 (June 28th 2023)","text":"Updated NCI Thesaurus (23.06d release) Updated biomarker data (CIViC) Updated Open Targets Platform (2023.06)","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-136-june-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.6 (June 1st 2023)","title":"Version 1.3.6 (June 1st 2023)","text":"Updated NCI Thesaurus (23.05d release) Cleaned biomarker alteration types","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-135-may-24th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.5 (May 24th 2023)","title":"Version 1.3.5 (May 24th 2023)","text":"Removed general words drug alias list Fixed bug biomarker alias parsing","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-133-may-15th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.3 (May 15th 2023)","title":"Version 1.3.3 (May 15th 2023)","text":"Added additional drug entries (primary indication non-cancer) Fixed bug parsing drugs Open Targets Platform","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-130-may-10th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.0 (May 10th 2023)","title":"Version 1.3.0 (May 10th 2023)","text":"Updated NCI Thesaurus (23.04d release) Drugs now provided ATC classification labels arguments filtering towards specific inhibitors etc now removed (e.g. is_alkylating_agent,is_angiogenesis_inhibitor etc.), filtering can performed user, e.g. considering drug class labels ATC drug targets drug_is_targeted -> drug_targeted_agent inhibitor_only -> drug_action_inhibition drug_approved_later_than -> drug_approval_year source_opentargets_only -> drug_source_opentargets drug_targeted_agent option improved basd ATC labeling drug_cancer_indication - logical indicating resulting drug records indicated cancer conditions (.e. approved conditions, listed clinical trials etc.) - defaults TRUE drug_classified_cancer - logical indicating resulting drug records classified “L” class ATC ( “ANTINEOPLASTIC IMMUNOMODULATING AGENTS”) - defaults TRUE","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-120-april-26th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.2.0 (April 26th 2023)","title":"Version 1.2.0 (April 26th 2023)","text":"Using sigven/phenOncoX v0.5.8 cancer phenotype matching Updated NCI Thesaurus (23.03d release) New helper function retrieve drug biomarkers (pharmOncoX:::get_biomarkers)","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-119-march-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.1.9 (March 1st 2023)","title":"Version 1.1.9 (March 1st 2023)","text":"Updated NCI Thesaurus (23.02d release) Updated biomarker data (CIViC) Updated Open Targets Platform (2023.02)","code":""}]
+[{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"our-pledge","dir":"","previous_headings":"","what":"Our Pledge","title":"Contributor Covenant Code of Conduct","text":"members, contributors, leaders pledge make participation community harassment-free experience everyone, regardless age, body size, visible invisible disability, ethnicity, sex characteristics, gender identity expression, level experience, education, socio-economic status, nationality, personal appearance, race, religion, sexual identity orientation. pledge act interact ways contribute open, welcoming, diverse, inclusive, healthy community.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"our-standards","dir":"","previous_headings":"","what":"Our Standards","title":"Contributor Covenant Code of Conduct","text":"Examples behavior contributes positive environment community include: Demonstrating empathy kindness toward people respectful differing opinions, viewpoints, experiences Giving gracefully accepting constructive feedback Accepting responsibility apologizing affected mistakes, learning experience Focusing best just us individuals, overall community Examples unacceptable behavior include: use sexualized language imagery, sexual attention advances kind Trolling, insulting derogatory comments, personal political attacks Public private harassment Publishing others’ private information, physical email address, without explicit permission conduct reasonably considered inappropriate professional setting","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"enforcement-responsibilities","dir":"","previous_headings":"","what":"Enforcement Responsibilities","title":"Contributor Covenant Code of Conduct","text":"Community leaders responsible clarifying enforcing standards acceptable behavior take appropriate fair corrective action response behavior deem inappropriate, threatening, offensive, harmful. Community leaders right responsibility remove, edit, reject comments, commits, code, wiki edits, issues, contributions aligned Code Conduct, communicate reasons moderation decisions appropriate.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"scope","dir":"","previous_headings":"","what":"Scope","title":"Contributor Covenant Code of Conduct","text":"Code Conduct applies within community spaces, also applies individual officially representing community public spaces. Examples representing community include using official e-mail address, posting via official social media account, acting appointed representative online offline event.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"enforcement","dir":"","previous_headings":"","what":"Enforcement","title":"Contributor Covenant Code of Conduct","text":"Instances abusive, harassing, otherwise unacceptable behavior may reported community leaders responsible enforcement [INSERT CONTACT METHOD]. complaints reviewed investigated promptly fairly. community leaders obligated respect privacy security reporter incident.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"enforcement-guidelines","dir":"","previous_headings":"","what":"Enforcement Guidelines","title":"Contributor Covenant Code of Conduct","text":"Community leaders follow Community Impact Guidelines determining consequences action deem violation Code Conduct:","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_1-correction","dir":"","previous_headings":"Enforcement Guidelines","what":"1. Correction","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Use inappropriate language behavior deemed unprofessional unwelcome community. Consequence: private, written warning community leaders, providing clarity around nature violation explanation behavior inappropriate. public apology may requested.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_2-warning","dir":"","previous_headings":"Enforcement Guidelines","what":"2. Warning","title":"Contributor Covenant Code of Conduct","text":"Community Impact: violation single incident series actions. Consequence: warning consequences continued behavior. interaction people involved, including unsolicited interaction enforcing Code Conduct, specified period time. includes avoiding interactions community spaces well external channels like social media. Violating terms may lead temporary permanent ban.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_3-temporary-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"3. Temporary Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: serious violation community standards, including sustained inappropriate behavior. Consequence: temporary ban sort interaction public communication community specified period time. public private interaction people involved, including unsolicited interaction enforcing Code Conduct, allowed period. Violating terms may lead permanent ban.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"id_4-permanent-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"4. Permanent Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Demonstrating pattern violation community standards, including sustained inappropriate behavior, harassment individual, aggression toward disparagement classes individuals. Consequence: permanent ban sort public interaction within community.","code":""},{"path":"https://sigven.github.io/pharmOncoX/CODE_OF_CONDUCT.html","id":"attribution","dir":"","previous_headings":"","what":"Attribution","title":"Contributor Covenant Code of Conduct","text":"Code Conduct adapted Contributor Covenant, version 2.0, available https://www.contributor-covenant.org/version/2/0/ code_of_conduct.html. Community Impact Guidelines inspired Mozilla’s code conduct enforcement ladder. answers common questions code conduct, see FAQ https://www.contributor-covenant.org/faq. Translations available https:// www.contributor-covenant.org/translations.","code":""},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"installation","dir":"Articles","previous_headings":"","what":"Installation","title":"Getting started","text":"","code":"if (!(\"remotes\" %in% installed.packages()) {   install.packages(\"remotes\") } remotes::install_github('sigven/pharmOncoX')"},{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-braf-targeted-drugs-list-records-per-indication","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get BRAF-targeted drugs, list records per indication","title":"Getting started","text":"","code":"library(pharmOncoX)  ## load the data cache_dir <- tempdir()  drugs <- get_drugs(   cache_dir = cache_dir,   drug_targeted_agent = T,     drug_target = c('BRAF')) #> INFO  [2023-10-06 13:44:15] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-10-06 13:44:17] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-10-06 13:44:31] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-10-06 13:44:38] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-10-06 13:44:40] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-10-06 13:44:50] Record set satisfying user-defined criteria: n = 328 #> INFO  [2023-10-06 13:44:50] Collapsing record set - providing output on a 'per_drug_target_indication' resolution #> INFO  [2023-10-06 13:44:50] Final record set: n = 239 records  ## Number of drug records nrow(drugs$records) #> [1] 239  ## Column names of drug records colnames(drugs$records) #>  [1] \"drug_id\"                      \"drug_name\"                    #>  [3] \"drug_type\"                    \"molecule_chembl_id\"           #>  [5] \"drug_action_type\"             \"drug_alias\"                   #>  [7] \"nci_concept_definition\"       \"opentargets\"                  #>  [9] \"drug_cancer_relevance\"        \"inhibition_moa\"               #> [11] \"is_salt\"                      \"is_adc\"                       #> [13] \"drug_blackbox_warning\"        \"nci_t\"                        #> [15] \"target_symbol\"                \"target_entrezgene\"            #> [17] \"target_genename\"              \"target_ensembl_gene_id\"       #> [19] \"target_type\"                  \"drug_max_phase_indication\"    #> [21] \"drug_approved_indication\"     \"drug_frac_cancer_indications\" #> [23] \"drug_approved_noncancer\"      \"drug_n_indications\"           #> [25] \"drug_year_first_approval\"     \"drug_max_ct_phase\"            #> [27] \"disease_efo_id\"               \"disease_efo_label\"            #> [29] \"primary_site\"                 \"drug_clinical_id\"             #> [31] \"drug_clinical_source\"         \"atc_code_level1\"              #> [33] \"atc_level1\"                   \"atc_code_level2\"              #> [35] \"atc_level2\"                   \"atc_code_level3\"              #> [37] \"atc_level3\""},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-braf-targeted-drugs-open-targets-platform-only-list-per-drug-only","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get BRAF-targeted drugs, Open Targets Platform only, list per drug only","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    drug_targeted_agent = T,   drug_action_inhibition = T,     drug_target = c('BRAF'),    drug_source_opentargets = T,    output_resolution = \"drug\" )  drugs$records <- drugs$records |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_braf_inhibitors <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-immune-checkpoint-inhibitors-list-per-drug-target-entry","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get immune checkpoint inhibitors, list per drug-target entry","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    drug_source_opentargets = F,   drug_classified_cancer = T,    output_resolution = \"drug2target\")  drugs$records <- drugs$records |>   dplyr::filter(     ((!is.na(atc_level3) &        atc_level3 == \"PD-1/PDL-1 inhibitors\") |      (!is.na(target_symbol) &       target_symbol == \"CTLA4\" |       target_symbol == \"TIGIT\"))   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     ) |>   dplyr::select(     drug_id,     drug_name,     drug_type,     target_symbol,     target_genename,     dplyr::everything()   )  dt_drugtable_ici <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-immune-checkpoint-inhibitors-indicated-for-tumor-subtypes-within-colonrectum-list-per-drug-target-entry","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get immune checkpoint inhibitors indicated for tumor subtypes within “Colon/Rectum”, list per drug-target entry","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug2target\",    drug_source_opentargets = T,   drug_indication_main = \"Colon/Rectum\")  drugs$records <- drugs$records |>   dplyr::filter(      ((!is.na(atc_level3) &        atc_level3 == \"PD-1/PDL-1 inhibitors\") |      (!is.na(target_symbol) &       target_symbol == \"CTLA4\" |       target_symbol == \"TIGIT\"))   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     ) |>   dplyr::select(     drug_id,     drug_name,     drug_type,     target_symbol,     target_genename,     dplyr::everything()   )  dt_drugtable_ici_colon <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-antimetabolite-drugs","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get antimetabolite drugs","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug\") #> INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:06] Object 'drug_map_name' sucessfully loaded #> INFO  [2023-10-06 13:45:06] Retrieved n = 30298 records #> INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:06] Object 'drug_map_alias' sucessfully loaded #> INFO  [2023-10-06 13:45:06] Retrieved n = 655065 records #> INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:06] Object 'drug_map_basic' sucessfully loaded #> INFO  [2023-10-06 13:45:06] Retrieved n = 31232 records #> INFO  [2023-10-06 13:45:06] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:06] Object 'drug_map_target' sucessfully loaded #> INFO  [2023-10-06 13:45:06] Retrieved n = 38215 records #> INFO  [2023-10-06 13:45:07] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:07] Object 'drug_map_indication' sucessfully loaded #> INFO  [2023-10-06 13:45:07] Retrieved n = 56512 records #> INFO  [2023-10-06 13:45:10] Record set satisfying user-defined criteria: n = 72161 #> INFO  [2023-10-06 13:45:10] Collapsing record set - providing output on a 'per_drug' resolution #> INFO  [2023-10-06 13:45:10] Final record set: n = 1079 records  drugs$records <- drugs$records |>   dplyr::filter(     stringr::str_detect(       atc_level2, \"ANTIMETABOLITES\"     )   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_metabolites <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-taxanes","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get taxanes","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug\") #> INFO  [2023-10-06 13:45:10] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:10] Object 'drug_map_name' sucessfully loaded #> INFO  [2023-10-06 13:45:10] Retrieved n = 30298 records #> INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:11] Object 'drug_map_alias' sucessfully loaded #> INFO  [2023-10-06 13:45:11] Retrieved n = 655065 records #> INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:11] Object 'drug_map_basic' sucessfully loaded #> INFO  [2023-10-06 13:45:11] Retrieved n = 31232 records #> INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:11] Object 'drug_map_target' sucessfully loaded #> INFO  [2023-10-06 13:45:11] Retrieved n = 38215 records #> INFO  [2023-10-06 13:45:11] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:11] Object 'drug_map_indication' sucessfully loaded #> INFO  [2023-10-06 13:45:11] Retrieved n = 56512 records #> INFO  [2023-10-06 13:45:14] Record set satisfying user-defined criteria: n = 72161 #> INFO  [2023-10-06 13:45:14] Collapsing record set - providing output on a 'per_drug' resolution #> INFO  [2023-10-06 13:45:15] Final record set: n = 1079 records  drugs$records <- drugs$records |>   dplyr::filter(     stringr::str_detect(       atc_level3, \"Taxanes\"     )   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_taxanes <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"get-platinum-compounds","dir":"Articles","previous_headings":"Retrieval of drugs - examples","what":"Get platinum compounds","title":"Getting started","text":"","code":"drugs <- get_drugs(   cache_dir = cache_dir,    output_resolution = \"drug\") #> INFO  [2023-10-06 13:45:15] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:15] Object 'drug_map_name' sucessfully loaded #> INFO  [2023-10-06 13:45:15] Retrieved n = 30298 records #> INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:16] Object 'drug_map_alias' sucessfully loaded #> INFO  [2023-10-06 13:45:16] Retrieved n = 655065 records #> INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:16] Object 'drug_map_basic' sucessfully loaded #> INFO  [2023-10-06 13:45:16] Retrieved n = 31232 records #> INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:16] Object 'drug_map_target' sucessfully loaded #> INFO  [2023-10-06 13:45:16] Retrieved n = 38215 records #> INFO  [2023-10-06 13:45:16] Reading from cache_dir = '/tmp/RtmpT04Il1', argument force_download = F #> INFO  [2023-10-06 13:45:16] Object 'drug_map_indication' sucessfully loaded #> INFO  [2023-10-06 13:45:16] Retrieved n = 56512 records #> INFO  [2023-10-06 13:45:19] Record set satisfying user-defined criteria: n = 72161 #> INFO  [2023-10-06 13:45:19] Collapsing record set - providing output on a 'per_drug' resolution #> INFO  [2023-10-06 13:45:20] Final record set: n = 1079 records  drugs$records <- drugs$records |>   dplyr::filter(     stringr::str_detect(       atc_level3, \"Platinum compounds\"     )   ) |>   dplyr::select(     -c(\"drug_alias\",        \"disease_main_group\",        \"drug_clinical_id\")) |>   dplyr::mutate(     disease_indication = stringr::str_replace_all(       disease_indication, \"\\\\|\",\", \")     )  dt_drugtable_platins <- DT::datatable(   drugs$records,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"reported-associations-between-brca12-alterations-and-drug-sensitivity","dir":"Articles","previous_headings":"Retrieval of biomarkers","what":"Reported associations between BRCA1/2 alterations and drug sensitivity","title":"Getting started","text":"Get evidence CIViC CGI cancer drug sensitivity BRCA1/2 alterations (somatically (tumor) inherited/germline)","code":"biomarkers <- get_biomarkers(   cache_dir = cache_dir) #> INFO  [2023-10-06 13:45:20] Downloading remote dataset from Google Drive to cache_dir #> INFO  [2023-10-06 13:45:24] Reading from cache_dir = ' (/tmp/RtmpT04Il1'), argument force_download = F #> INFO  [2023-10-06 13:45:24] Object 'biomarkers' sucessfully loaded #> INFO  [2023-10-06 13:45:24] md5 checksum is valid: fe0159f12bb564506cdf1087cfca4b99  brca1_biomarkers <- list() for(source in c('civic','cgi')){   brca1_biomarkers[[source]] <-      biomarkers$data[[source]]$variant |>      dplyr::filter(       !is.na(symbol) & (symbol == \"BRCA1\" | symbol == \"BRCA2\")) |>     dplyr::group_by(variant_id, symbol, variant_consequence) |>     dplyr::summarise(       variant_alias = paste(variant_alias, collapse=\", \"),        .groups = \"drop\") |>      dplyr::inner_join(       biomarkers$data[[source]]$clinical, by = \"variant_id\") |>     dplyr::select(       variant_id, symbol, variant_consequence, variant_alias,       biomarker_source, biomarker_source_datestamp,       molecular_profile_name, evidence_id, variant_origin,       primary_site, evidence_id, source_id,       evidence_url, therapeutic_context,       evidence_description, evidence_type, evidence_level,       clinical_significance) |>      dplyr::distinct() |>      dplyr::rename(literature_id = source_id) |>     dplyr::filter(evidence_type == \"Predictive\") |>     dplyr::select(       symbol, primary_site,       therapeutic_context,       molecular_profile_name,        evidence_level,       dplyr::everything()     ) }  brca1_biomarkers_all <-    dplyr::bind_rows(brca1_biomarkers[['civic']],                    brca1_biomarkers[['cgi']]) |>     dplyr::arrange(evidence_level)     dt_brca1_biomarkers <- DT::datatable(   brca1_biomarkers_all,   escape = FALSE,   extensions = c(\"Buttons\", \"Responsive\"),    width = \"100%\",   options = list(     buttons = c(\"csv\", \"excel\"),      dom = \"Bfrtip\") )"},{"path":"https://sigven.github.io/pharmOncoX/articles/pharmOncoX.html","id":"session-info","dir":"Articles","previous_headings":"","what":"Session Info","title":"Getting started","text":"","code":"# set eval = FALSE if you don't want this info (useful for reproducibility)  # to appear sessionInfo() #> R version 4.3.1 (2023-06-16) #> Platform: x86_64-pc-linux-gnu (64-bit) #> Running under: Ubuntu 22.04.3 LTS #>  #> Matrix products: default #> BLAS:   /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3  #> LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so;  LAPACK version 3.10.0 #>  #> locale: #>  [1] LC_CTYPE=C.UTF-8       LC_NUMERIC=C           LC_TIME=C.UTF-8        #>  [4] LC_COLLATE=C.UTF-8     LC_MONETARY=C.UTF-8    LC_MESSAGES=C.UTF-8    #>  [7] LC_PAPER=C.UTF-8       LC_NAME=C              LC_ADDRESS=C           #> [10] LC_TELEPHONE=C         LC_MEASUREMENT=C.UTF-8 LC_IDENTIFICATION=C    #>  #> time zone: UTC #> tzcode source: system (glibc) #>  #> attached base packages: #> [1] stats     graphics  grDevices utils     datasets  methods   base      #>  #> other attached packages: #> [1] pharmOncoX_1.4.5 #>  #> loaded via a namespace (and not attached): #>  [1] jsonlite_1.8.7    dplyr_1.1.3       compiler_4.3.1    crayon_1.5.2      #>  [5] tidyselect_1.2.0  stringr_1.5.0     assertthat_0.2.1  jquerylib_0.1.4   #>  [9] systemfonts_1.0.4 textshaping_0.3.6 yaml_2.3.7        fastmap_1.1.1     #> [13] R6_2.5.1          generics_0.1.3    curl_5.1.0        knitr_1.44        #> [17] htmlwidgets_1.6.2 tibble_3.2.1      desc_1.4.2        rprojroot_2.0.3   #> [21] bslib_0.5.1       pillar_1.9.0      rlang_1.1.1       DT_0.29           #> [25] utf8_1.2.3        cachem_1.0.8      stringi_1.7.12    lgr_0.4.4         #> [29] xfun_0.40         fs_1.6.3          sass_0.4.7        memoise_2.0.1     #> [33] cli_3.6.1         withr_2.5.1       pkgdown_2.0.7     magrittr_2.0.3    #> [37] crosstalk_1.2.0   digest_0.6.33     lifecycle_1.0.3   vctrs_0.6.3       #> [41] evaluate_0.22     gargle_1.5.2      glue_1.6.2        ragg_1.2.5        #> [45] googledrive_2.1.1 fansi_1.0.4       httr_1.4.7        rmarkdown_2.25    #> [49] purrr_1.0.2       ellipsis_0.3.2    pkgconfig_2.0.3   tools_4.3.1       #> [53] htmltools_0.5.6"},{"path":[]},{"path":"https://sigven.github.io/pharmOncoX/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Sigve Nakken. Author, maintainer.","code":""},{"path":"https://sigven.github.io/pharmOncoX/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Nakken S.  (2023)  pharmOncoX: Targeted non-targeted anti-cancer drugs drug regimens.  R package version 1.4.5.  (https://github.com/sigven/pharmOncoX)","code":"@Manual{,   title = {pharmOncoX: Targeted and non-targeted anti-cancer drugs and drug regimens},   author = {Sigve Nakken},   year = {2023},   note = {R package version 1.4.5},   url = {https://github.com/sigven/pharmOncoX}, }"},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"pharmoncox-","dir":"","previous_headings":"","what":"Molecularly targeted cancer drugs and biomarkers","title":"Molecularly targeted cancer drugs and biomarkers","text":"pharmOncoX provides access targeted non-targeted cancer drugs, including comprehensive annotations per target, drug mechanism--action, approval dates, clinical trial phases various indications etc. data largely based drug-target-indication associations provided Open Targets Platform (Ochoa et al., Nucleic Acids Res., 2021). Associations retrieved Open Targets Platform integrated cancer-relevant indications/conditions (provided sigven/phenOncoX), allowing user retrieve drugs indicated main tumor types (e.g. Lung, Colon/Rectum etc.) Drug-target associations Open Targets Platform furthermore integrated appended drug information NCI Thesaurus, showing also non-targeted cancer drugs (chemotherapeutic agents etc.), various drug regimens. provide anti-cancer drugs pharmOncoX drug class labeling Anatomical Therapeutic Chemical (ATC) Classification System, enabling filtering drugs according main mechanisms action. Currently (late April 2023), pharmOncoX built upon following releases external databases: Open Targets Platform (2023.02) ChEMBL (v31) NCI Thesaurus (23.04d)","code":""},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"getting-started","dir":"","previous_headings":"","what":"Getting started","title":"Molecularly targeted cancer drugs and biomarkers","text":"Installation instructions Usage examples","code":""},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"contact","dir":"","previous_headings":"","what":"Contact","title":"Molecularly targeted cancer drugs and biomarkers","text":"sigven ifi.uio.","code":""},{"path":"https://sigven.github.io/pharmOncoX/index.html","id":"code-of-conduct","dir":"","previous_headings":"","what":"Code of Conduct","title":"Molecularly targeted cancer drugs and biomarkers","text":"Please note project released Contributor Code Conduct. participating project agree abide terms.","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":null,"dir":"Reference","previous_headings":"","what":"Get curated cancer biomarker datasets — get_biomarkers","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"Downloads preprocessed datasets local cache directory returns curated set genomic biomarkers multiple sources (CIViC, CGI, MitelmanDB) dataset comes list object, three elements: metadata - data frame metadata regarding drug resources used data - list four elements ('civic','cgi','mitelmandb','custom_fusions') fpath - path cache file","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"","code":"get_biomarkers(cache_dir = NA, force_download = F)"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"cache_dir Local directory data download force_download Logical indicating local cache force downloaded (.e. set TRUE re-download even data exists cache)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_biomarkers.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Get curated cancer biomarker datasets — get_biomarkers","text":"entry source-spefic (CGI, CIViC etc.) entry data list contains list three data frames: variant - list biomarker variants, extensively populated according variant aliases (identifer - column variant_id) clinical - cross-references variants recorded variant data frame clinical evidence items (identifier - column evidence_id) underlying literature evidence (identifier - column source_id) literature - lists literature source_id's listed clinical data frame","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drug_records.html","id":null,"dir":"Reference","previous_headings":"","what":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","title":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","text":"Function retrieves pharmOncoX data Google Drive","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drug_records.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","text":"","code":"get_drug_records(cache_dir = NA, force_download = F)"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drug_records.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Function that retrieves pharmOncoX data from Google Drive — get_drug_records","text":"cache_dir Local directory data download force_download Logical indicating local cache force downloaded (.e. set TRUE re-download even data exists cache)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":null,"dir":"Reference","previous_headings":"","what":"Get antineoplastic drugs and drug regimens — get_drugs","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"Downloads preprocessed datasets local cache directory returns selected set drugs based various criteria set user. dataset comes list object, two elements: metadata - data frame metadata regarding drug resources used records - data frame drug records","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"","code":"get_drugs(   cache_dir = NA,   force_download = FALSE,   exclude_salt_forms = TRUE,   exclude_adc = TRUE,   drug_targeted_agent = FALSE,   drug_is_approved = FALSE,   drug_target = NULL,   drug_action_type = NULL,   drug_indication_main = NULL,   drug_source_opentargets = FALSE,   drug_cancer_indication = TRUE,   drug_classified_cancer = TRUE,   drug_has_blackbox_warning = FALSE,   drug_approval_year = 1939,   drug_minimum_phase_any_indication = 0,   output_resolution = \"drug2target2indication\",   drug_action_inhibition = F )"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"cache_dir local cache directory data retrieval force_download force download data remote repository even data exists cache exclude_salt_forms exclude salt forms drugs exclude_adc exclude antibody-drug conjugates (ADCs) drug_targeted_agent logical indicating resulting drug records contain drugs considered targeted agents (.e. chemotherapeutic drugs/immunosuppressants) drug_is_approved logical indicating resulting drug records contain approved drugs drug_target character vector drug targets (gene symbols) drug records included results drug_action_type character vector drug action types include drug record list - possible values \"INHIBITOR\",\"AGONIST\",\"MODULATOR\",\"ANTAGONIST\", \"BLOCKER\",\"ACTIVATOR\",\"BINDING AGENT\",\"OPENER\", \"STABILISER\",\"CROSS-LINKING AGENT\",DISRUPTING AGENT\",\"\" drug_indication_main character vector main tumor types drug(s) indicated. Possible values: \"Adrenal Gland\",\"Biliary Tract\", \"Bladder/Urinary Tract\",\"Bone\",\"Breast\",\"Cervix\",\"CNS/Brain\", \"Colon/Rectum\",\"Esophagus/Stomach\",\"Eye\",\"Head Neck\",\"Kidney\", \"Liver\",\"Lung\",\"Lymphoid\",\"Myeloid\",\"Ovary/Fallopian Tube\", \"Pancreas\",\"Penis\",\"Peripheral Nervous System\",\"Peritoneum\", \"Pleura\",\"Prostate\",\"Skin\",\"Soft Tissue\",\"Testis\",\"Thymus\", \"Thyroid\",\"Uterus\",\"Vulva/Vagina\" drug_source_opentargets logical indicating resulting drug records contain drug records Open Targets Platform/ChEMBL drug_cancer_indication logical indicating resulting drug records indicated cancer conditions (approved conditions, found clinical trials etc.) drug_classified_cancer logical indicating resulting drug records classified \"L\" class ATC ( \"ANTINEOPLASTIC IMMUNOMODULATING AGENTS\") drug_has_blackbox_warning logical indicating resulting drug records contain drugs black box warnings drug_approval_year include records drugs approved later date (year) drug_minimum_phase_any_indication include drug records clinical phase (indication) greater equal phase output_resolution dictate output record resolution ('drug','drug2target','drug2target2indication') drug_action_inhibition logical indicating return drug records inhibitory mechanism--action","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_drugs.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Get antineoplastic drugs and drug regimens — get_drugs","text":"records data frame contains following columns (selected columns shown based value output_resolution) drug_id - drug identifier (pharmaOncoX) drug_name - primary drug name (upper case, NCI Thesaurus) drug_type - type drug molecule (Antibody, small molecule etc) molecule_chembl_id - ChEMBL compound identifier drug_action_type - main action elicited drug (antagonist, inhibitor, stabiliser etc) drug_alias - collection unambiguous drug aliases (separated '|') nci_concept_definition - detailed description drug mechanism--action (NCI Thesaurus) opentargets - logical - drug found Open Targets Platform resource is_salt - logical - drug record represents salt form (excluded default) is_adc - logical - drug record represents antibody-drug conjugate (ADC - excluded default) drug_blacbox_warning - logical indicating drug blackbox warning nci_t - NCI thesaurus identifier target_symbol - gene symbol drug target target_entrezgene - Entrez gene identifier drug target target_genename - gene name/description drug target target_ensembl_gene_id - Ensembl gene identifier drug target target_type - type drug target (single protein, protein family etc.) drug_max_phase_indication - maximum clinical phase drug (given indication) drug_approved_indication - logical indicating drug approved indication drug_frac_cancer_indications - fraction drug indications cancers drug_approved_noncancer - logical indicating drug approved non-cancer disease drug_n_indications - number indications given drug (approved indications, clinical trials etc) drug_year_first_approval - year drug first approved drug_max_ct_phase - maximum clinical phase drug (indication) disease_efo_id - EFO (Experimental Factor Ontology) identifier drug indication disease_efo_label - EFO (Experimental Factor Ontology) label drug indication primary_site - primary tumor site/type (obtained https://github.com/sigven/oncoPhenoMap) drug_clinical_id - drug clinical identifier (clinicaltrials.gov, DailyMed, FDA etc.) drug_clinical_source - underlying source drug entry (DailyMed, clinicaltrials.gov, FDA etc.) atc_code_level1 - drug identifier ATC (level 1) atc_level1 - drug label ATC (level 1) atc_code_level1 - drug identifier ATC (level 2) atc_level2 - drug label ATC (level 2) atc_code_level3 - drug identifier ATC (level 3) atc_level3 - drug label ATC (level 3)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_on_off_label_drugs.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"Utility function get -label/-label drugs (complete)","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/get_on_off_label_drugs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"","code":"get_on_off_label_drugs(cache_dir = NA)"},{"path":"https://sigven.github.io/pharmOncoX/reference/get_on_off_label_drugs.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function to get on-label/off-label drugs (not complete) — get_on_off_label_drugs","text":"cache_dir Local cache directory","code":""},{"path":"https://sigven.github.io/pharmOncoX/reference/tidyeval.html","id":null,"dir":"Reference","previous_headings":"","what":"Tidy eval helpers — tidyeval","title":"Tidy eval helpers — tidyeval","text":"https://cran.r-project.org/web/packages/dplyr/vignettes/programming.html","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-145-october-6th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.5 (October 6th 2023)","title":"Version 1.4.5 (October 6th 2023)","text":"Updated NCI Thesaurus - 23.09d Updated CIViC data Added drug class (ATC) get_on_off_label_drugs()","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-144-september-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.4 (September 1st 2023)","title":"Version 1.4.4 (September 1st 2023)","text":"Updated NCI Thesaurus - 23.08d Updated CIViC data Updated Mitelman database (20230803) get_biomarkers() now exported main function","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-143-august-7th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.3 (August 7th 2023)","title":"Version 1.4.3 (August 7th 2023)","text":"NCI Thesaurus 23.07e","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-142-august-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.2 (August 1st 2023)","title":"Version 1.4.2 (August 1st 2023)","text":"Added biomarker aliases Updated CIViC data","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-141-july-23rd-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.1 (July 23rd 2023)","title":"Version 1.4.1 (July 23rd 2023)","text":"Added missing biomarker aliases synonymous variants","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-140-july-11th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.4.0 (July 11th 2023)","title":"Version 1.4.0 (July 11th 2023)","text":"Updated metadata Updated CIViC","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-138-july-5th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.8 (July 5th 2023)","title":"Version 1.3.8 (July 5th 2023)","text":"Cleaned biomarker data (CIViC)","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-137-june-28th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.7 (June 28th 2023)","title":"Version 1.3.7 (June 28th 2023)","text":"Updated NCI Thesaurus (23.06d release) Updated biomarker data (CIViC) Updated Open Targets Platform (2023.06)","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-136-june-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.6 (June 1st 2023)","title":"Version 1.3.6 (June 1st 2023)","text":"Updated NCI Thesaurus (23.05d release) Cleaned biomarker alteration types","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-135-may-24th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.5 (May 24th 2023)","title":"Version 1.3.5 (May 24th 2023)","text":"Removed general words drug alias list Fixed bug biomarker alias parsing","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-133-may-15th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.3 (May 15th 2023)","title":"Version 1.3.3 (May 15th 2023)","text":"Added additional drug entries (primary indication non-cancer) Fixed bug parsing drugs Open Targets Platform","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-130-may-10th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.3.0 (May 10th 2023)","title":"Version 1.3.0 (May 10th 2023)","text":"Updated NCI Thesaurus (23.04d release) Drugs now provided ATC classification labels arguments filtering towards specific inhibitors etc now removed (e.g. is_alkylating_agent,is_angiogenesis_inhibitor etc.), filtering can performed user, e.g. considering drug class labels ATC drug targets drug_is_targeted -> drug_targeted_agent inhibitor_only -> drug_action_inhibition drug_approved_later_than -> drug_approval_year source_opentargets_only -> drug_source_opentargets drug_targeted_agent option improved basd ATC labeling drug_cancer_indication - logical indicating resulting drug records indicated cancer conditions (.e. approved conditions, listed clinical trials etc.) - defaults TRUE drug_classified_cancer - logical indicating resulting drug records classified “L” class ATC ( “ANTINEOPLASTIC IMMUNOMODULATING AGENTS”) - defaults TRUE","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-120-april-26th-2023","dir":"Changelog","previous_headings":"","what":"Version 1.2.0 (April 26th 2023)","title":"Version 1.2.0 (April 26th 2023)","text":"Using sigven/phenOncoX v0.5.8 cancer phenotype matching Updated NCI Thesaurus (23.03d release) New helper function retrieve drug biomarkers (pharmOncoX:::get_biomarkers)","code":""},{"path":"https://sigven.github.io/pharmOncoX/news/index.html","id":"version-119-march-1st-2023","dir":"Changelog","previous_headings":"","what":"Version 1.1.9 (March 1st 2023)","title":"Version 1.1.9 (March 1st 2023)","text":"Updated NCI Thesaurus (23.02d release) Updated biomarker data (CIViC) Updated Open Targets Platform (2023.02)","code":""}]